Document:

EX-10.10

 Exhibit 10.10 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE HILLEVAX, INC. HAS DETERMINED THE INFORMATION
(I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO HILLEVAX, INC. IF PUBLICLY DISCLOSED. 
 LICENSE AGREEMENT

 BY AND BETWEEN 

TAKEDA VACCINES, INC. 

AND 
 HILLEVAX, INC.

 LICENSE AGREEMENT 

This License Agreement (this “Agreement”) is made effective as of July 2, 2021 (the
“Effective Date”) by and between Takeda Vaccines, Inc., a company incorporated under the laws of Delaware having its principal place of business at 75 Sidney Street, Cambridge, Massachusetts 02139, U.S.A.
(“Takeda”), and HilleVax, Inc., a company incorporated under the laws of Delaware having its principal place of business at 601 Union Street, Suite 3200, Seattle, Washington, 98101, U.S.A.
(“Licensee”). Licensee and Takeda are sometimes referred to herein individually as a “Party” and collectively as the “Parties.” 

RECITALS 

WHEREAS, Takeda is a pharmaceutical company engaged in the research, development and commercialization of products
useful in the amelioration, treatment or prevention of human diseases and conditions; 
 WHEREAS, Licensee was
recently formed for the purposes of engaging in the research and development, and if successful, commercialization of vaccine products; and 

WHEREAS, Licensee wishes to be granted, and Takeda desires to grant, a license in the Territory (as defined below)
under certain patents, patent applications, know-how, and other proprietary information for the further development of the Compound and Product and commercialization of the Product (as those terms are defined
below). 
 NOW, THEREFORE, in consideration of the foregoing and the mutual agreements set forth below, and other
good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows: 
 ARTICLE 1
– DEFINITIONS 
 1.1    “Affiliate” means, with respect to a particular Party, a person,
corporation, partnership, or other entity that controls, is controlled by or is under common control with such Party. For the purposes of this definition, the word “control” (including, with correlative meaning, the terms “controlled
by” or “under the common control with”) means the actual power, either directly or indirectly through one or more intermediaries, to direct or cause the direction of the management and policies of such entity, whether by the ownership
of fifty percent (50%) or more of the voting stock of such entity, or by contract or otherwise. 

1.2    “Ancillary Agreements” means the Clinical Supply Agreement attached hereto as Exhibit C, any other
Clinical Supply Agreement entered into pursuant to Section 5.6, and any Commercial Supply Agreement entered into pursuant to Section 5.7, and any Transitional Services Agreement. 

1.3    “Applicable Law” means all applicable statutes, ordinances, regulations, rules, or orders of any
kind whatsoever of any Governmental Authority, including the U.S. Food, Drug and Cosmetic Act, (21 U.S.C. §301 et seq.) (the “FFDCA”), Prescription Drug Marketing Act, the Generic Drug Enforcement Act of 1992 (21 U.S.C.
§335a et seq.), U.S. Patent Act (35 U.S.C. §1 et seq.), Federal Civil False Claims Act (31 U.S.C. §3729 et seq.), and the Anti-Kickback Statute (42 U.S.C. 

  
 - 1 - 

 
§1320a-7b et seq.), all as amended from time to time, together with any rules, regulations, and compliance guidance promulgated thereunder. 

1.4    “Bankruptcy Laws” has the meaning set forth in Section 13.5(b). 

1.5    “Bayh-Doyle Act” means the Patent and Trademark Law Amendments Act of 1980, as amended, codified
at 35 U.S.C. §§ 200-212, as well as any regulations promulgated pursuant thereto, including 37 C.F.R. Part 401, and any successor statutes or regulations. 

1.6    “Biosimilar Product” means, with respect to any Product, on a Product-by-Product basis and country-by-country basis, a biologic product (a) for which the licensing, approval, or
marketing authorization relies in whole or in part on a prior approval, licensing or marketing authorization granted such Product; (b) that is “biosimilar” to such Product, as the term “biosimilar” is defined in 42 U.S.C.
§ 262(i)(2); and (c) that has been licensed by the FDA or other Regulatory Authority outside of the United States by reference to such Product, as set forth at 42 USC 262(k)(4) or other analogous applicable Law outside of the United
States. A Product licensed, marketed, sold, manufactured, or produced by or on behalf of either Party or its Affiliates (or any (Sub)licensees or distributors in their capacity as (Sub)licensee or distributor for such Party or any of its Affiliates)
will not constitute a Biosimilar Product. 
 1.7    “BLA” means (a) a Biologics License
Application as defined in the United States Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 301 et seq., as amended from time to time, together with any rules, regulations and requirements promulgated thereunder (including all additions,
supplements, extensions, and modifications thereto), including any amendments thereto, or (b) any corresponding foreign application, including, with respect to the European Union, a Marketing Authorization Application filed with the EMA
pursuant to the Centralized Approval Procedure or with the applicable Regulatory Authority of a country in Europe with respect to the mutual recognition or any other national approval procedure, including any amendments thereto. 

1.8    “Breaching Party” has the meaning set forth in Section 13.2(a). 

1.9    “Business Day” means a day other than Saturday, Sunday or any other day on which commercial banks
located in the State of New York, U.S., or Japan, are authorized or obligated by Applicable Law to close. 

1.10    “Calendar Quarter” means the respective periods of three (3) consecutive calendar months
ending on March 31, June 30, September 30 and December 31; provided, however, that (a) the first Calendar Quarter of the Term shall extend from the Effective Date to the end of the first complete Calendar Quarter thereafter; and
(b) the last Calendar Quarter of the Term shall end upon the expiration or termination of this Agreement. 

1.11    “Calendar Year” means the twelve (12)-month period ending on December 31; provided however, that
(a) the first Calendar Year of the Term shall begin on the Effective Date and end on December 31, 2021; and (b) the last Calendar Year of the Term shall end on the date of expiration or termination of this Agreement. 

1.12    “Change of Control” means any of the following: (a) the acquisition by a Third Party,
directly or indirectly, of the beneficial ownership of any voting security of a Party, or increase in 

  
 - 2 - 

 
\the percentage ownership of such Third Party in the voting securities of a Party through stock redemption, cancellation or other recapitalization, where immediately after such acquisition or
increase such Third Party is, directly or indirectly, the beneficial owner of voting securities representing fifty percent (50%) or more of the total voting power of all of the then-outstanding voting securities of a Party; (b) the consummation
of a merger, consolidation, recapitalization, reorganization, amalgamation, arrangement, share exchange, tender or exchange offer, private purchase, business combination or other transaction of a Party, other than any such transaction which would
result in stockholders or equity holders of a Party, or an Affiliate of a Party, immediately prior to such transaction coming to own not more than fifty percent (50%) of the outstanding securities of the surviving entity (or its parent entity)
immediately following such transaction; (c) the stockholders or equity holders of a Party approve a plan of complete liquidation of a Party, or an agreement for the sale or disposition by a Party of all or a substantial portion of a
Party’s assets, other than to an Affiliate; or (d) the exclusive license sale or other transfer to a Third Party of all or substantially all of a Party’s assets which relate to this Agreement. 

1.13    “Claim” has the meaning set forth in Section 15.1. 

1.14    “Clinical Supply Agreement” means the Clinical Supply Agreement attached hereto as Exhibit C, as
such Clinical Supply Agreement may be modified or amended in accordance with the terms thereof. 

1.15    “Clinical Trial” means any human clinical study or trial of a Product in the Field. 

1.16    “Commercialization” means all activities undertaken in support of the promotion, marketing, sale
and distribution (including importing, exporting, transporting, customs clearance, warehousing, invoicing, handling and delivering products to customers) of products. “Commercialize” means to engage in Commercialization activities. 

1.17    “Commercialization Plan” means a plan prepared by the applicable Party pursuant to
Section 7.2 containing an overview of the general strategy and a high-level budget for Commercializing the Products in the Field in such Party’s respective territory. 

1.18    “Commercially Reasonable Efforts” means, with respect to the efforts to be expended, or
considerations to be undertaken, by a Party or its Affiliate with respect to any objective, activity or decision to be undertaken hereunder, reasonable, good faith efforts to accomplish such objective, activity or decision as a similarly situated
pharmaceutical company would normally use to accomplish a similar objective, activity or decision under similar circumstances, it being understood and agreed that with respect to the Development, Manufacture, seeking and obtaining Regulatory
Approval, or Commercialization of the Compound or a Product, such Party and its Affiliates may take into account, without limitation: (a) issues of efficacy, safety, and expected and actual approved labeling, (b) the expected and actual
competitiveness of alternative products sold by Third Parties in the marketplace in the relevant territory, (c) the expected and actual product profile of the Compound or Product, (d) the expected and actual patent and other proprietary
position of the Product in the relevant territory, (e) the likelihood of Regulatory Approval and/or pricing approval in the relevant territory given the regulatory structure involved, including regulatory or data exclusivity, (f) the
expected and actual profitability and return on investment of 

  
 - 3 - 

 
the Compound or Product, taking into consideration amounts owed hereunder, and (g) all other relevant scientific, technical, regulatory and commercial factors. 

1.19    “Common Stock” shall have the meaning set forth in Section 2.2(a). 

1.20    “Commercial Supply Agreement” shall have the meaning set forth in Section 5.7. 

1.21    “Company Core Data Sheet” or “CCDS” means, a document prepared by the Marketing
Authorization Holder containing, in addition to safety information, material related to indications, dosing, pharmacology and other information concerning the Product (see GVP Annex IV, ICH-E2C(R2) Guideline).

 1.22    “Competing Product” shall mean, other than any Product, any vaccine product that includes
any norovirus virus-like particles and that is being developed for or is approved for the prevention or minimization of symptoms caused by norovirus infection. 

1.23    “Compound” means the combination of GI.1 and GII.4 norovirus VLPs coded as of the Effective Date
by Takeda as TAK-214 and any derivatives thereof, including any analogs, prodrugs, sequence variations, mutations, chemical and/or posttranslational modifications thereof, including only one of the GI.1 or
GII.4 VLPs or combinations of one or both GI.1 and GII.4 VLPs with other VLPs or non-VLP antigens capable of eliciting an immune response to prevent or minimize disease and/or infections caused by norovirus.

 1.24    “Confidential Information” means all non-public or
proprietary Information disclosed by a Party to the other Party under this Agreement, without regard as to whether any of such Information is marked “confidential” or “proprietary,” or disclosed in oral, written, graphic, or
electronic form. Confidential Information shall include the terms and conditions of this Agreement. 

1.25    “Control” (and other correlative terms) means, with respect to any Information, Patent, Trademark
or other intellectual property right, ownership or possession by a Party, or, where expressly provided, its Affiliates, of the ability (without taking into account any rights granted by one Party to the other Party under the terms of this Agreement)
to grant access, a license or a sublicense to such Information, Patent, Trademark or other intellectual property right without violating the terms of any agreement or other arrangement [(***)] with, or necessitating the consent of, any Third Party
[(***)], at such time that the Party would be first required under this Agreement to grant the other Party such access, license or sublicense; [***]. 

1.26    “Cure Period” has the meaning set forth in Section 13.2(a). 

1.27     “Detectible Defect” has the meaning set forth in the Clinical Supply Agreement. 

1.28    “Development” means all (i) non-clinical and
clinical development activities, including toxicology, pharmacology, and other non-clinical efforts, statistical analysis, the performance of Clinical Trials, including the Manufacturing of the Product for use
in the Clinical Trials, and (ii) other activities reasonably necessary in order to obtain or maintain, Regulatory Approval of the Product in the Field. When used as a verb, “Develop” means to engage in Development activities. 

  
 - 4 - 

 1.29    “Development Plan” means a detailed written
plan prepared by Licensee for the Development activities to which such plan relates, and which plan shall (a) identify the Development objectives, projected timeline and activities to be conducted pursuant to this Agreement with respect to the
Product during the Term; and (b) contain a reasonably detailed budget identifying the anticipated expenses associated with such Development activities. “Development Plan” includes the “Initial Development Plan”. 

1.30    “Disclosing Party” has the meaning set forth in Section 11.1. 

1.31    “Dispute” or “Disputes” has the meaning set forth in Section 14.1. 

1.32    “Drug Product” has the meaning set forth in the Clinical Supply Agreement. 

1.33    “EMA” means the European Medicines Agency or any successor agency or authority having
substantially the same function. 
 1.34    “Existing Commercial Sublicensee” has the meaning set forth
in Section 4.3(d). 
 1.35    “Exploit” or “Exploitation” means to research,
make, import, export, distribute, use, sell, or offer for sale, including to Develop, Commercialize, register, modify, enhance, improve, hold, keep (whether for disposal or otherwise), transport, distribute, promote, market, or otherwise dispose of,
or to have performed any of the foregoing. 
 1.36    “FDA” means the U.S. Food and Drug
Administration, or any successor agency thereto. 
 1.37    “FFDCA” means the Federal Food, Drug and
Cosmetic Act under United States Code, Title 21, as amended. 
 1.38    “Field” means all human uses.

 1.39    “First Commercial Sale” means, on a country-by-country basis, the first sale of a Product by a Party, its Affiliates or its (Sub)licensees to an end user or prescriber for use, consumption or resale of the Product in a country in such
Party’s respective territory in the Field where Regulatory Approval of the Product has been obtained. 

1.40    “Force Majeure” means any event beyond the reasonable control of the affected Party including
embargoes; war or acts of war, including terrorism; insurrections, riots, or civil unrest; strikes, lockouts or other labor disturbances; epidemics, fire, floods, earthquakes or other acts of nature; or acts, omissions or delays in acting by any
governmental authority (including the refusal of the competent government agencies to issue required Regulatory Approvals due to reasons other than the affected Party’s negligence or willful misconduct or any other cause within the reasonable
control of the affected Party), and failure of plant or machinery (provided that such failure could not have been prevented by the exercise of skill, diligence, and prudence that would be reasonably and ordinarily expected from a skilled and
experienced person engaged in the same type of undertaking under the same or similar circumstances).    In addition, a Force Majeure may include reasonable measures affirmatively taken by a Party or its Affiliates to respond to
any epidemic, pandemic, or spread of infectious disease (including the COVID-19 pandemic), such as requiring 

  
 - 5 - 

 
employees to stay home, closures of facilities, delays of Clinical Trials, or cessation of activities in response to an epidemic or other Force Majeure event. 

1.41    “Fully-Diluted Capitalization” means the outstanding shares of Common Stock of Licensee on
a fully diluted basis, including (i) outstanding shares of preferred stock (on an as-converted basis), (ii) outstanding vested and unvested stock options (on an
as-exercised basis) and all shares of Common Stock held in reserve in any of the Company’s equity incentive plans that are not then yet allocated for outstanding and unexercised stock options,
(iii) outstanding warrants (on an as-exercised basis), and (iv) other outstanding convertible securities (on an as-converted basis). 

1.42    “GAAP” means generally accepted accounting principles in the U.S. 

1.43    “Generic Competition Percentage” means, with respect to a particular Product in a particular
country, all units of the Biosimilar Product(s) for such Product sold in such country divided by the sum of: (a) all units of such Product sold in such country, plus (b) all units of all Biosimilar Product(s) sold in such country, where,
in each case, the number of units of a Product and each Biosimilar Product sold shall be based on the [***]. 

1.44    “Good Clinical Practices” or “GCP” means the then-current standards, practices
and procedures promulgated or endorsed by the FDA as set forth in the guidelines adopted by the International Conference on Harmonization (“ICH”), titled “Guidance for Industry E6 Good Clinical Practice: Consolidated
Guidance,” (or any successor document) including related regulatory requirements imposed by the FDA and comparable regulatory standards, practices and procedures promulgated by the EMA or other Regulatory Authority applicable to the Territory,
as they may be updated from time to time.  
 1.45    “Good
Laboratory Practices”, “GLP”, or “cGLP” means the then-current standards, practices and procedures promulgated or endorsed by the FDA as set forth in 21 C.F.R. Part 58 (or any successor statute or
regulation), including related regulatory requirements imposed by the FDA and comparable regulatory standards, practices and procedures promulgated by the EMA or other Regulatory Authority applicable to the Territory, as they may be updated from
time to time, including applicable guidelines promulgated under the ICH. 
 1.46    “Governmental
Authority” means any multi-national, federal, state, local, municipal or other government authority of any nature (including any governmental division, subdivision, department, agency, bureau, branch, office, commission, council, court or
other tribunal). 
 1.47    “IFRS” means International Financial Reporting Standards. 

1.48    “IND” means an Investigational New Drug application as defined in the FFDCA, as amended, and
applicable regulations promulgated hereunder by the FDA, or any corresponding foreign application for a clinical trial authorization for a product filed with a Regulatory Authority in any other regulatory jurisdiction outside the U.S., the filing of
which is necessary to commence or conduct clinical testing of a pharmaceutical product in humans in such jurisdiction. 

1.49    “Indemnitee” shall have the meaning set forth in Section 15.3(a). 

1.50    “Indemnifying Party” shall have the meaning set forth in Section 15.3(a). 

  
 - 6 - 

 1.51    “Information” means information, inventions,
concepts, compounds, compositions, formulations, formulas, practices, procedures, processes, methods, knowledge, know-how, trade secrets, technology, techniques, designs, drawings, correspondence, computer
programs, documents, apparatus, results, strategies, regulatory documentation, information and submissions pertaining to, or made in association with, filings with any Government Authority or patent office, data, including pharmacological,
toxicological, non-clinical and clinical data, analytical and quality control data, manufacturing data and descriptions, patent and legal data, market data, financial data or descriptions, devices, assays,
chemical formulations, specifications, material, product samples and other samples, physical, chemical and biological materials and compounds, and the like, in written, electronic, oral or other tangible or intangible form, now known or hereafter
developed, whether or not patentable. 
 1.52    “Information Sharing Committee” shall have the meaning
set forth in Section 12.1. 
 1.53    “Initial Development Plan” means the initial Development
Plan for the Product attached to this Agreement as Exhibit A. 
 1.54    “Initiation” means the first
dosing of a human subject in a Clinical Trial of a Product by Licensee, its Affiliate, or its (Sub)licensee. 

1.55    “Inventions” means any and all inventions, discoveries and developments, whether or not
patentable, made, conceived and/or reduced to practice in the course of performance of activities under this Agreement whether made, conceived and/or reduced to practice solely by, or on behalf of, Takeda, Licensee, the Parties jointly, or any
Affiliate of the same. 
 1.56    “Involved Employee” has the meaning set forth in
Section 10.3(d). 
 1.57    “Joint Know-How” means all
Information and Inventions jointly created by Licensee and Takeda under this Agreement and during the Term that is necessary or useful to Exploit the Compound or Product in the Field. Joint Know-How excludes
any Information or Inventions contained within a Joint Patent. 
 1.58    “Joint Intellectual Property”
means, collectively, Joint Know-How and Joint Patents. 
 1.59    “Joint
Inventions” shall have the meaning set forth in Section 9.1. 
 1.60    “Joint Patents”
means all Patents covering or claiming any Joint Invention. 
 1.61    “Knowledge” means, as applied to
a Party, that such Party [***]. 
 1.62    “Knowledge Group” means, with respect to each Party, [***]
of such Party or any Affiliates of such Party. 
 1.63    “Labeling” means, to the extent required by
the applicable Regulatory Approval, all labels and other written, printed, or graphic matters (1) upon any article or any of its containers or wrappers, or (2) accompanying such an article, including healthcare professional Prescribing
Information (e.g. US PI, EU SmPC), medication guides, patient information leaflets and artworks 

  
 - 7 - 

 
(including mock-ups of the outer and immediate packaging), packaging, web sites, and other promotional materials. 

1.64    “Licensee Indemnitee” shall have the meaning set forth in Section 15.2. 

1.65    “Licensee Intellectual Property” means, collectively, Licensee
Know-How and Licensee Patents. 
 1.66    “Licensee Know-How” means collectively (i) any Information Controlled by Licensee or its Affiliates (other than Takeda Know-How licensed to Licensee) as of the Effective
Date that are necessary to Exploit a Compound or Product in the Field and (ii) any Information which first become Controlled by Licensee or its Affiliates after the Effective Date that are directed to a Compound or Product in the Field,
including any Information disclosed by Licensee to Takeda under Section 12.2. Licensee Know-How excludes any Information contained within a Licensee Patent. 

1.67    “Licensee Japan Development Activities” means the following Development activities to be
performed by Licensee, each as set forth in the Initial Development Plan and further qualified in Section 5.4: (i) an immunogenicity Phase 1 Clinical Trial in Japanese healthy volunteers designed to meet PMDA criteria, (ii) the inclusion
of Japanese subjects in Japan in Licensee’s Phase 3 Clinical Trial (Phase 3 portion if Licensee conducts Phase 2b /Phase 3 Clinical Trials), and (iii) the inclusion of Japanese subjects in any immuno-bridging Clinical Trial. 

1.68    “Licensee Patents” means all Patents Controlled by Licensee or its Affiliates, as of the
Effective Date or during the Term (other than Takeda Patents licensed to Licensee) that are necessary or reasonably useful to Exploit Compounds or Products in the Field. There are no Licensee Patents as of the Effective Date and accordingly there
are no Licensee Patents listed in Exhibit B as of the Effective Date. Licensee shall update Exhibit B from [***] to include future Licensee Patents and provide a copy thereof to Takeda. 

1.69    “Licensee Royalty Term” means, on a country-by-country and Product-by-Product basis, the period commencing on the First Commercial Sale of a Product by Licensee,
its Affiliates or (Sub)licensees in such country in the Territory and continuing until the later of: 

(a)    the expiration of the last to expire Valid Claim in a Takeda Compound Patent or Joint Patent
covering the composition of matter, Manufacture or approved use of the Compound or such Product in such country; 

(b)    the expiration of the applicable Regulatory Exclusivity in such country; or 

(c)    [***] after First Commercial Sale of such Product by Licensee, its Affiliates or (Sub)licensees in
such country. 
 1.70    “Licensee Third Party License” has the meaning set forth in
Section 8.7(a). 
 1.71    “Licensee Third Party Royalties” shall have the meaning set forth in
Section 8.7(a). 

  
 - 8 - 

 1.72    “Life Technologies Agreement” means the SF9
Cell Line License Agreement effective as of November 21, 2013 between Life Technologies Corporation and Takeda Vaccines (Montana), Inc. 

1.73    “Life Technologies Assignment Agreement” means the Assignment Agreement attached hereto as
Exhibit L. 
 1.74    “Losses” shall have the meaning set forth in Section 15.1. 

1.75    “MAA” or “Marketing Authorization Application” means an application for
Regulatory Approval filed with the EMA. 
 1.76    “Marketing Authorization Holder” or
“MAH” means the Person that owns the applicable Regulatory Approval. 

1.77    “Manufacture” or “Manufacturing” means all activities related to the
manufacturing of the Compound or the Product, or any ingredient thereof, including manufacturing for Development and Commercialization, labeling, packaging, in-process and finished Product testing, release of
the Compound or the Product or any ingredient thereof, quality assurance activities related to manufacturing and release of the Compound or the Product, ongoing stability tests and regulatory activities related to any of the foregoing. 

1.78    “Net Sales” means, with respect to any Product, the gross amounts invoiced and/or received
(whichever is the first to occur) by a Party, its Affiliates and (Sub)licensees for sales of such Product to Third Parties, less the following deductions, to the extent such deductions are paid, incurred or otherwise taken, reasonable and customary,
provided to Third Parties, and actually allowed with respect to such sales: 
 (a)    [***]; 

(b)    [***]; 

(c)    [***]; 

(d)    [***]; and 

(e)    [***]. 

Notwithstanding the foregoing, amounts received or invoiced by such Party, its Affiliates or (Sub)licensees for the sale of such Product among
such Party, its Affiliates or (Sub)licensees for resale shall not be included in the computation of Net Sales hereunder. In any event, any amounts received or invoiced by such Party, its Affiliates or (Sub)licensees shall be accounted for only once.
For purposes of determining Net Sales, a Product shall be deemed to be sold when recorded by such Party, its (Sub)licensee or Affiliate in accordance with GAAP or IFRS, as the case may be. Net Sales shall be accounted for in accordance with standard
accounting practices, as practiced by such Party, its Affiliates, or its respective (Sub)licensees in the relevant country, but in any event in accordance with GAAP or IFRS, as consistently applied in such country (except that notwithstanding any
GAAP or IFRS guidance to the contrary, pursuant to subsection (d) above, 

  
 - 9 - 

 
sales taxes and that portion of the annual fee on prescription drug manufacturers imposed by the Patient Protection and Affordable Care Act, Pub. L.
No. 111-148 (as amended) may be deducted from Net Sales). For clarity, a particular deduction may only be accounted for once in the calculation of Net Sales. Net Sales shall exclude any samples of a
Product transferred or disposed of at no cost for promotional, Development or educational purposes. 
 The Net Sales of any Product sold as
a component of a combination or bundled product that consists of (i) a Product (or the Compound) together with (ii) one or more other active products or compounds for the treatment or prevention of diseases other than those caused by
norovirus (a “Combination Product”) shall be calculated as follows: 

(x)    [***]; 

(y)    [***]; and 

(z)    [***]. 

1.79    “Non-Breaching Party” has the meaning set forth in
Section 13.2(a). 
 1.80    “Patents” means all: (a) patents, including any utility or design
patent; (b) patent applications, including provisionals, substitutions, divisionals, continuations, continuations in-part or renewals; (c) patents of addition, restorations, extensions, supplementary
protection certificates, registration or confirmation patents, patents resulting from post-grant proceedings, re-issues and re-examinations; (d) other patents or
patent applications claiming priority directly or indirectly to: (i) any such specified patent or patent application specified in (a) through (c), or (ii) any patent or patent application from which a patent or patent application
specified in (a) through (c) claim direct or indirect priority; (e) inventor’s certificates; (f) other rights issued from a Governmental Authority similar to any of the foregoing specified in (a) through (e), including but
not limited to utility models; and (g) in each of (a) through (f), whether such patent, patent application or other right arises in the U.S. or any other jurisdiction in the world. 

1.81    “Person” means an individual, sole proprietorship, partnership, limited partnership, limited
liability partnership, corporation, limited liability company, business trust, joint stock company, trust, incorporated association, joint venture or similar entity or organization, including a government or political subdivision, department or
agency of a government. 
 1.82    “Phase 1 Clinical Trials” means a Clinical Trial of a Product with
the endpoint of determining initial tolerance, safety, or immunogenicity information in single dose, single ascending dose, multiple dose and/or multiple ascending dose regimens, as more fully described in U.S. federal regulation 21 C.F.R. §
312.21(a) and its equivalents in other jurisdictions. 
 1.83    “Phase 2 Clinical Trial” means a
Clinical Trial of a Product on human subjects, including possibly dose-ranging studies or “proof-of concept” efficacy studies, the principal purposes of which are to make a preliminary determination
that such product is safe for its intended use and to obtain sufficient information about such product’s efficacy or dose-response information to permit the design of further Clinical Trials. 

  
 - 10 - 

 1.84    “Phase 3 Clinical Trial” means a pivotal
Clinical Trial of a pharmaceutical product, with a defined dose or a set of defined doses, which trial is designed to ascertain efficacy and safety of such product, in a manner that is generally consistent with 21 CFR § 312.21(c), as amended
(or its successor regulation), and its equivalents in other jurisdictions, for the purpose of enabling the preparation and submission of a BLA with the FDA or any other applicable Regulatory Authority. 

1.85    “PMDA” means the Pharmaceuticals and Medical Devices Agency of Japan. 

1.86    “Product” means any pharmaceutical product, including all forms, presentations, strengths, doses
and formulations (including any method of delivery), containing a Compound (a) alone or (b) in combination with at least one other active ingredient (including other VLPs) to prevent or minimize disease and/or infections caused by
norovirus. 
 1.87    “Product BLA” means any BLA filed anywhere in the world which seeks Regulatory
Approval for a Product in the Field, including any supplements or amendments thereto. 
 1.88    “Product
Complaint” means all Information that has come to the attention of either Party, its Affiliates or its (Sub)licensees, concerning any dissatisfaction regarding a Product of such a nature and magnitude that it is required under Applicable
Law to be collected, maintained and reported to a Regulatory Authority, including reports of actual or suspected product tampering, contamination, mislabeling or inclusion of improper ingredients. 

1.89    “Product IND” means any IND filed anywhere in the world pertaining to a Product, including any
supplements or amendments thereto. 
 1.90    “Product Infringement” has the meaning set forth in
Section 9.5(b)(i). 
 1.91    “Product Trademarks” means the Trademark(s) to be used by Licensee
or its Affiliates or its (Sub)licensees for the Exploitation of Products in the Field in the Territory and any registrations thereof or any pending applications relating thereto in the Territory (excluding, in any event, any trademarks, service
marks, names or logos that include any corporate name or logo of the Parties or their Affiliates). 

1.92    “Qualified Financing” means a financing resulting in gross aggregate cash proceeds to Licensee of
at least $[***], either through the issuance of (i) convertible notes, or (ii) Series A preferred stock, in either case consistent with the terms of the Side Letter Agreement between the Parties dated on or about the Effective Date. 

1.93    “Receiving Party” shall have the meaning set forth in Section 11.1. 

1.94    “Regulatory Approval” means all approvals (including supplement, amendment, or pre- and post-approval), licenses, registrations or authorizations of any national, regional, state or local Regulatory Authority, department, bureau, commission, council or other Governmental Authority, that are
necessary for the Commercialization of the Product in a country or countries (but excluding approval of any application for pricing or reimbursement for the Product by any Governmental Authority). 

  
 - 11 - 

 1.95    “Regulatory Authority” means any applicable
Governmental Authority involved in granting Regulatory Approval, including in the U.S., the FDA and any other applicable Governmental Authority having jurisdiction over the approval of a Compound or a Product. 

1.96    “Regulatory Exclusivity” means any exclusive marketing rights or data protection or other
exclusivity rights conferred by any Regulatory Authority with respect to a Product in a country or jurisdiction, other than a Patent right, including, in the United States, orphan drug exclusivity, pediatric exclusivity, rights conferred in the U.S.
under the Drug Price Competition and Patent Term Restoration Act, 21 U.S.C. 355, as amended (the “Hatch-Waxman Act”). 

1.97    “Regulatory Materials” means all regulatory applications, submissions, notifications,
registrations, Regulatory Approvals or other submissions, including any written correspondence or meeting minutes, made to, made with, or received from a Regulatory Authority that are necessary or reasonably desirable in order to Develop,
Manufacture, market, sell or otherwise Commercialize a Product in the Field. Regulatory Materials include the Product INDs and the Product BLAs, and amendments and supplements thereto. 

1.98    “Royalty Term” means the Licensee Royalty Term or the Takeda Royalty Term, as applicable. 

1.99    “Sole Inventions” shall have the meaning set forth in Section 9.1. 

1.100    “(Sub)licensees” of a Party shall mean any Third Party that has been granted a license or
sublicense by such Party (or such Party’s Affiliates or other (Sub)licensees) to Exploit the Compound or any Product. For the sake of clarity, (a) Takeda, its Affiliates, and any Third Party to which Takeda and/or its Affiliates grants
such a license or sublicense shall not be deemed a (Sub)licensee of Licensee (unless, and only to the extent that, such Third Party is granted such a licensee or sublicense by Licensee, its Affiliates, or (Sub)licensee, including after expansion of
the Territory pursuant to Section 7.1(b), as applicable), and (b) Licensee, its Affiliates, and any Third Party to which Licensee and/or its Affiliates grants such a license or sublicense shall not be deemed a (Sub)licensee of Takeda
(unless, and only to the extent that, such Third Party is granted such a licensee or sublicense by Takeda, its Affiliates, or (Sub)licensee, including after termination of this Agreement, as applicable). 

1.101    “TAK-214” means the product under development as of the
Effective Date by Takeda and coded by Takeda as TAK-214, which is an intramuscular norovirus bivalent virus-like particle (“VLP”) vaccine adjuvanted with Aluminum Hydroxide [Al(OH)3] and
contains two norovirus VLPs, one containing a GI.1 genogroup sequence (GI.1VLP) and the other containing a GII.4 genogroup sequence (Takeda’s GII.4 VLP has a composite sequence based on three different GII.4 norovirus genotypes and is referred
to as GII.4c). 
 1.102    “Takeda Compound Patents” means (a) the Patents set forth on Exhibit D
as of the Effective Date and listed as Takeda Compound Patents therein, and any provisionals, substitutions, divisionals, continuations, continuations in-part, renewals, registration or confirmation patents,
patents resulting from post-grant proceedings, re-issues, re-examinations, patents of addition, restorations, extensions, or supplementary protection certificates of
such Patents, and (b) all other Patents Controlled by Takeda or its Affiliates as of the Effective Date or during the Term which 

  
 - 12 - 

 
[***] claim the composition of matter of, formulation of, or a method of making or using the Compound or Product. Takeda shall update Exhibit D from time to time as necessary to include future
Takeda Compound Patents and provide a copy thereof to Licensee. 
 1.103    “Takeda Fiscal Year” means
the twelve (12) month period commencing on April 1 ending on March 31; provided, however, that (a) the first Takeda Fiscal Year of the Term shall begin on the Effective Date and end on March 31, 2022; and (b) the last Takeda
Fiscal Year of the Term shall end on the date of expiration or termination of this Agreement. 

1.104    “Takeda General Patents” means (a) the Patents set forth on Exhibit D as of the Effective
Date and listed as Takeda General Patents therein, (b) any provisionals, substitutions, divisionals, continuations, continuations in-part, renewals, registration or confirmation patents, patents resulting
from post-grant proceedings, re-issues, re-examinations, patents of addition, restorations, extensions, or supplementary protection certificates of the patents in
subsection (a) above, [***], (c) all other Patents that claim any [***] useful to Exploit the Compound or Product [***], and (d) all other Patents Controlled by Takeda or its Affiliates as of the Effective Date or during the Term that are
not Takeda Compound Patents, but that (i) are necessary to Exploit the Compound or Product in the Field in the Territory, or (ii) claim the composition of matter of, formulation of, or a method of making or using the Compound or Product.
[***]. The Takeda General Patents as of the Effective Date are set forth in Exhibit D. Takeda shall update Exhibit D from time to time as necessary to include future Takeda General Patents and provide a copy thereof to Licensee. For the avoidance of
doubt, for the purpose of this Agreement, patents having been assigned Takeda’s internal case number P20930 (US 10,501,500 and equivalents thereof, as listed in Exhibit D) are deemed Takeda General Patents, not Takeda Compound Patents.

1.105    “Takeda Indemnitee” shall have the meaning set forth in Section 15.1. 

1.106    “Takeda Intellectual Property” means, collectively, Takeda
Know-How and Takeda Patents. For the sake of clarity, Takeda Intellectual Property does not include any rights granted to Takeda under the Life Technologies Agreement. 

1.107    “Takeda Know-How” means collectively (a) any
Information Controlled by Takeda or its Affiliates (other than Licensee Know-How licensed to Takeda) as of the Effective Date that are necessary to Exploit a Compound or Product in the Field and (b) any
Information which first become Controlled by Takeda or its Affiliates after the Effective Date that are directed to a Compound or Product in the Field, including any Information disclosed by Takeda to Licensee under Section 12.2. Takeda Know-How excludes any (i) Information contained within a Takeda Patent, and (ii) any Information licensed to Takeda under the Life Technologies Agreement. 

1.108    “Takeda Patents” means the Takeda Compound Patents and the Takeda General Patents. 

1.109    “Takeda Product Trademark” and “Takeda Product Trademarks” (collectively
“Takeda Product Trademark(s)”) means the Trademark or Trademarks to be owned and used by Takeda or its Affiliates or its (Sub)licensees for the Exploitation of Products in the Field outside the Territory and any registrations thereof or
any pending applications relating thereto (excluding, in any event, any trademarks, service marks, names or logos that include any corporate name or logo of the 

  
 - 13 - 

 
Parties or their Affiliates). Notwithstanding anything to the contrary in this Agreement, Takeda Product Trademarks will not include any Product Trademarks. 

1.110    “Takeda Royalty Term” means, on a country-by-country and Product-by-Product basis, the period commencing on the First Commercial Sale of a Product by Takeda, its
Affiliates or (Sub)licensees in such country outside of the Territory and continuing until the later of: 

(a)    the expiration of the last to expire Valid Claim in a Licensee Patent or Joint Patent covering the
composition of matter, Manufacture or approved use of the Compound or such Product in such country; 

(b)    the expiration of the applicable Regulatory Exclusivity in such country; or 

(c)    [***] after First Commercial Sale of such Product by Takeda, its Affiliates or (Sub)licensees in
such country. 
 1.111    “Takeda Third Party License” has the meaning set forth in
Section 8.7(e). 
 1.112    “Takeda Third Party Royalties” shall have the meaning set forth in
Section 8.7(e). 
 1.113    “Tax” or “Taxes” shall mean any form of tax or
taxation, levy, duty, charge, social security charge, contribution or withholding of whatever nature (including any related fine, penalty, surcharge or interest) imposed by, or payable to, any government, state or municipality, or any local, state,
federal or other fiscal, revenue, customs, or excise authority, body or official. 

1.114    “Territory” means worldwide, excluding Japan. Pursuant to Section 7.1(b), the Territory may
be expanded to be worldwide. In such event, “Territory” will mean worldwide effective as of the effective date of such expansion pursuant to Section 7.1(b). 

1.115    “Term” shall have the meaning set forth in Section 13.1. 

1.116    “Third Party” means a Person other than Takeda and Licensee and their respective Affiliates.

 1.117    “Top-Line Data” means, with respect to a Clinical
Trial, a summary of demographic data, the data for the primary endpoint(s), the data for any secondary endpoint(s), if such secondary endpoint(s) are applicable, and a summary of safety data, in each case which are based on an unblinded, locked
database and wherein all data are collected in a 21 CFR 11 validated database with a complete audit trail. 

1.118    “Trademark” means (a) any word, name, symbol, color, designation or device or any
combination thereof that functions as a source identifier, including any trademark, trade dress, brand mark, service mark, trade name, brand name, logo, business symbol or domain names, whether or not registered, or any application, renewal,
extension, or modification thereto; and (b) all goodwill associated therewith. 
 1.119    “Transfer
Plan” means the transfer plan set forth in Exhibit E. 

  
 - 14 - 

 1.120    “Transitional Services Agreement” means any
Transitional Services Agreement entered into between the Parties after the Effective Date. 
 1.121    “Up-Front Shares” shall have the meaning set forth in Section 2.2(a). 

1.122    “U.S. Government Rights” means collectively, any and all rights the federal government of the
United States or any agency thereof may have to Takeda Intellectual Property conceived, discovered, developed, or otherwise made under the Takeda U.S. Government Contracts listed in Exhibit N. 

1.123    “Valid Claim” means (a) a claim of an issued and unexpired Patent included within the
Takeda Patents, the Licensee Patents or the Joint Patents, to the extent such claim has not been revoked, held invalid or unenforceable by a patent office, court or other governmental agency of competent jurisdiction in a final order, from which no
further appeal can be taken, and which claim has not been disclaimed, denied or admitted to be invalid or unenforceable through reissue, re-examination or disclaimer; or (b) a claim of any patent
application (where such claim was filed in good faith and where no reasonable arguments against patentability of such claim are known) within the Takeda Patents, the Licensee Patents or the Joint Patents, to the extent such claim has not been
canceled, withdrawn, or abandoned or pending for more than [***] from its earliest priority date. A claim of a Patent licensed to a Party under this Agreement will not cease to be considered a Valid Claim for the purpose of this Agreement if
the revocation of such claim or such claim being held invalid or unenforceable is caused by any action of such Party or any of its Affiliates or (Sub)licensees. 

1.124    “VLPs” means virus-like particles. 

1.125    “Warrant” shall have the meaning set forth in Section 2.2(b). 

ARTICLE 2 – UP-FRONT EQUITY AND WARRANTS 

2.1    Up-Front Equity and Warrant. 

(a)    Up-Front Equity. In partial consideration for
Licensee’s rights in and to the Takeda Intellectual Property licensed hereunder and other rights granted hereunder, on or before the Effective Date, Licensee will issue and deliver to Takeda Five Hundred Thousand (500,000) shares (the
“Up-Front Shares”) of Common Stock, par value $0.0001 (“Common Stock”), which represents [***] of the Fully-Diluted Capitalization calculated immediately prior to the
closing of the Qualified Financing (and, for the avoidance of doubt, excluding any Series A preferred stock and any convertible promissory notes that are converted into the securities issued in the Qualified Financing). To implement the issuance of
the Up-Front Shares, the Parties shall execute and deliver to one another a Stock Issuance Agreement in the form attached hereto as Exhibit F. The Up-Front Shares shall
be of the same class as the initial founders’ shares of Common Stock issued to Frazier Life Sciences X, L.P. (the “Frazier Up-Front Shares”). 

(b)    Warrant Coverage. In partial consideration for Licensee’s rights in and to the Takeda
Intellectual Property licensed hereunder and other rights granted hereunder, on the Effective Date, Licensee will issue to Takeda a warrant to purchase additional shares of Common Stock with an exercise price equal to the par value of $0.0001 per
share, in the form attached hereto 

  
 - 15 - 

 
as Exhibit G (the “Warrant”). The number of shares of Common Stock subject to the Warrant shall be equal to [***] of the Fully-Diluted Capitalization calculated
immediately prior to the closing of the Qualified Financing (and, for the avoidance of doubt, excluding any Series A preferred stock and any convertible promissory notes that are converted into the securities issued in the Qualified Financing). The
Warrant will be exercisable by Takeda on a cashless, net-exercise basis as more particularly set forth in the Warrant.       

(c)    Additional Warrant Coverage; Minimum IPO Ownership. In partial consideration for
Licensee’s rights in and to the Takeda Intellectual Property licensed hereunder and other rights granted hereunder, in the event that the shares of Common Stock issued to Takeda pursuant to Section 2.1(a) and issued or issuable upon
cashless, net exercise of the Warrant issued pursuant to Section 2.1(b) together represent less than [***] of the Fully-Diluted Capitalization calculated immediately prior to the earlier of a Licensee Change of Control or the closing of the
first underwritten initial public offering of the Common Stock (including, for the avoidance of doubt, any Series A preferred stock and any shares of Common Stock issued upon conversion of convertible promissory notes that are issued in the
Qualified Financing, but excluding shares of Common Stock newly issued in such initial public offering itself) then Licensee shall issue an additional Warrant to Takeda upon such Licensee Change of Control or the closing of such initial public
offering. The number of shares of Common Stock subject to such additional Warrant shall be calculated such that the additional shares issuable upon cashless, net exercise of such additional Warrant, together with the shares of Common Stock issued to
Takeda pursuant to Section 2.1(a) and issued or issuable upon cashless, net exercise of the Warrant issued pursuant to Section 2.1(b), represent an aggregate of [***] of the Fully-Diluted Capitalization calculated immediately prior to, as
applicable, such Licensee Change of Control or the closing of the first underwritten initial public offering of the Common Stock (including, for the avoidance of doubt, any shares of Common Stock issued upon any conversion of convertible promissory
notes and any Series A preferred stock that are issued in the Qualified Financing, but excluding shares of Common Stock newly issued in such initial public offering itself). 

(d)    Exercise of Warrant. The Warrants will be exercisable as set forth therein. 

(e)    Ancillary Documents. Takeda shall be required to enter into any agreements related to
the Common Stock that Frazier Life Sciences X, L.P. is required to enter into in connection with the Qualified Equity Financing related to the Frazier Up-Front Shares. 

(f)    No Partnership Interest. Licensee and Takeda hereby acknowledge they do not intend to create
a partnership interest for Takeda under U.S. tax laws by reason of Licensee’s issuance of the Warrant. 
 ARTICLE 3 – FINANCIAL
STATEMENTS 
 3.1    Licensee Financial Statements. Licensee shall provide Takeda with [***]. 

ARTICLE 4 – LICENSES AND ASSIGNMENT 

4.1    Licenses from Takeda to Licensee. Subject to the terms and conditions of this Agreement and
subject to any U.S. Government Rights, Takeda on behalf of itself and its Affiliates hereby 

  
 - 16 - 

 
grants to Licensee (a) an exclusive (even as to Takeda and its Affiliates), nontransferable (except as provided in Section 16.4), royalty-bearing license, with the right to grant
sublicenses solely in accordance with Section 4.3, under the Takeda Intellectual Property and Takeda’s rights to the Joint Intellectual Property, solely to Commercialize Products in the Field in the Territory, (b) a non-exclusive, nontransferable (except as provided in Section 16.4) license, with the right to grant sublicenses solely in accordance with Section 4.3, under the Takeda Intellectual Property and
Takeda’s rights to the Joint Intellectual Property, to Develop Compounds and Products anywhere in the world (subject to Takeda’s prior written consent, not to be unreasonably withheld, conditioned or delayed, with respect to any Clinical
Trials outside of the Territory, which Takeda hereby grants with respect to the Licensee Japan Development Activities) and Manufacture Compounds and Products anywhere in the world, in each case, solely (i) for the Exploitation of Compounds and
Products in the Field in the Territory, (ii) to perform the Licensee Japan Development Activities, or (iii) to supply Product to Takeda pursuant to any Clinical Supply Agreement or Commercial Supply Agreement, and (c) a worldwide, non-exclusive, fully paid-up, royalty-free, non-transferable (except as provided in Section 16.4) license, with the right to
sublicense through multiple tiers, under Takeda’s rights to the Joint Intellectual Property, to Exploit compounds (other than the Compound) and products (other than the Product and other norovirus vaccines, including Competing Products).
Notwithstanding any language to the contrary, Takeda retains (x) the right to Develop and Manufacture Compound and Product anywhere in the world, including inside the Territory (subject to Licensee’s prior written consent, not to be
unreasonably withheld, conditioned or delayed, with respect to any Clinical Trials in the Territory), (y) the exclusive right to Commercialize the Compound and Product outside of the Territory, and (z) the exclusive right to Commercialize the
Compound and Product outside of the Field.    Except to the extent prohibited or required by Applicable Law, the Licensee shall be responsible, [***], for all recordals of the licenses granted to it under this Agreement,
including all filing and other actions required to make such recordals, [***]. 
 4.2    Licenses and Grant-Back Sub-Licenses from Licensee to Takeda. 
 (a)    Subject to the
terms and conditions of this Agreement, Licensee hereby grants to Takeda (i) a limited, non-exclusive, non-transferable (except as provided in Section 16.4),
fully paid-up, royalty-free, license, with the right to grant sublicenses solely in accordance with Section 4.3, under the Licensee Intellectual Property and Licensee’s rights to the Joint
Intellectual Property that is necessary or useful to enable Takeda to Develop and Manufacture the Compound and Products anywhere in the world (but with respect to Clinical Trials inside the Territory, subject to the second sentence of
Section 4.1) solely for Commercialization of Products in the Field outside the Territory and to perform its obligations under this Agreement, (ii) a limited, exclusive, non-transferable (except as
provided in Section 16.4), royalty-bearing license, with the right to grant sublicenses solely in accordance with Section 4.3, under the Licensee Intellectual Property and Licensee’s rights to the Joint Intellectual Property, to
(1) Commercialize Products outside of the Territory and (2) Commercialize Products outside of the Field, (iii) a worldwide, non-exclusive, fully paid-up,
royalty-free, non-transferable (except as provided in Section 16.4) license, with the right to further sublicense through multiple tiers, under Licensee’s rights to the Joint Intellectual Property,
to Exploit compounds (other than the Compound) and products (other than the Product and other norovirus vaccines, including Competing Products), and (iv) an exclusive nontransferable (except as provided in Section 16.4) license, with the
right to grant sublicenses 

  
 - 17 - 

 
solely in accordance with Section 4.3 to use the Product Trademark(s) solely for Commercialization of a Product in the Field outside of the Territory.     

(b)    Subject to the terms and conditions of this Agreement, Licensee hereby grants back to Takeda a
limited, exclusive, fully paid-up, royalty-free, non-transferable (except as provided in Section 16.4) sublicense, with the right to further sublicense solely in
accordance with Section 4.3, under the Takeda Intellectual Property and Takeda’s rights to the Joint Intellectual Property solely as, and to the extent necessary or useful, to enable Takeda in the Field in the Territory, to exercise its
express rights and perform its obligations under this Agreement and the Ancillary Agreements. 

4.3    Sublicensing. 

(a)    [***], Licensee shall have the right to grant sublicenses to Commercialize the Product in the Field
in the Territory, through multiple tiers, under the rights granted to Licensee under Section 4.1, to its Affiliates and to one or more Third Parties. Licensee shall have the right to grant sublicenses to its rights to Develop and Manufacture
the Compound and Product (i) to its Affiliates, with the right to sublicense in accordance with this Section 4.3(a), (ii) to any Third Party to whom Licensee, in accordance with the previous sentence, has granted a sublicense to
Commercialize the Product in the Field in the Territory, and (iii) to one or more vendors, contract research organizations and the like to the extent necessary or useful to Develop and/or Commercialize the Product in accordance with
Licensee’s express rights under this Agreement; provided that the right to grant sublicenses to Takeda General Patents shall be limited to the extent needed for manufacturing the Compound and Product for Exploitation in the Field in the
Territory. 
 (b)    Takeda shall have the right to grant one or more licenses or sublicenses, as the
case may be, under the rights granted to Takeda under Section 4.2, (i) to its Affiliates, with the right to sublicense in accordance with this Section 4.3(b), (ii) to any Third Party, provided that Takeda and its Affiliates may not
sublicense all or substantially all Commercialization rights to the Product outside of the Territory without Licensee’s prior written consent, which consent shall not be unreasonably withheld, conditioned or delayed, and (iii) to one or
more vendors, contract research organizations and the like, to the extent necessary or useful to Develop and/or Commercialize the Product in accordance with Takeda’s express rights under this Agreement. 

(c)    Each sublicense shall refer to and be subordinate to this Agreement and, except to the extent the
Parties otherwise agree in writing, any such sublicense must be consistent in all material respects with the terms and conditions of this Agreement. Each Party shall remain responsible for the performance of this Agreement and the performance of its
(Sub)licensees hereunder. 
 (d)     Upon an early termination of Licensee’s license rights under
this Agreement [***]. [***]. 
 4.4    No Implied Licenses. No license or other right is or shall be
created or granted hereunder by implication, estoppel, or otherwise. All licenses and rights are or shall be granted only as expressly provided in this Agreement. All rights not expressly granted by a Party under this Agreement are reserved by the
Party and may not be used by the other Party for any purpose. 

  
 - 18 - 

 4.5     Exports and Restrictions on Competition. 

(a)    Exports. Licensee shall neither, and shall cause its Affiliates and (Sub)licensees to
neither, whether directly or indirectly through a Third Party, (i) sell or promote a Product outside of the Field or outside of the Territory, nor (ii) export or distribute a Product outside of the Territory other than for Exploitation in
the Field in the Territory. 
 (b)    Competing Product Activities. During the Term, each Party
shall not, and shall cause its Affiliates not to, whether directly or indirectly through a Third Party (including any (Sub)licensee), without the other Party’s prior written consent, Commercialize any Competing Product anywhere in the world.

 4.6    Assignment of Life Technologies Agreement. On the Effective Date the Parties shall execute the Life
Technologies Assignment Agreement, which shall be effective as of the Effective Date. Notwithstanding any language to the contrary, except for the previous sentence, none of the terms of this Agreement, including Article 10, shall apply with respect
to the Life Technologies Agreement, including any rights or licenses thereunder to Information or other intellectual property. Takeda shall have obtained from Life Technologies an acknowledgement for such assignment in the form set forth on Exhibit
M. 
 4.7    Government Rights and Reservation.    Licensee acknowledges and
agrees that the rights under this Agreement are subject to certain rights required to be granted to the Government of the United States of America. These U.S. Government Rights include, without limitation, a nonexclusive, nontransferable,
irrevocable, paid-up license to practice or have practiced throughout the world for or on behalf of the United States the Takeda Intellectual Property generated, developed, or “made” under the Takeda
Government Contracts listed in the leftmost column of the table included in Exhibit N (the “Takeda Government Contracts”). For clarity, these U.S. Government Rights do not include rights to [***]. 

ARTICLE 5 – DEVELOPMENT AND SUPPLY 

5.1    Overview of Product Development. Each Party’s Development of the Compound and the Product in the Field
in or for its respective territory and Licensee’s performance of the Licensee Japan Development Activities shall be conducted in a manner consistent with the principle of seeking and maintaining Regulatory Approvals in the Field in such
Party’s respective territory (and in Japan with respect to Licensee’s performance of the Licensee Japan Development Activities) that include the appropriate Labeling for the Product in light of the clinical data. [***], Licensee shall
notify Takeda so that Licensee and Takeda can discuss in good faith whether such data support conducting immuno-bridging Clinical Trials to obtain Regulatory Approval of the Product for non-infant (including
children up to 18 years old, adults and older adults 65 years of age and older) populations. After such discussions between the Parties, Licensee shall determine whether the clinical data support conducting such immuno-bridging Clinical Trials,
provided that Licensee will consider in good faith any comments of Takeda with respect to such determination. If Licensee determines that the clinical data support conducting such immuno-bridging Clinical Trials, then as soon as is reasonably
practical after making such determination, Licensee shall seek advice from the key Regulatory Authorities (e.g.; FDA, EMA, and PMDA) regarding the acceptability of immune-bridging Clinical Trials to obtain Regulatory Approval of the Product
for 

  
 - 19 - 

 
non-infant (including children up to 18 years old, adults and older adults 65 years of age and older) populations (the “Immuno-Bridging Regulatory
Authority Consultations”). Licensee shall (1) notify Takeda in advance any Immuno-Bridging Regulatory Authority Consultations, (2) consider in good faith any advice provided by Takeda with respect to any Immuno-Bridging Regulatory
Authority Consultations, (3) unless prohibited by the PMDA, allow Takeda to attend any such meetings (including telephone and web meetings) with the PMDA regarding Immuno-Bridging Regulatory Authority Consultations, and (4) keep Takeda
informed in a timely manner of any communications from or to the applicable Regulatory Authority regarding all Immuno-Bridging Regulatory Authority Consultations. 

5.2    Licensee and Takeda Development. Licensee (itself or through its Affiliates or (Sub)licensees) shall be
solely responsible for: (a) all of Licensee’s, and its Affiliates’ and their respective (Sub)licensees’ and Third Party contractors’ activities related to the Development of the Compound and the Product in the Field for
Commercialization in the Territory; and (b) all expenses, including Third Party expenses, related to such Development activities. In addition, Licensee shall, [***], conduct the Licensee Japan Development Activities in accordance with this
Agreement and the Initial Development Plan, as the Licensee Japan Development Activities may be amended pursuant to Section 5.4. If Takeda determines that any other Development activities (including Clinical Trials) other than the Licensee
Japan Development Activities are needed or helpful to obtain Regulatory Approval in Japan, then Takeda shall notify Licensee. Unless the Parties agree otherwise in writing, Takeda shall be responsible for the performance of such other Development
activities which are needed or helpful to obtain Regulatory Approval in Japan. Except for the Licensee Japan Development Activities or as otherwise expressly agreed by the Parties in writing, Takeda (itself or through its Affiliates or
(Sub)licensees) shall be solely responsible for: (i) all of Takeda’s, and its Affiliates’ and their respective (Sub)licensees’ and Third Party contractors’ activities related to the Development of the Compound and the
Product in the Field for Commercialization outside of the Territory; and (ii) all expenses, including Third Party expenses, related to such Development activities. 

5.3    Development Efforts. Licensee shall use Commercially Reasonable Efforts to Develop the Compound and the
Product in order to Commercialize the Product in the Field in the Territory, including Development for non-infant (including children up to 18 years old, adults and older adults 65 years of age and older)
populations. Based on the results of the Immuno-Bridging Regulatory Authority Consultations, Licensee shall, after discussions with Takeda and in good faith taking into consideration Takeda’s comments and suggestions provided during such
discussions, have the right to determine whether to pursue immune-bridging Clinical Trials as a pathway to seek Regulatory Approval in the Territory of the Product for non-infant (including children up to 18
years old, adults and older adults 65 years of age and older) populations, provided that when making such determination Licensee shall take into account Japan as if it were part of the Licensee’s Territory. 

5.4    Development Plan. 

(a)    Initial Development Plan and Updates. The Initial Development Plan is set
forth in Exhibit A. [***], Licensee shall update and amend, as appropriate, the then-current Development Plan and shall provide a copy of a proposed updated and amended Development Plan to Takeda. Licensee shall provide Takeda with an opportunity to
review and 

  
 - 20 - 

 
comment on the proposed updated and amended Development Plan. Licensee shall consider in good faith any such comments of Takeda when finalizing the updated and amended Development Plan. [***]
after finalizing the updated and amended Development Plan, Licensee shall provide a copy thereof to Takeda. The Development Plan will include the Licensee Japan Development Activities. Notwithstanding any language to the contrary, without
Takeda’s prior written consent, Licensee may neither update nor amend any of the Licensee Japan Development Activities in any updated or amended Development Plan. 

(b)    Phase 1 Clinical Trials and Materials. Unless the Parties otherwise agree in
writing, Licensee shall conduct, in accordance with Initial Development Plan, the immunogenicity Phase 1 Clinical Trial in Japanese healthy volunteers designed to meet PMDA criteria; provided that if the PMDA requires in such immunogenicity Phase 1
Clinical Trial the use of a formulation of Product that is different from whichever formulation of Product that Licensee utilizes for its pediatric Phase 2/Phase 3 Clinical Trials    Takeda supplies Licensee at Takeda’s cost
sufficient supply of such different PMDA required formulation of Product as reasonably required for the performance of such immunogenicity Phase 1 Clinical Trial unless otherwise agreed by the Parties. 

(c)    Phase 1 Clinical Trials Cost and Time Overruns. Licensee shall [***] notify
Takeda if Licensee, in good faith, anticipates that (i) Licensee will incur more than [***], or (ii) despite Licensee’s use of Commercially Reasonable Efforts (as if Japan were part of the Territory), Licensee will not be able to
complete such immunogenicity Phase 1 Clinical Trial prior to [***]. In any notice of an anticipated Phase 1 Cost Overrun, Licensee shall identify the additional costs and expenses Licensee in good faith expects to be incurred by Licensee in order to
complete such immunogenicity Phase 1 Clinical Trial (including as evidenced by proposals from Third Party contractors to the extent available). After Takeda’s receipt of any such notice of an anticipated Phase 1 Cost Overrun, Takeda shall have
the option, in its sole discretion, of either agreeing to reimburse Licensee for such identified additional costs and expenses or declining to reimburse Licensee for such costs and expenses. If Takeda does not provide written notice to Licensee that
Takeda elects to reimburse Licensee for such identified additional costs and expenses within [***] after Takeda’s receipt of any such notice of an anticipated Phase 1 Cost Overrun, then Takeda will be deemed to have elected to decline to
reimburse Licensee for such identified additional costs and expenses. In any notice of an anticipated Phase 1 Time Overrun, Licensee shall include the additional details regarding the causes of the anticipated Phase 1 Time Overrun and the expected
timing to complete such immunogenicity Phase 1 Clinical Trial.    After Takeda’s receipt of any such notice of a Phase 1 Time Overrun, Takeda and Licensee shall in good faith discuss whether to make any amendments to the
Licensee Japan Development Activities, including to extend the time period for such immunogenicity Phase 1 Clinical Trial. Notwithstanding anything to the contrary in this Agreement, Licensee shall not be required to perform such immunogenicity
Phase 1 Clinical Trial if (x) Licensee provides a notice of an anticipated Phase 1 Cost Overrun in accordance with this section and Takeda elects to decline to reimburse Licensee for the additional costs and expenses set forth in such notice,
or (y) despite Licensee’s use of Commercially Reasonable Efforts (as if Japan were part of the Territory) such immunogenicity Phase 1 Clinical Trial cannot be completed prior to the second anniversary of the first activation of a clinical
site for such immunogenicity Phase 1 Clinical Trial unless the Parties mutually agree to amend the Licensee Japan Development Activities to extend the time period for completing the immunogenicity Phase 1 Clinical Trial. 

  
 - 21 - 

 (d)    Inclusion of Japanese Subjects
in Phase 3 and Immuno-bridging Trials. Licensee will use Commercially Reasonable Efforts (as if Japan were part of the Licensee’s Territory) to include in (i) Licensee’s Phase 3 Clinical Trial (Phase 3 portion
if Licensee conducts Phase 2b /Phase 3 Clinical Trials) for the Product, the number of Japanese subjects suggested by the PMDA after consultations with the PMDA, and (ii) any immuno-bridging Clinical Trial conducted by Licensee for the Product,
the number of Japanese subjects suggested by the PMDA after consultations with the PMDA; provided that inclusion of such Japanese subjects in either such Clinical Trial does not materially delay or adversely impact the conduct of Licensee’s
Development of the Product for the Territory. As set forth in Section 6.1(b), Takeda shall timely provide necessary assistance reasonably requested by Licensee in connection with the Licensee Japan Development Activities. Takeda will reimburse
Licensee for [***]. 
 (e)    Inability to Perform Licensee Japan Development
Activities. In the event that Licensee in good faith believes that it cannot perform one or more of the Licensee Japan Development Activities, Licensee shall [***] notify Takeda of the activity Licensee believes it cannot perform and the reasons
therefor. After receipt of any such notice, Takeda and Licensee shall discuss in good faith such matter including whether to make any amendments to the Licensee Japan Development Activities. Notwithstanding any language to the contrary,
Licensee’s providing of such notice shall in no way relieve Licensee of its obligations to perform the Licensee Japan Development Activities in accordance with the terms of this Agreement. 

5.5    Transfer of Information and Assistance. In accordance with the Transfer Plan set forth in Exhibit E, Takeda
will (i) after consummation of the Qualified Financing, transfer any currently existing Product INDs and other regulatory authorizations for the Compound in the Territory, (ii) after consummation of the Qualified Financing, transfer any
regulatory authorizations, if any, currently held by Takeda in Japan that Licensee and Takeda mutually agree (such agreement not to be unreasonably withheld, conditioned or delayed) are required by Licensee in order for Licensee to perform the
Licensee Japan Development Activities, (iii) transfer to Licensee the existing technical and clinical Information for the Compound and Product identified on Exhibit E at no charge, and (iv) provide reasonable assistance from and access to
Takeda employees with relevant knowledge related to the Compound and Product, including technical transfer of the manufacturing process and assays to Licensee or its Third Party manufacturer. Takeda shall provide Licensee, without charge, up to a
total aggregate of [***] of assistance and access described in subsection (iv) above. Once such total aggregate [***] has been reached, Takeda shall not have any obligation to provide any additional assistance or access and accordingly any
additional reasonable requests for support made by Licensee may be provided at Takeda’s sole discretion and, if provided by Takeda, [***].    Except as expressly provided under the Transfer Plan, Takeda shall not be
obligated to provide a technical transfer of the current Manufacturing process for the Compound or Product to Licensee or its designated Third Party manufacturer. Notwithstanding anything to the contrary, the time limitations and hourly charges set
forth in this Section 5.5, above, shall not apply with respect to the performance of any of Takeda’s obligations expressly set forth in this Agreement (other than the transfer, assistance and access described in this Section 5.5,
above). In addition to any Information disclosed pursuant to Article 12, during the Term, (i) at either Party’s reasonable request, the other Party will cooperate with the requesting Party to transfer any technical and clinical data for
the Compound and Product developed after the 

  
 - 22 - 

 
Effective Date, (ii) each Party will have the right to access and, in accordance with the terms of this Agreement, use such data, and, in accordance with Section 6.3, to reference the
other Party’s Regulatory Materials, for use in connection with the Exploitation of the Compound and Product in such Party’s respective territory, and (iii) Licensee shall also provide Takeda with all necessary Information in
Licensee’s or any of its Affiliate’s Control that is requested by Takeda and that is needed to support Regulatory Material filing requirements outside the Territory. 

5.6    Clinical Supply Agreement. In accordance with the Clinical Supply Agreement attached as Exhibit C and the
Quality Agreement set forth in the Clinical Supply Agreement, Takeda may supply the specific quantity of Clinical Trial materials set forth therein to Licensee, for use in the pediatric Phase 2 Clinical Trials and the Phase 1 Clinical Trial in
healthy Japanese subjects set forth in the Initial Development Plan, and [***]. Takeda’s inability to supply the same as set forth in the Clinical Supply Agreement shall not constitute a breach of Takeda’s obligations under this Agreement
or any of the Ancillary Agreements. Licensee shall be solely responsible for the Manufacture and supply of any and all additional quantities of Product needed by Licensee, including all additional Clinical Trial materials and Product for
Commercialization. If Takeda is required to or elects to perform any additional Clinical Trials outside the Territory beyond the Licensee Japan Development Activities, then the Parties shall use good faith efforts to enter into a supply agreement
whereby Licensee would supply Takeda with the quantity of Clinical Trial materials needed for such additional Clinical Trials. The terms of any such supply agreement shall be negotiated in good faith by the Parties based upon reasonable and
customary terms typically associated with supply of Clinical Trial materials utilizing, as appropriate, terms from the Clinical Supply Agreement attached hereto as Exhibit C . 

5.7     Commercial Supply. 

(a)    If requested by Takeda, the Parties shall use good faith efforts to enter into a supply agreement
governing the supply of Product by Licensee (directly or indirectly through its Affiliate(s) or its Third Party manufacturer) to Takeda for Commercialization in the Field outside of the Territory (the “Commercial Supply Agreement”).
The terms of any such Commercial Supply Agreement shall be negotiated in good faith by the Parties based upon reasonable and customary terms typically associated with supply of pharmaceutical products for Commercialization, including reasonable and
customary forecasting and ordering provisions, the Product pricing as set forth in Section 5.7(b), an obligation of Licensee to ensure that Licensee (including through its Affiliate(s) or any Third Party manufacturer) will have sufficient
capacity and capability to supply Product both for Licensee for the Territory and for any amounts forecasted by Takeda pursuant to the terms of the Commercial Supply Agreement, and an obligation for Takeda to reimburse Licensee for any reasonable
incremental direct costs incurred by Licensee, including any Third Party Manufacturer expenses, in connection with capital expenditures and other Manufacturing related activities required in order to meet any amounts forecasted by Takeda pursuant to
the terms of the Commercial Supply Agreement (other than any cost and expenses included in the Product price in the Commercial Supply Agreement or previously reimbursed pursuant to Section 5.7(c)). 

(b)    The Product price in the Commercial Supply Agreement shall be as follows: (i) [***], or (ii) [***].

  
 - 23 - 

 (c)    Prior to execution of the Commercial Supply
Agreement, subject to this Section 5.7(c) below, Licensee will ensure that Licensee (including through its Affiliates or any Third Party manufacturer) will have sufficient capacity and capability to supply Product both for Licensee for the
Territory and for any amounts reasonably estimated by Takeda for Takeda’s sale outside of the Territory; provided that Takeda has provided Licensee with a non-binding good-faith estimate of Takeda’s
Product requirements for sale outside of the Territory (the “Takeda Product Estimate”) and, in accordance with this Section 5.7(c) below, Takeda reimburses Licensee, within [***] after receipt of an invoice therefor, for
[***]. The Takeda Product Estimate shall include (i) the estimated [***] quantity of Product required in the [***]. Takeda shall provide the first Takeda Product Estimate approximately [***] prior to Takeda’s anticipated Product BLA filing
date in Japan and may update the Takeda Product Estimate not more than [***]. If, prior to execution of the Commercial Supply Agreement, it is necessary for Licensee to incur such costs and expenses [***] in order to meet such Takeda Product
Estimate, then Licensee shall notify Takeda of any such costs and expenses expected to be incurred by Licensee, and Takeda shall have the option of either, within [***] after such notification, (A) agreeing to reimburse Licensee for such costs
and expenses (in which case Licensee shall ensure that Licensee (including through its Affiliate(s) or any such Third Party) has sufficient capacity and capability to meet such Takeda Product Estimate) or (B) declining to reimburse Licensee for
such costs and expenses (in which case Licensee shall have no obligation to ensure that Licensee (including through its Affiliates or any such Third Party) has sufficient capacity and capability to meet such Takeda Product Estimate). For the sake of
clarity, (1) unless and until a Commercial Supply Agreement is executed by the Parties, Licensee shall not be under any obligation to supply Product to Takeda for Commercialization, and (2) the Commercial Supply Agreement shall not require
Takeda to reimburse any such costs and expenses incurred by Licensee that Takeda has previously paid Licensee hereunder pursuant to the immediately previous sentence. 

5.8    Records; Disclosure of Data and Results. 

(a)    In conformity with standard pharmaceutical industry practices and the terms and
conditions of this Agreement, each Party shall prepare and maintain, or shall cause to be prepared and maintained, complete and accurate written records of its Development of the Products, for a minimum of [***], Licensee shall provide to Takeda a
reasonably detailed report consisting of (a) an update on the progress of Licensee’s Development and Commercialization activities, including (i) key achievements or milestones to date in the reporting period, and (ii) studies
that were run or are in process and (b) a summary of the planned Development and Commercialization activities for the upcoming [***], such as anticipated commercial launches in various countries and other commercial milestones. At least [***]
prior to the start of each [***], commencing with the first [***], and ending with the [***] in which Regulatory Approval has been obtained for a Product in Japan, Takeda shall provide to Licensee a reasonably detailed report consisting of
(x) an update on the progress of Takeda’s Development and Commercialization activities, including (i) key achievements or milestones to date in the reporting period, and (ii) studies that were run or are in process and (y) [***].

 (b)    As set forth in the Transfer Plan, Takeda will transfer possession and/or
responsibility of certain records to Licensee, including records currently maintained in Third Party storage facilities. [***]. 

  
 - 24 - 

 5.9    Materials Transfer. In
order to facilitate the Development activities contemplated by this Agreement, after consummation of the Qualified Financing, Takeda shall make available (at the Takeda location where currently located or transfer ownership for materials not in
Takeda’s possession) to Licensee the biological materials or chemical compounds set forth on Exhibit O and any additional materials mutually agreed upon by the Parties after the Effective Date (collectively, “Materials”) for
use by Licensee in furtherance of such Development activities. All such Materials will be used only in furtherance of the Development activities conducted in accordance with this Agreement, will not be used or delivered to or for the benefit of any
Third Party, except to or for subcontractors, without the prior written consent of Takeda, and will be used in compliance with all Applicable Law. The Materials supplied under this Agreement must be used with prudence and appropriate caution in any
experimental work because not all of their characteristics may be known. With respect to any Materials made available to Licensee, if requested by Takeda, Licensee shall provide a portion of such Materials to Takeda if Licensee would still have
sufficient remaining quantity for its Development activities. [***.] 
 5.10    
Transitional Services Agreement. The Parties shall use good faith efforts to negotiate and finalize a Transitional Services Agreement within [***] after the Effective Date. 

ARTICLE 6 – REGULATORY 

6.1    Regulatory Materials and Assistance. 

(a)    Licensee shall have the sole right and responsibility, and shall exercise Commercially Reasonable
Efforts, to prepare, obtain, and maintain, as applicable, the Regulatory Materials in the Territory, including the Product INDs and other submissions, and to conduct communications with the relevant Regulatory Authorities, related to or needed for
the Commercialization of Product in the Field in the Territory. Licensee shall have the sole responsibility, and shall exercise Commercially Reasonable Efforts (as if Japan were part of the Licensee’s Territory), to prepare, obtain, and
maintain, as applicable, the Regulatory Materials in Japan, including the Product INDs and other submissions (but excluding any Product BLA), and to conduct communications with the PMDA, in each case related to and as needed to conduct Licensee
Japan Development Activities, provided that with respect to any such Regulatory Materials in Japan, Licensee shall (1) keep Takeda informed in a timely manner, compliant with the reporting requirements of the PMDA, of the notification of any
action by, or notification or other information which it receives from the PMDA to any such Regulatory Materials, (2) allow Takeda to review any such Clinical Trial protocols and other Regulatory Materials and shall consider in good faith any
such comments of Takeda when finalizing any such Clinical Trial protocols and other Regulatory Materials, and (3) unless prohibited by the PMDA, allow Takeda to attend meetings (including telephone and web meetings) with the PMDA. Takeda or its
applicable Affiliate or (Sub)licensees, or any of their Third Party contractors, will be solely responsible for all Regulatory Materials, including the Product INDs, for (i) any Clinical Trials conducted by Takeda in the Territory consented to
by Licensee pursuant to the second sentence of Section 4.1, (ii) Takeda’s, or any of its Affiliates or (Sub)licensees’ or any of their Third Party contractors’ non-clinical Development or
Manufacturing activities in the Territory, and (iii) the 

  
 - 25 - 

 
conduct of any Development activities (other than the Licensee Japan Development Activities) outside of the Territory. Except with respect to any Clinical Trials conducted by Takeda in the
Territory consented to by Licensee pursuant to the second sentence of Section 4.1, all Product INDs generated after the Effective Date with respect to the Product in the Field in the Territory under this Agreement shall be owned by, and shall
be the sole property and held in the name of, Licensee or its designee. Except with respect to (x) any Clinical Trials conducted by Licensee outside of the Territory consented to by Takeda pursuant to subsection (b) of the first sentence
of Section 4.1, and (y) any Clinical Trials conducted by Licensee in Japan for the Licensee Japan Development Activities, all Product INDs generated after the Effective Date with respect to the Product in the Field outside of the Territory
under this Agreement shall be owned by, and shall be the sole property and held in the name of, Takeda or its designee. All Product INDs for any Clinical Trials conducted by Licensee in Japan with respect to the Licensee Japan Development Activities
shall be owned by, and shall be the sole property and held in the name of Licensee or its designee (the “Licensee Japan INDs”), but may be transferred to Takeda pursuant to Section 6.1(c). 

(b)    Takeda shall provide advice as reasonably requested by Licensee in connection with any regulatory
activities that are required to be performed in order to conduct the Licensee Japan Development Activities outside of the Territory, and otherwise reasonably cooperate with Licensee pursuant to Section 6.6 in connection with any meetings with
Regulatory Authorities outside of the Territory. 
 (c)    Takeda shall have the sole and exclusive
right to submit Product BLAs outside of the Territory. Licensee shall provide any assistance reasonably requested by Takeda in preparing the filing of any such Product BLAs, including (i) providing any necessary or reasonably useful documents
or data utilized in Licensee’s (or any of its Affiliates’ or (Sub)licensees’) Product BLAs as soon as reasonably practical after such documents or data, respectively, become available, and (ii) assisting Takeda with responding to
any requests for information from the PMDA in accordance with Section 6.6. If Takeda determines that it is necessary or helpful to own the Licensee Japan INDs for purposes of submitting any INDs, conducting other Development Activities,
including Clinical Trials, or submitting a Product BLA in Japan, then it shall notify Licensee and Licensee shall thereafter cooperate with Takeda to transfer ownership thereof to Takeda as promptly as possible, at Takeda’s cost, taking into
account any impact of such transfer on Licensee’s ability to perform the Licensee Japan Development Activities. 

6.2    Regulatory Expenses. Except with respect to (a) any Clinical Trials conducted by Takeda in the
Territory consented to by Licensee pursuant to the second sentence of Section 4.1, (b) Takeda’s, and any of its Affiliates and (Sub)licensees, and any of their Third Party contractors’ other Development or Manufacturing activities in
the Territory, and (c) any Product IND filing costs required for the performance of the Licensee Japan Development Activities, Licensee shall bear all expenses incurred related to the preparation, maintenance, formatting and filing of the
Regulatory Materials in the Field in the Territory and for the Licensee Japan Development Activities in Japan. Except with respect to (i) any Clinical Trials conducted by Licensee outside of the Territory consented to by Takeda pursuant to
subsection (b) of the first sentence of Section 4.1, (ii) the Licensee Japan Development Activities (except as otherwise provided in the proceeding sentence), and (iii) Licensee’s, and any of its Affiliates and (Sub)licensees,
and any of their Third Party contractors’ other Development or Manufacture activities outside of the Territory, Takeda shall bear all expenses incurred related to the preparation, maintenance, formatting and

  
 - 26 - 

 
filing of the Regulatory Materials outside the Territory. Takeda shall reimburse Licensee for any Product IND filing costs required for the performance of the Licensee Japan Development
Activities within [***] after receipt of an invoice therefor. 
 6.3    Rights of Reference to Regulatory
Materials. Each Party hereby grants to the other Party a right of reference to all Regulatory Materials filed by such Party, its Affiliates or (Sub)licensee for the Products solely for the purpose of seeking, obtaining and maintaining Regulatory
Approvals for, and the Commercialization of, the Products in such other Party’s respective territory. 

6.4    Labeling Information Exchange/Labeling Agreement.    If requested by either Party, the
Parties shall in good faith negotiate the terms of a Labeling agreement that includes methods and/or procedures for sharing information related to Labeling and the management of Labeling information, including CCDS. If the Parties mutually agree
upon such a Labeling agreement it shall be attached hereto as Exhibit H. Subject to any limitations in any such Labeling Agreement, Licensee shall be solely responsible for the review and approval of all Labeling for the Product in the Territory.

 6.5    Pharmacovigilance and Drug Safety Agreement. Within [***] of the Effective Date of this Agreement, the
Parties will enter into a mutually acceptable pharmacovigilance agreement (PVA) setting forth in detail the Parties’ respective obligations with regards to safety data exchange and pharmacovigilance for the Product. The Parties agree to revise
the PVA 1) prior to commencement of any Takeda-sponsored Development Activities in Japan, if Takeda determines such Development Activities are necessary in addition to the Licensee Japan Development Activities, as described in Section 5.2 and
2) for post-marketing surveillance purposes at an appropriate time before the First Commercial Sale of the Product by either Party, its Affiliates, or any of its (Sub)licensees anywhere in the world. In the event of a conflict between any of the
provisions of the PVA and this Agreement in matters of a business, financial or legal nature, the terms of this Agreement shall prevail. For matters of pharmacovigilance, the terms of the PVA shall prevail. 

6.6    Regulatory Authority Communications Received by a Party. 

Each Party shall keep the other Party informed in a timely manner, compliant with the reporting requirements of Regulatory Authorities in their
respective territories (and with respect to the Licensee Japan Development Activities, Licensee shall keep Takeda informed in a timely manner, compliant with reporting requirements of the PMDA), of the notification of any action by, or notification
or other information which it receives from any Regulatory Authority which: (a) raises any material concerns regarding the safety or efficacy of a Compound or a Product; (b) indicates or suggests a potential material liability of either
Party to Third Parties in connection with a Product; (c) is reasonably likely to lead to a recall or market withdrawal of a Product; or (d) relates to expedited and periodic reports of adverse events with respect to a Product, or Product
Complaints, and which may have a material impact on obtaining or maintaining Regulatory Approval or the continued Commercialization of a Product, as then conducted. Each Party shall reasonably cooperate with and assist the other Party in complying
with regulatory obligations and communications, including by providing to such other Party, in a timely manner after a request, Information and documentation in such Party’s possession as may be necessary or helpful for such

  
 - 27 - 

 
other Party to prepare a response to an inquiry from a Regulatory Authority, and by having no more than two (2) of its employees or representatives participate in any meeting with a
Regulatory Authority at such other Party’s reasonable request and expense. Each Party shall provide the other Party in a timely manner with a copy of all correspondence received from a Regulatory Authority specifically regarding the matters
referred to above. 
 6.7    Audit. 

(a)    If a Regulatory Authority desires to conduct an inspection or audit of any Licensee facility or any
Affiliate or Third Party facility under contract with Licensee with regard to a Product, then Licensee shall notify Takeda as soon as practicably possible after receipt of such notification of such audit or inspection and provide copies of any
materials provided to it by the applicable Regulatory Authority; provided, that Licensee shall not be required to notify Takeda of audits or inspections that are of a routine nature or that do not relate to a Product, except where such audits result
in communications or actions of such Regulatory Authority which have an impact upon the Product. In addition, if a Regulatory Authority conducts an unannounced inspection or audit of any Licensee facility or any Affiliate or Third Party facility
under contract with Licensee with regard to a Product, then Licensee shall notify Takeda within twenty-four (24) hours of commencement of such audit or inspection. Licensee shall cooperate, and shall use reasonable efforts to cause the contract
facility to cooperate, with such Regulatory Authority and Takeda during such inspection or audit. Following receipt of the inspection or audit observations of such Regulatory Authority, Licensee shall [***] provide Takeda with a copy of the
inspection or audit report and also provide Takeda with copies of any written communications received from Regulatory Authorities with respect to such facilities in a timely manner after receipt, to the extent such written communications relate to
Products or the Manufacture thereof, and shall prepare the response to any such observations. Licensee shall provide Takeda with a copy of any proposed response to such communications and shall implement Takeda’s reasonable comments with
respect to such proposed response. Licensee agrees to conform its activities under this Agreement to any commitments made in such a response. 

(b)    If a Regulatory Authority in the Territory desires to conduct a GCP inspection or audit of any
Takeda facility or any Affiliate or Third Party facility under contract with Takeda, in each case with regard to any Takeda Clinical Trial Information provided to Licensee under this Agreement that Licensee has submitted to such Regulatory Authority
in the Territory in order to obtain Regulatory Approval of the Product, then Takeda shall notify Licensee as soon as practicably possible after receipt of such notification of such audit or inspection and provide copies of any materials provided to
it by the applicable Regulatory Authority; provided, that Takeda shall not be required to notify Licensee of audits or inspections that are of a routine nature or that do not relate to Licensee’s Regulatory Approval of a Product, except where
such audits result in communications or actions of such Regulatory Authority which have an impact upon Licensee’s Regulatory Approval for Product in the Territory. In addition, if a Regulatory Authority in the Territory conducts an unannounced
GCP inspection or audit of any Takeda facility or any Affiliate or Third Party facility under contract with Takeda, in each case with regard to any Takeda Clinical Trial Information provided to Licensee under this Agreement that Licensee has
submitted to such Regulatory Authority in the Territory in order to obtain Regulatory Approval of a Product, then Takeda shall notify Licensee within [***] of commencement of such audit or inspection. Takeda shall cooperate, and shall use reasonable
efforts to cause the contract facility to cooperate, with 

  
 - 28 - 

 
such Regulatory Authority during such inspection or audit. Following receipt of the inspection or audit observations of such Regulatory Authority, Takeda shall [***] provide Licensee with a copy
of the inspection or audit report and also provide Licensee with copies of any written communications received from Regulatory Authorities with respect to such facilities in a timely manner after receipt, to the extent such written communications
relate to any Takeda Clinical Trial Information provided to Licensee under this Agreement that Licensee has submitted to such Regulatory Authority in order to obtain Regulatory Approval for a Product, and shall prepare the response to any such
observations. Takeda shall provide Licensee with a copy of any proposed response to such communications and shall consider in good faith including Licensee’s reasonable comments with respect to such proposed response. 

ARTICLE 7 – COMMERCIALIZATION 

7.1    Commercialization Efforts.  

(a)    Licensee (itself or through its Affiliates and (Sub)licensees) shall use Commercially Reasonable
Efforts to Commercialize the Product in the Field in the Territory throughout the Term. 
 (b)    If
(i) prior to receipt of Regulatory Approval for a Product in Japan, Takeda has neither performed (neither directly itself, nor indirectly through its Affiliates, any of their (Sub)licenesees or subcontractors, or through Licensee) any Clinical
Trials nor any material regulatory activities with respect to the Product for Japan for [***], other than due to Force Majeure or Licensee’s failure to perform its obligations under this Agreement, the Commercial Supply Agreement, or any other
Ancillary Agreement, including the Licensee Japan Development Activities, or (ii) after receipt of Regulatory Approval for a Product in Japan, Takeda does not use Commercially Reasonable Efforts to Commercialize the Product in the Field in
Japan, then Licensee shall provide Takeda written notice thereof.    If within [***] after Takeda’s receipt of such notice issued by Licensee in accordance with this Section 7.1(b), Takeda, as applicable, (A) with
respect to subsection (i) above, neither commences performing (neither directly itself, nor indirectly through its Affiliates, any of their (Sub)licenesees or subcontractors, or through Licensee) any Clinical Trials nor any material regulatory
activities with respect to the Product for Japan, or (ii) with respect to subsection (ii) above, does not commence using Commercially Reasonable Efforts to Commercialize the Product in the Field in Japan, then the Territory will be
expanded to be worldwide, effective as of the end of such [***] period and the terms of Section 13.7 shall apply. After receipt of any such notice, pursuant to Article 14 Takeda may also dispute whether Licensee had the right to issue such
notice, and if Takeda does dispute such notice, then notwithstanding the previous sentence, the Territory shall not be expanded to be worldwide during the pendency of such dispute. 

7.2    Commercialization Plan and Activities.    Commencing [***] in advance of the expected
First Commercial Sale of a Product in the Territory, Licensee shall submit a Commercialization Plan for the Territory to the Information Sharing Committee for review and discussion. Thereafter, Licensee shall submit an updated Commercialization Plan
for the Territory to the Information Sharing Committee for review and discussion at least [***] during the Term. Commencing [***] in advance of the expected First Commercial Sale of a Product outside the Territory, Takeda shall submit a
Commercialization Plan for outside the Territory to the Information Sharing Committee for review and discussion. Thereafter, Takeda shall submit an updated Commercialization Plan 

  
 - 29 - 

 
for outside the Territory to the Information Sharing Committee for review and discussion at least [***] during the Term. Each Commercialization Plan must include at least the information set
forth in Exhibit K. Licensee, itself and/or through its (Sub)licensees, will be solely responsible for all Commercialization activities in the Field in the Territory, including the marketing, strategy, pricing, promotion, physician targeting,
reimbursement, branding, Manufacturing (except in the instance wherein Takeda supplies Licensee with Clinical Trial materials as set forth in the Clinical Supply Agreement), supply, distribution and sale of the Product in the Field in the Territory
in accordance with Licensee’s Commercial Plan. Licensee shall be solely responsible for the review and approval of all promotional materials used in the Territory to ensure compliance with Applicable Law, including submission, where
appropriate, to the FDA and other applicable Regulatory Authorities. Takeda, itself and/or through its Affiliates and/or (Sub)licensees, will be solely responsible for all Commercialization activities in the Field outside the Territory, including
the marketing, strategy, pricing, promotion, physician targeting, reimbursement, branding, Manufacturing (except for Licensee’s Manufacturing obligations set forth in any Commercial Supply Agreement, and if needed, Clinical Supply Agreement
whereby Licensee supplies Takeda with Clinical Trial Materials), supply, distribution and sale of the Product in the Field outside the Territory in accordance with Takeda’s Commercial Plan. Takeda shall be solely responsible for the review and
approval of all promotional materials used in the Territory to ensure compliance with Applicable Law, including submission, where appropriate, to the PMDA. 

7.3    Commercialization Expenses. Licensee shall bear all expenses incurred related to the Commercialization of
Products in the Field in the Territory, including, but not limited to, the marketing, strategy, pricing, promotion, physician targeting, reimbursement, branding, Manufacturing, supply, distribution and sale of the Product in the Field in the
Territory. Takeda shall bear all expenses incurred related to the Commercialization of Products in the Field outside the Territory, including the marketing, strategy, pricing, promotion, physician targeting, reimbursement, branding, Manufacturing,
supply, distribution and sale of the Product in the Field outside the Territory. 
 7.4    Commercialization
Reports. Upon the First Commercial Sale of the Product in the Territory, Licensee will provide Takeda [***] progress reports on Commercialization activities for the Product in the Territory in the form attached hereto as Exhibit I. [***], Takeda
will provide Licensee [***] progress reports on Commercialization activities for the Product outside the Territory in the form attached hereto as Exhibit I. 

ARTICLE 8 – PAYMENT 

8.1    Upfront Cash Payment. In partial consideration for Licensee’s rights in and to the Takeda
Intellectual Property licensed hereunder and other rights granted hereunder Licensee shall pay to Takeda, or Takeda’s designated Affiliate, a one-time upfront fee of [***] within [***] after the
consummation of a Qualified Financing. As further partial consideration for Licensee’s rights in and to the Takeda Intellectual Property licensed hereunder and other rights granted hereunder Licensee shall pay to Takeda, or Takeda’s
designated Affiliate, an additional one-time upfront fee of [***] (the “Additional Up-Front Fee”) if [***] or more of the proceeds from the Qualified Financing
was derived through the issuance of convertible notes. Licensee shall pay to Takeda, or Takeda’s designated Affiliate, the Additional Up-Front Fee within [***] after receipt of an invoice therefor,
provided that Takeda may not deliver such invoice unless and until (i) one lot of 

  
 - 30 - 

 
Drug Product is released (in accordance with the Quality Agreement set forth in the Clinical Supply Agreement) and bulk packaged and Takeda notifies Licensee (which notice may be by e-mail) of the same, and (ii) Licensee applies (which shall be in Licensee’s sole discretion) to any Regulatory Authority to utilize such Drug Product for Clinical Trial purposes (in which event Licensee
shall [***] notify Takeda of the same). Such upfront payment(s) shall be non-refundable and non-creditable against any other payments made by Licensee hereunder.
Notwithstanding the previous sentence, Licensee shall not be required to pay the Additional Up-Front Fee if all of the following conditions are met: (i) Licensee, in accordance with Section 8(A) of
the Clinical Supply Agreement, has notified Takeda of one or more Detectable Defects with respect to such lot of Drug Product, (ii) if requested to do so by Takeda, pursuant to Section 8(C) of the Clinical Supply Agreement, Licensee shall,
within [***] of such request by Takeda, provide samples of any Drug Product alleged to be defective and copies of written reports or investigations performed to date by or on behalf of Licensee on such Drug Product, (iii) Takeda agrees that
such lot of Drug Product contained such Detectable Defect(s) or a Third Party independent laboratory determines in accordance with Section 8(D) of the Clinical Supply Agreement that such lot of Drug Product contained such Detectable Defect(s),
and (iv) the number of prefilled syringes in such lot of Drug Product rejected by Takeda prior to release by Takeda plus the number of prefilled syringes that were released by Takeda but are subsequently determined either by agreement of
Licensee and Takeda or by a Third Party independent laboratory pursuant to Section 8(D) of the Clinical Supply Agreement to contain Detectable Defects exceeds [***] of the total number of prefilled syringes manufactured for such lot. 

8.2    Milestones. In partial consideration for Licensee’s rights in and to the Takeda Intellectual
Property licensed hereunder and other rights granted to Licensee hereunder, Licensee shall owe to Takeda one-time milestone payments upon the first achievement of each of the events set forth in the table in
this Section 8.2 below. Licensee shall [***] notify Takeda in writing following the achievement of each milestone event described below. Thereafter, Takeda shall submit to Licensee an invoice for the corresponding milestone payment set forth
below. Within [***] of Licensee’s receipt of any such invoice, Licensee shall remit the applicable milestone payment to Takeda. Each milestone payment by Licensee pursuant to this Section 8.2 shall be payable only once, regardless of the
number of times that such milestone event is achieved for the Products. All amounts listed in are in U.S. Dollars. For clarity, the total amount payable to Takeda under this Section 8.2 if all sales milestone events are achieved is $[***]. 

 

			
	Milestones	  	Payment Amount
		
	 [***]
	  	$[***]
		
	 [***]
	  	$[***]
		
	 [***]
	  	$[***]
		
	 [***]
	  	$[***]
		
	 [***]
	  	$[***]

  
 - 31 - 

 In the event two (2) or more Net Sales Milestone events are achieved in the same
Calendar Year, Licensee shall pay to Takeda each milestone payment corresponding to the respective milestone event. For the avoidance of doubt, the total aggregate Net Sales by Licensee, its Affiliates and (Sub)licensees of all Products in the Field
in the Territory in the applicable Calendar Year period shall be used in determining whether the Net Sales milestones have been achieved. 

8.3    Royalties.  

(a)    Licensee’s Royalty Obligations. Subject to Sections
8.5-8.8 below, and during the applicable Licensee Royalty Term, in partial consideration for Licensee’s rights in and to the Takeda Intellectual Property and other rights granted to Licensee hereunder,
Licensee shall pay to Takeda a running royalty at the following incremental royalty rates, on total aggregate Net Sales of the Product by Licensee, its Affiliates and (Sub)licensees in the Territory during each Calendar Year. 

 

			
	Net Sales in the Territory	  	Royalty Rate
		
	 [***]
	  	[***]%
		
	 [***]
	  	[***]%
		
	 [***]
	  	[***]%

 (b)    Takeda’s Royalty Obligations. Subject to Sections 8.5-8.8 below, and during the applicable Takeda Royalty Term, in partial consideration for Takeda’s rights in and to the Licensee Intellectual Property and other rights granted to Takeda hereunder, Takeda shall
pay to Licensee a running royalty at the following incremental royalty rates, on total aggregate Net Sales of the Product by Takeda, its Affiliates or (Sub)licensees outside the Territory during each Takeda Fiscal Year. 

(i)    If Takeda is not required (as determined by Takeda in good faith), in order to obtain the first
Regulatory Approval of the Product for Japan, to perform any additional Clinical Trials beyond the Licensee Japan Development Activities, then Takeda will pay to Licensee the following royalties on total aggregate Net Sales of the Product by Takeda,
its Affiliates and (Sub)licensees outside the Territory during the applicable Takeda Royalty Term. 
  

			
	Net Sales outside of the Territory	  	Royalty Rate
		
	 [***]
	  	[***]%
		
	 [***]
	  	[***]%
		
	 [***]
	  	[***]%

  
 - 32 - 

 (ii)    If Takeda is required (as determined by Takeda
in good faith), in order to obtain the first Regulatory Approval of the Product for Japan, to perform any additional Clinical Trials beyond the Licensee Japan Development Activities, then Takeda will pay to Licensee the following royalties on total
aggregate Net Sales of the Product by Takeda, its Affiliates and (Sub)licensees outside the Territory during the applicable Takeda Royalty Term. 
  

			
	Net Sales outside of the Territory	  	Royalty Rate
		
	 [***]
	  	[***]%
		
	 [***]
	  	[***]%
		
	 [***]
	  	[***]%

 8.4    Royalty Term. Royalties under Section 8.3 shall be payable on
Net Sales on a Product-by-Product and country-by-country basis beginning upon the First
Commercial Sale of each Product in a country in the applicable Party’s respective territory until the expiration of the applicable Royalty Term in such country (at which time sales in such country shall be excluded from all calculations of
aggregate Net Sales hereunder). 
 8.5    Royalty Reduction for Generic Competition. Subject to the
limitation set forth in Section 8.8, the royalty rates set forth in Section 8.3 for Net Sales in such country (after any previous reduction(s), if any, made pursuant to Section 8.6) shall be reduced, on a country-by-country basis by [***] at the end of the first to occur Calendar Quarter during which the Generic Competition Percentage in such country during such time period is
greater than or equal to [***]. 
 8.6    Royalty Reduction for Patent Expiry. Subject to the limitation
set forth in Section 8.8, during the applicable Royalty Term with respect to any Product being Commercialized in the United States, following expiration of the last to expire Valid Claim in a Takeda Patent published in the FDA’s Purple
Book, the royalty rates for such Product set forth in Section 8.3 for Net Sales (after any previous reduction(s), if any, made pursuant to this Section 8.5) shall be reduced by [***] of the original royalty percentage amount until the end
of the Royalty Term (e.g.; [***]). 
 8.7    Payment for Third Party Licenses. 

(a)    During the Term, Licensee will have the right, following reasonable consultation with Takeda, to
negotiate and obtain a license under one or more Patents (other than any license granted in settlement of any litigation as contemplated under Section 9.6) from one or more Third Parties (each such Third Party license is referred to herein as a
“Licensee Third Party License”) if in the absence of a license under such Third Party Patents, the Exploitation of the applicable Compound or Product in the Field in the Territory in a manner consistent with Licensee’s
obligation to use Commercially Reasonable Efforts to Develop and Commercialize the Compound and the Product under this Agreement would, in Licensee’s good faith assessment, upon advice of legal counsel, bear a high risk to infringe such Third
Party Patents. Except as set forth in Section 8.7(c) or to the extent of any Claim for which Takeda provides indemnification under Section 15.2, 

  
 - 33 - 

 
or as the Parties may otherwise agree in writing, Licensee shall bear any payments associated with any royalties owed to any Third Party for such a Third Party License (collectively, the
“Licensee Third Party Royalties”). 
 (b)    In the event that Takeda disputes
Licensee’s determination that any Licensee Third Party Royalties are properly subject to the royalty offset provided under this Section 8.7 or Licensee’s allocation of any such Licensee Third Party Royalties to a Product, Takeda may
by written notice to Licensee require that such dispute be resolved in accordance with Article 14; provided that Licensee shall have the right to take royalty reductions pursuant to this Section 8.7 pending resolution of any such dispute;
provided further, that if any such dispute is resolved in favor of Takeda, then within [***] of such resolution, Licensee shall pay to Takeda any adjustment in royalties due pursuant to this Section 8.7 as required by such resolution.

(c)    Subject to the limitation set forth in Section 8.8, Licensee may credit up to [***] of the
amount of any Licensee Third Party Royalties paid by Licensee under a Licensee Third Party License pursuant to Section 8.7(a), or paid under any license granted in settlement of any claim of infringement of any Third Party claim of infringement
under Section 9.6, against royalties payable to Takeda under Section 8.3. Licensee may take such credit during the Calendar Quarter for which royalties are payable hereunder; provided, that in no event will such credit reduce the royalties
payable to Takeda for such Calendar Quarter by more than [***]. 
 (d)    This Section 8.7 shall
not apply to any Licensee Third Party Royalties payable by Licensee or any of its Affiliates or (Sub)licensees under any license or other agreement or understanding, written or oral, between Licensee or any of its Affiliates or (Sub)licensees, on
the one hand, and any Third Party, on the other hand, in existence as of the Effective Date. 

(e)    During the Term, Takeda will have the right, following reasonable consultation with Licensee, to
negotiate and obtain a license under one or more Patents (other than any license granted in settlement of any litigation as contemplated under Section 9.6) from one or more Third Parties (each such Third Party license is referred to herein as a
“Takeda Third Party License”) if in the absence of a license under such Third Party Patents, the Exploitation of the applicable Compound or Product in the Field outside the Territory in a manner consistent with Takeda’s
obligation to use Commercially Reasonable Efforts to Commercialize the Product under this Agreement would, in Takeda’s good faith assessment, upon advice of legal counsel, bear a high risk to infringe such Third Party Patents. Except as set
forth in Section 8.7(g) or to the extent of any Claim for which Licensee provides indemnification under Section 15.1, or as the Parties may otherwise agree in writing, Takeda shall bear any payments associated with any royalties owed to
any Third Party for such a Third Party License (collectively, the “Takeda Licensee Third Party Royalties”). 

(f)    In the event that Licensee disputes Takeda’s determination that any Takeda Third Party
Royalties are properly subject to the royalty offset provided under this Section 8.7 or Takeda’s allocation of any such Takeda Third Party Royalties to a Product, Licensee may by written notice to Takeda require that such dispute be
resolved in accordance with Article 14; provided that Takeda shall have the right to take royalty reductions pursuant to this Section 8.7 pending resolution of any such dispute; provided further, that if any such dispute is resolved in

  
 - 34 - 

 
favor of Licensee, then within [***] of such resolution, Takeda shall pay to Licensee any adjustment in royalties due pursuant to this Section 8.7 as required by such resolution.

(g)    Subject to the limitation set forth in Section 8.8, Takeda may credit up to [***] of the
amount of any Takeda Third Party Royalties paid by Takeda under a Takeda Third Party License pursuant to Section 8.7(e), or paid under any license granted in settlement of any claim of infringement of any Third Party claim of infringement under
Section 9.6, against royalties payable to Licensee under Section 8.3. Takeda may take such credit during the Calendar Quarter for which royalties are payable hereunder; provided, that in no event will such credit reduce the royalties
payable to Licensee for such Calendar Quarter by more than [***]. 
 (h)    This Section 8.7 shall
not apply to any Takeda Third Party Royalties payable by Takeda or any of its Affiliates or (Sub)licensees under any license or other agreement or understanding, written or oral, between Takeda or any of its Affiliates or (Sub)licensees, on the one
hand, and any Third Party, on the other hand, in existence as of the Effective Date. 
 8.8    Limitation on Royalty
Reductions. Notwithstanding anything contained in this Agreement to the contrary, the reductions and offsets to royalties provided in Sections 8.5, 8.6, and 8.7 may not, individually or in the aggregate, reduce the royalties payable with
respect to Net Sales of any Product sold by (a) Licensee, its Affiliates and its and their (Sub)licensees in any country during a Calendar Quarter during the applicable Licensee Royalty Term by more than [***] of the original royalty percentage
amount owed to Takeda pursuant to Section 8.3(a) (i.e., [***]) or (b) Takeda, its Affiliates and its and their (Sub)licensees in any country during a Calendar Quarter during the applicable Takeda Royalty Term by more than [***] of
the original royalty percentage amount owed to Licensee pursuant to Section 8.3(b)(i) (i.e., [***]) or pursuant to Section 8.3(b)(ii) ([i.e., [***]). 

8.9    Manner of Payment. No later than [***], each Party shall provide the other Party with a written
report containing such Party’s reasonable good faith estimate of the following information for the Calendar Quarter in order to allow such other Party to comply with internal accounting procedures: the amount of total aggregate gross sales
(U.S. dollars) of the Products by such Party, its Affiliates, and its (Sub)licensees, an itemized calculation of Net Sales by such Party, its Affiliates, or its (Sub)licensees showing deductions, to the extent practicable, provided for in the
definition of “Net Sales,” a calculation of the royalty payment due on such sales, an accounting of the number of units and prices for the Products sold, the application of the reductions, if any, made in accordance with this Article 8,
and any information required by such other Party for the purpose of calculating royalties. Within [***] following the end of each Calendar Quarter, each Party shall provide the other Party with a report containing the actual (not estimated)
information described above in respect of such Calendar Quarter for such other Party’s review and confirmation within [***] from receipt. In the event that either Party determines that the calculation of Net Sales for a Calendar Quarter
deviates from the amounts previously reported to such Party for any reason (such as, on account of additional amounts collected or Product returns), the Parties shall reasonably cooperate to reconcile any such deviations to the extent necessary
under applicable legal or financial reporting requirements.    Within the later of (a) [***] from the end of the Calendar Quarter, or (b) [***] following the receiving Party’s written confirmation of the applicable quarterly
report, the paying Party shall pay all amounts due to the other Party pursuant to this Article 8 with respect to Net Sales for such Calendar Quarter. 

  
 - 35 - 

 8.10    Exchange Rate. All amounts due to either Party
hereunder will be expressed in U.S. Dollars. The rate of exchange to be used in computing the amount of currency equivalent in U.S. Dollars owed to a Party under this Agreement will be the exchange rate used by such Party in its financial reporting
in accordance with GAAP or IFRS. 
 8.11    Taxes. 

(a)    Withholding Tax. The amounts payable pursuant to this Agreement (“Payments”)
shall not be reduced on account of any Taxes unless required by Applicable Law. The paying Party shall deduct and withhold from the Payments any Taxes that it is required by Applicable Law to deduct or withhold. Notwithstanding the foregoing, if the
Party receiving such Payment is entitled under any applicable tax treaty to a reduction of rate of, or the elimination of, or recovery of, applicable withholding tax, it may deliver to the paying Party or the appropriate Governmental Authority the
prescribed forms necessary to reduce the applicable rate of withholding or to relieve the paying Party of its obligation to withhold tax. In such case the paying Party shall apply the reduced rate of withholding, or not withhold, as the case may be,
provided that paying Party is in receipt of evidence, in a form reasonably satisfactory to it, for example the receiving Party’s delivery of all applicable documentation at least [***] prior to the time that the Payments are due. If, in
accordance with the foregoing, the paying Party withholds any amount, it shall pay to the receiving Party the balance when due, make timely payment to the proper taxing authority of the withheld amount, and send the receiving Party proof of such
payment within [***] following that payment. 

(b)    Assignment.    If Licensee assigns its rights and obligations
hereunder to an Affiliate or Third Party in compliance with Section 16.4 and if such Affiliate or Third Party shall be required by Applicable Law to withhold any additional Taxes from or in respect of any amount payable under this Agreement as
a result of such assignment, then any such amount payable under this Agreement shall be increased to take into account the additional Taxes withheld as may be necessary so that, after making all required withholdings, the payee Party receives an
amount equal to the sum it would have received as of the Effective Date. For the avoidance of doubt, if Takeda assigns its right and obligations under this Agreement in compliance with Section 16.4, Takeda shall not be entitled to any
additional payments with respect to Taxes arising as a result of Takeda’s assignment. 
 8.12    Audit.
Each Party shall maintain complete and accurate records in sufficient detail to permit the other Party to confirm the accuracy of the calculation of royalty and other payments under this Agreement. Upon reasonable prior notice, such records
shall be available during regular business hours for a period of [***] from the end of the Calendar Year or Takeda Fiscal Year, as applicable, to which they pertain for examination at such other Party’s expense, and not more often [***], by an
independent certified public accountant selected by such other Party and reasonably acceptable to such Party, for the sole purpose of verifying the accuracy of the financial reports furnished by such Party pursuant to this Agreement. Any such
auditor shall not disclose such Party’s Confidential Information, except to the extent such disclosure is necessary to verify the accuracy of the financial reports furnished by such Party or the amount of payments due to such other Party under
this Agreement during the prior [***]. Any amounts shown to be owed to such other Party but unpaid shall be paid within [***] from the accountant’s report, plus interest (as set forth in Section 8.13) from the original due date. Any
amounts shown to have been overpaid shall 

  
 - 36 - 

 
be refunded within [***] from the accountant’s report. The auditing Party shall bear the full expense of such audit unless such audit discloses an underpayment by the audited Party of more
than [***] of the amount due, in which case such audited Party shall bear the full expense of such audit. 

8.13    Manner of Payment, Late Payment. All payments due to a Party hereunder shall be made in U.S. Dollars
by wire transfer of immediately available funds into an account designated by such Party. If a Party does not receive payment of any sum due to it on or before the due date, simple interest shall thereafter accrue on the sum due to until the date of
payment at the per annum rate of [***] over the then-current prime rate quoted by Citibank in New York City or the maximum rate allowable by Applicable Law, whichever is lower. 

ARTICLE 9 – INTELLECTUAL PROPERTY MATTERS 

9.1    Ownership of Inventions. Inventorship shall be determined in accordance with U.S. patent laws. Each Party
shall own any Inventions made solely by its own employees, agents, or independent contractors in the course of conducting any activities under this Agreement, together with all intellectual property rights therein (the “Sole
Inventions”). The Parties shall jointly own any Inventions that are made jointly by employees, agents, or independent contractors of each Party in the course of performing activities under this Agreement, together with all intellectual
property rights therein (the “Joint Inventions”). 
 9.2    Disclosure of Inventions. 

(a)    Each Party shall promptly disclose to the other Party any Inventions that such Party believes are
patentable Joint Inventions. 
 (b)    Takeda shall inform Licensee of any Sole Inventions discovered or
generated by its employees, agents or independent contractors, and all Information relating to such Inventions to the extent necessary for the use of such Invention in the Exploitation of a Product in the Field in the Territory and, to the extent
patentable, for the preparation, filing and maintenance of any Patent with respect to such invention in accordance with Section 9.3. 

(c)    Licensee shall inform Takeda of any Sole Inventions discovered or generated by its employees,
agents or independent contractors, and all Information relating to such Inventions to the extent necessary for the use of such Invention in the Exploitation of a Product in the Field outside the Territory and, to the extent patentable, for the
preparation, filing and maintenance of any Patent with respect to such Invention in accordance with Section 9.3. 

9.3    Prosecution of Patents. 

(a)    Takeda General Patents. Takeda shall continue to have the sole right and authority to
prepare, file, prosecute and maintain the Takeda General Patents at its own expense on a worldwide basis. 

(b)    Licensee Patents. Except as otherwise provided in this Section 9.3(b), Licensee shall
have the sole right and authority to prepare, file, prosecute and maintain the Licensee Patents on a worldwide basis at its own expense. Licensee shall provide Takeda a reasonable opportunity 

  
 - 37 - 

 
to review and comment on material communications from any patent authority outside of the Territory regarding the Licensee Patents and drafts of any material filings or responses to be made to
such patent authorities in advance of submitting such filings or responses. Licensee shall consider Takeda’s comments regarding such communications and drafts in good faith. In the event that Licensee elects not to continue the prosecution or
maintenance of a Licensee Patent in any country outside of the Territory, then Licensee shall provide Takeda with written notice of such determination within a period of time reasonably necessary to allow Takeda to determine its interest in such
Licensee Patent(s) (which notice from Licensee shall be given no later than [***] prior to any final deadline for any pending action or response that may be due with respect to such Licensee Patent(s) with the applicable patent authority). In the
event Takeda provides written notice expressing its interest in assuming responsibility for all costs and responsibility associated with the prosecution and maintenance of such Licensee Patent in such country, Licensee will provide any assistance
reasonably requested by Licensee associated with the prosecution and maintenance of such Licensee Patent. In such circumstances, Licensee shall and hereby does grant to Takeda an exclusive license to all of its right, title and interest in the
relevant Licensee Patent. 
 (c)    Takeda Compound Patents and Joint Patents. 

(i) Except as otherwise provided in this Section 9.3(c)(i), Licensee shall have the sole right and responsibility to
prepare, file, prosecute and maintain the Takeda Compound Patents and the Joint Patents in the Territory at its own expense. The Parties shall confer and mutually agree to a filing strategy, including the jurisdictions in which to file a patent
application, and Licensee shall provide Takeda a reasonable opportunity to review and comment on material communications from any patent authority in the Territory regarding the Takeda Compound Patents and the Joint Patents and drafts of any
material filings or responses to be made to such patent authorities in advance of submitting such filings or responses. Licensee shall consider Takeda’s comments regarding such communications and drafts in good faith. Any claim amendment of a
Takeda Compound Patent that will limit claims such that a Compound or Product would no longer be covered by such Takeda Compound Patent will require Takeda’s consent. In the event that Licensee elects not to continue the prosecution or
maintenance of a Takeda Compound Patent or Joint Patent in any country in the Territory or, with Takeda ́s consent as provided in this Section 9.3(c)(i), elects to amend the claims of any Takeda Compound Patent such that a Compound or
Product would no longer be covered by such Takeda Compound Patent, then Licensee shall provide Takeda with written notice of such determination within a period of time reasonably necessary to allow Takeda to determine its interest in such Takeda
Compound Patent or Joint Patent (which notice from Licensee shall be given no later than [***] prior to any final deadline for any pending action or response that may be due with respect to such Takeda Compound Patent or Joint Patent with the
applicable patent authority). In the event Takeda provides written notice expressing its interest assuming responsibility for all costs and responsibility associated with the prosecution and maintenance of such Takeda Compound Patent or Joint Patent
in such country, Licensee will provide any assistance reasonably requested by Takeda associated with the prosecution and maintenance of such Takeda Compound Patent or Joint Patent. In such circumstances with respect to a Joint Patent, Licensee shall
and hereby does grant to Takeda an exclusive license to all of its right, title and interest in the relevant Joint Patent in such country. In such circumstances with respect to a Takeda Compound Patent, unless the Parties otherwise mutually agree,
Licensee’s license to such Takeda Compound Patent will cease to exist without further notice. 

  
 - 38 - 

 (ii) Except as otherwise provided in this Section 9.3(c)(ii), Takeda
shall have the sole right and responsibility to prepare, file, prosecute and maintain equivalents outside the Territory of the Takeda Compound Patents and of the Joint Patents outside the Territory at its own expense. With regard to such patents and
patent applications, the Parties shall confer and mutually agree to a filing strategy, and Takeda shall provide Licensee a reasonable opportunity to review and comment on material communications from any patent authority regarding such patents and
patent applications and drafts of any material filings or responses to be made to such patent authorities in advance of submitting such filings or responses. Takeda shall consider Licensee’s comments regarding such communications and drafts in
good faith. Any claim amendment of any such patent application that will limit claims such that a Compound or Product would no longer be covered by such patent application will require Licensee’s consent. In the event that Takeda elects not to
continue the prosecution or maintenance of such patent or patent application outside the Territory, then Takeda shall provide Licensee with written notice of such determination within a period of time reasonably necessary to allow Licensee to
determine its interest in such patent or patent application (which notice from Takeda shall be given no later than [***] prior to any final deadline for any pending action or response that may be due with respect to such patent or patent application
with the applicable patent authority). In the event Licensee provides written notice expressing its interest assuming responsibility for all costs and responsibility associated with the prosecution and maintenance of such patent or patent
application outside the Territory, Takeda will provide any assistance reasonably requested by Licensee associated with the prosecution and maintenance of such patent or patent application. In such circumstances with respect to such patent or patent
application, Takeda shall and hereby does grant to Licensee an exclusive license to all of its right, title and interest in such patent or patent application. 

(d)    Cooperation in Prosecution. Each Party shall provide the other Party reasonable assistance
and cooperation in the Patent prosecution efforts provided above in this Section 9.3 (including with respect to equivalents outside the Territory of the Takeda Compound Patents and of the Joint Patents), including providing any necessary powers
of attorney and executing any other required documents or instruments for such prosecution, as well as further actions as set forth below. 

(i)    The Parties shall respectively prepare, file, maintain and prosecute the Takeda Compound Patents,
Licensee Patents, Joint Patents and Japanese equivalents of the Takeda Compound Patents and of the Joint Patents as set forth in this Section 9.3. As used herein, “prosecution” of such Patents shall include all communication, payment
of due official fees and other interaction with any patent office or patent authority having jurisdiction over a patent application in connection with pre-grant proceedings. 

(ii)    All communications between the Parties relating to the preparation, filing, prosecution or
maintenance of the Takeda Patents, the Licensee Patents, the Joint Patents, and equivalents outside the Territory thereof, including copies of any draft or final documents or any communications received from or sent to patent offices or patenting
authorities with respect to such Patents and equivalents outside the Territory, shall be considered Confidential Information and subject to the confidentiality provisions of Article 11 to the extent they are not publicly accessible from the relevant
patent authority. 

  
 - 39 - 

 (iii)    Assignments to Licensee Patents and Joint
Patents shall be effected as follows: (1) employees or agents of Licensee that are named as inventors on Licensee Patents shall assign their interest in such Patents to Licensee; and (2) employees or agents of Takeda or Licensee that are
named as inventors on Joint Patents shall assign their interest in such Patents to their respective employer. 

(iv)    For decisions regarding patent term extensions, in the Territory with respect to extensions
pursuant to 35 U.S.C. §156 et. seq. and in other jurisdictions pursuant to supplementary protection certificates, and in all jurisdictions with respect to any other extensions that are now or become available in the future, wherever applicable,
for the Takeda Compound Patents, Licensee Patents or Joint Patents that cover the Product, Licensee will consult Takeda no later than [***] after the first submission of a market authorization request for the Product anywhere within the Territory,
and will consider Takeda ́s recommendations in good faith. The final decision regarding such patent term extension shall rest with Licensee, and Licensee, at its sole cost and expense, shall have the sole right and responsibility to apply for
such patent term extension. Takeda shall cooperate with Licensee to provide necessary information and assistance, as Licensee may reasonably request, in obtaining patent term extension or supplemental protection certificates in any country in the
Territory where applicable to a Takeda Compound Patent, Licensee Patent and Joint Patent. 
 9.4    Purple Book
Listing. Subject to Section 9.3, Licensee shall be solely responsible for listing and maintaining all appropriate Takeda Compound Patents, Licensee Patents and Joint Patents in the Purple Book in the United States, the Patent List in Canada
or the equivalent in other countries in the Territory, [***]. Upon request of Licensee, Takeda shall cooperate with Licensee to file appropriate information with the FDA for listing any Takeda Compound Patents and any Joint Patents in the Purple
Book in the United States, the Patent List in Canada or the equivalent in other countries in the Territory. 

9.5    Infringement of Patents by Third Parties. 

(a)    Notification. Each Party shall promptly notify the other Party in writing of any existing,
alleged or threatened infringement of the Takeda Patents, Joint Patents or Licensee Patents (or of any equivalent outside the Territory of any of the foregoing) in the Field of which it becomes aware, and shall provide all Information in such
Party’s possession or control demonstrating such infringement. 
 (b)    Infringement
Action. 
 (i)    “Product Infringement” shall mean any Third Party engaged in any
existing, alleged or threatened infringement of any Takeda Compound Patent, Licensee Patent or Joint Patent related to the making, using, importing, offering for sale or selling a Product in the Field. Licensee shall have the first right, but not
the obligation, to bring an appropriate suit or other action against any Product Infringement in the Territory, subject to Section 9.5(b)(ii) through 9.5(b)(iv), below. Takeda shall have the first right, but not the obligation, to bring an
appropriate suit or other action against any Product Infringement outside of the Territory, subject to Section 9.5(b)(ii) through 9.5(b)(iv), below. 

  
 - 40 - 

 (ii)    Each Party shall notify the other Party of its
election to take any action in accordance with Section 9.5(b)(i) within [***] before any time limit set forth in an Applicable Law or regulation, including the time limits set forth under the Hatch-Waxman Act (21 U.S.C. § 355). In the
event a Party does not so elect, such Party shall so notify the other Party in writing, and the other Party shall have the right, but not the obligation, to commence a suit or take action to enforce the applicable Takeda Compound Patent, Licensee
Patent or Joint Patent against such Third Party at its own expense. If one Party elects to bring suit or take action against the Product Infringement, then the other Party shall have the right, prior to commencement of the trial, suit or action, to
join any such suit or action. 
 (iii)    Each Party shall provide to the Party enforcing any such
rights under this Section 9.5(b) reasonable assistance in such enforcement, at such enforcing Party’s request and expense, including joining such action as a party plaintiff if required by Applicable Law to pursue such action. Each Party
shall confer upon the other Party any authority, as a licensee under such the applicable Patents, necessary for such other Party to enforce those Patents pursuant to Section 9.5(b)(i) and (ii). The enforcing Party shall keep the other Party
regularly informed of the status and progress of such enforcement efforts, shall reasonably consider the other Party’s comments on any such efforts, including determination of litigation strategy, filing of important papers to the competent
court, which consent shall not be unreasonably withheld, conditioned or delayed. 
 (iv)    Subject to
this Section 9.5(b)(iv), the enforcing Party shall be [***]. 
 (c)    Settlement. [***].

 (d)    Allocation of Proceeds. If either Party recovers monetary damages from any Third Party
in a suit or action brought under Sections 9.5(b), or 9.5(c), or any royalties from a license agreement with a Third Party related to any alleged Product Infringement, whether such damages or royalties result from the infringement of Takeda Compound
Patents, Licensee Patents or Joint Patents, such recovery shall be allocated first to the reimbursement of any expenses incurred by the Parties in such litigation, action or license, and any remaining amounts shall be split as follows: [***]. 

9.6    Infringement of Third Party Rights. 

(a)    Notice. If any Product used or sold by a Party, its Affiliates, or (Sub)licensees becomes the
subject of a Third Party’s claim or assertion of infringement of a Patent, the Party first having notice of the claim or assertion shall promptly notify the other Party, the Parties shall agree on and enter into an “identity of interest
agreement” wherein such Parties agree to their shared, mutual interest in the outcome of such potential dispute, and thereafter, the Parties shall promptly meet to consider the claim or assertion and the appropriate course of action. 

(b)    Defense. Licensee shall have the first right, but not the obligation, to defend any such
Third Party claim or assertion of infringement of a Patent as described in Section 9.6(a) above in the Territory, at Licensee’s expense. Takeda shall have the first right, but not the obligation, to defend any such Third Party claim or
assertion of infringement of a Patent as described in Section 9.6(a) above outside the Territory, at Takeda’s expense. If such first Party does not commence actions to defend such claim within [***] after it receives notice thereof (or
within [***] after it 

  
 - 41 - 

 
should have given notice thereof to the other Party as required by Section 9.6(a)), then to the extent allowed by the Applicable Laws, such other Party shall have the right, but not the
obligation, to control the defense of such claim by legal counsel of its choice, at such other Party’s expense. The non-defending Party shall reasonably cooperate with the Party conducting the defense of
the claim or assertion, including if required to conduct such defense, furnishing a power of attorney. If the defending Party recovers monetary damages from any such Third Party asserting such a claim of infringement as a result of counter claims
brought by such defending Party based on any Takeda Compound Patent or Joint Patent, or any royalties from a license agreement with such Third Party, such recovery shall be allocated first to the reimbursement of any expenses incurred by the
defending Party in such litigation, action or license, and any remaining amounts shall be split as follows: [***]. 

(c)    Settlement; Licenses. Neither Party shall enter into any settlement of any claim described
in this Section 9.6 that affects the other Party’s rights or interests without such other Party’s written consent, which consent shall not be unreasonably withheld, conditioned or delayed. Each Party shall have the right to decline to
defend or to tender defense of any such claim to the other Party upon reasonable notice, including if the other Party fails to agree to a settlement that such Party proposes. 

9.7    Patent Oppositions and Other Proceedings. 

(a)    Third Party Patent Rights. If either Party desires to bring an opposition, action for
declaratory judgment, nullity action, interference, declaration for non-infringement, reexamination or other attack upon the validity, title or enforceability of a Patent owned or controlled by a Third Party
and having one or more claims that covers the Product, or the use, making, sale, offer for sale or importation of the Product (except insofar as such action is a counterclaim to or defense of, or accompanies a defense of, a Third Party’s claim
or assertion of infringement under Section 9.6, in which case the provisions of Section 9.6 shall govern), such Party shall so notify the other Party and the Parties shall promptly confer to determine whether to bring such action or the
manner in which to settle such action. Each Party shall have the exclusive right, but not the obligation, to bring at its own expense and in its sole control such action in its respective territory. If such Party does not bring such an action in its
territory, within [***] of notification thereof pursuant to this Section 9.7(a) (or earlier, if required by the nature of the proceeding), then the other Party shall have the right, but not the obligation, to bring, at such other Party’s
sole expense, such action. The Party not bringing an action under this Section 9.7(a) shall be entitled to separate representation in such proceeding by legal counsel of its own choice and at its own expense, and shall cooperate fully with the
Party bringing such action. 
 (b)    Parties’ Patent Rights. If any Takeda Compound Patent,
Joint Patent or Licensee Patent has become by the Effective Date or becomes on or after the Effective Date the subject of any proceeding commenced by a Third Party in connection with an opposition, reexamination request, action for declaratory
judgment, nullity action, interference or other attack upon the validity, title or enforceability thereof (except insofar as such action is a counterclaim to or defense of, or accompanies a defense of, an action for infringement against a Third
Party under Section 9.5, in which case the provisions of Section 9.5 shall govern), then the Party responsible for filing, preparing, prosecuting and maintaining such Patent as set forth in Section 9.3, shall control such defense at
its own expense. The controlling Party shall permit the non-controlling Party to 

  
 - 42 - 

 
participate in the proceeding to the extent permissible under Applicable Law, and to be represented by its own legal counsel in such proceeding, at the
non-controlling Party’s expense. If either Party decides that it does not wish to defend against such action, then the other Party shall have a backup right to assume defense of such Third Party action at
its own expense. Any awards or amounts received in defending any such Third Party action shall be allocated between the Parties as provided in Section 9.5(d). A list of proceedings commenced by a Third Party in connection with an opposition,
reexamination request, action for declaratory judgment, nullity action, interference or other attack upon the validity, title or enforceability thereof before the Effective Date is attached hereto as Exhibit D. 

9.8    Product Trademarks and Takeda Product Trademarks. 

(a)    Generally. Licensee shall have the sole right to determine the Trademarks to be used with
respect to the Exploitation of a Product in the Field in the Territory. Takeda shall have the sole right to determine the Trademarks to be used with respect to the Exploitation of a Product outside of the Territory, including any Takeda Product
Trademarks. 
 (b)    Licensee Product Trademarks.  

(i)    If Licensee, in its sole discretion, elects to use a Product Trademark with respect to the
Exploitation of a Product in the Field in the Territory, Licensee shall own all right, title, and interest to such Product Trademark, and shall be responsible, [***], for the registration, prosecution, maintenance and enforcement thereof. 

(ii)    Takeda may, in its sole discretion, elect to use a Product Trademark with respect to the
Exploitation of such Product in the Field outside of the Territory under the license grant set forth in Section 4.2. If Takeda so elects to use a Product Trademark, Licensee shall file, register and maintain such Product Trademarks outside of
the Territory at Takeda’s cost. Takeda may also, in its sole discretion, elect to use a Takeda Product Trademark with respect to the Exploitation of such Product in the Field outside the Territory. 

(iii)    In the event Takeda exercises its rights under Section 4.2 to use the Product Trademarks,
Takeda recognizes Licensee’s rights in, under and to the Product Trademarks and shall not at any time impair Licensee’s rights to the Product Trademarks. 

(iv)    In the event Takeda exercises its rights under Section 4.2 to use the Product Trademarks,
Takeda shall not make any representation indicating that it has any right, title or interest in or to the ownership or use of the Product Trademarks except under the terms of this Agreement, and Takeda acknowledges that nothing in this Agreement
shall give Takeda any right, title or interest in or to any Product Trademark except under the terms of this Agreement. 

(v)     Each Party shall provide to the other Party prompt written notice of any actual or threatened
infringement of any Product Trademarks and of any actual or threatened claim that the use of any Product violates the rights of any Third Party. 

(vi)    Licensee shall at its sole discretion, be responsible for defending and enforcing the Product
Trademarks, including the settlement of any actions relating to the same 

  
 - 43 - 

 
and, in connection therewith, will consider in good faith and reasonably address Takeda’s input and comments with respect to use outside the Territory. Any award of damages or other recovery
from an infringement action concerning the Product Trademarks pursuant to this Section 9.8(b)(vi) shall be retained solely and exclusively by Licensee. 

(c)    Takeda Product Trademarks. [***]. 

ARTICLE 10 – REPRESENTATIONS AND WARRANTIES 

10.1    Mutual Representations, Warranties and Covenants. Each of the Parties hereby represents and warrants to the
other Party as of the Effective Date and covenants that: 
 (a)    Organization. It is a
corporation duly organized, validly existing, and in good standing under the laws of the jurisdiction of its organization, and has all requisite power and authority, corporate or otherwise, to execute, deliver, and perform this Agreement. 

(b)    Binding Agreement. This Agreement is a legal and valid obligation binding upon such
Party and enforceable in accordance with its terms, subject to the effects of bankruptcy, insolvency, or other laws of general application affecting the enforcement of creditor rights, judicial principles affecting the availability of specific
performance, and general principles of equity (whether enforceability is considered a proceeding at law or equity). 

(c)    Authorization. The execution, delivery, and performance of this Agreement by such
Party have been duly authorized by all necessary corporate action and do not conflict with, violate or result in a breach of any agreement, instrument, or understanding, oral or written, to which it is a party or by which it is bound (including, in
the case of Takeda and its Affiliates, the Agreement and Plan of Merger), nor violate any Applicable Law or any order, writ, judgment, injunction, decree, determination, or award of any court or governmental body, or administrative or other agency
presently in effect applicable to such Party. 
 (d)    No Further Approval. It is not
aware of any government authorization, consent, approval, license, exemption of or filing or registration with any court or governmental department, commission, board, bureau, agency or instrumentality, domestic or foreign, under any Applicable Law,
currently in effect, necessary for, or in connection with, the transactions contemplated by this Agreement or any other agreement or instrument executed in connection herewith, or for the performance by it of its obligations under this Agreement and
such other agreements (save for Regulatory Approvals and similar authorizations from Regulatory Authorities necessary for the Exploitation of the Compound and the Product as contemplated hereunder). 

(e)    No Inconsistent Obligations. Neither Party is under any obligation, contractual or
otherwise, to any Person that conflicts with or is inconsistent in any material respect with the terms of this Agreement, or that would impede the diligent and complete fulfillment of its obligations hereunder. 

(f)    Transparency Reporting. Each Party shall be responsible for tracking and reporting transfers
of value initiated and controlled by its and its Affiliates’ employees, contractors, 

  
 - 44 - 

 
and agents pursuant to the requirements of the marketing reporting laws of any Government Authority, including Section 6002 of the Patient Protection and Affordable Care Act, commonly
referred to as the “Sunshine Act.” 
 10.2    Additional Representations, Warranties and Covenants of
Takeda. Takeda represents and warrants as of the Effective Date and covenants to Licensee that: 

(a)    As of the Effective Date, Takeda has all rights necessary to grant, and the U.S. Government does
not hold any rights or property interests that prevent or prohibit Takeda’s ability to grant, the licenses under the Takeda Compound Patents and Takeda General Patents listed on Exhibit D as of the Effective Date and the Takeda Know-How Controlled by Takeda or any of its Affiliates as of the Effective Date, and rights of cross-reference under Regulatory Materials existing as of the Effective Date that it grants to Licensee in this
Agreement. As of the date Takeda includes any additional Takeda Compound Patents or Takeda General Patents on Exhibit D, Takeda shall have all rights necessary to grant the license under such additional Takeda Compound Patents and Takeda General
Patents that it grants to Licensee in this Agreement. During the Term, Takeda shall have all rights necessary to grant the rights of cross-reference under Regulatory Materials that it grants to Licensee in this Agreement. 

(b)    As of the Effective Date, the Takeda Compound Patents set forth in Exhibit D represent all Patents
that Takeda or any of its Affiliates Controls that claim TAK-214 or a Product comprising TAK-214 as the sole active ingredient in the Field in the Territory. As of the
date Takeda provides Licensee any update of Exhibit D, the Takeda Compound Patents set forth in Exhibit D represent all Patents that Takeda or any of its Affiliates Controls that claim TAK-214 or a Product
comprising TAK-214 as the sole active ingredient in the Field in the Territory. As of the later of the Effective Date or the date on which any Takeda Compound Patent is first set forth on Exhibit D, Takeda is
the sole and exclusive owner of the entire right, title and interest in such Takeda Compound Patent free of any encumbrance, lien, or claim of ownership by any Third Party, except to the extent otherwise expressly stated on Exhibit D. As of the
Effective Date, Exhibit D lists all Patents Controlled by Takeda or its Affiliates needed to conduct Exploitation of the Compound and Product in the Field and in the Territory as conducted by Takeda prior to the Effective Date. 

(c)    As of the Effective Date, to Takeda’s Knowledge, there is no actual or threatened infringement
or misappropriation of the Takeda Know-How or Takeda Compound Patents by any Person in the Territory.    Takeda shall notify Licensee promptly after becoming aware of any actual or
threatened infringement or misappropriation of the Takeda Know-How or Takeda Compound Patents by any Person in the Territory. 

(d)    As of the date on which any Takeda Compound Patent is first set forth on Exhibit D, such Takeda
Compound Patent is being diligently prosecuted in the Territory in accordance with Applicable Law, and, to Takeda’s Knowledge, such Takeda Compound Patent has been filed and maintained properly and correctly and all applicable fees have been
paid on or before the due date for payment. 
 (e)    As of the date on which any Takeda Compound Patent
is first set forth on Exhibit D, such Takeda Compound Patent does not fail to properly identify each and every inventor of the 

  
 - 45 - 

 
claims thereof as determined in accordance with Applicable Law of the jurisdiction in which such Takeda Compound Patent is issued or such application is pending; except in each case to the extent
otherwise expressly stated on Exhibit D as of the date on which any such Takeda Compound Patent is first set forth on Exhibit D. 

(f)    As of the Effective Date, to Takeda’s Knowledge, the Takeda
Know-How has been kept confidential or has been disclosed to Third Parties only under terms of confidentiality. To the Knowledge of Takeda, no breach of such confidentiality has been committed by any Third
Party. 
 (g)    The inventions claimed or disclosed by any Takeda Compound Patent (i) were not
conceived, discovered, developed, or otherwise made in connection with any research activities funded, in whole or in part, by the federal government of the U.S. or any agency thereof, (ii) are not a “subject invention” as that term
is described in 35 U.S.C. Section 201(f), and (iii) are not otherwise subject to the provisions of the Bayh-Dole Act; except in each case to the extent otherwise expressly stated on Exhibit D as of the date on which any such Takeda
Compound Patent is first set forth on Exhibit D. 
 (h)    As of the Effective Date, neither Takeda nor
any of its Affiliates has been debarred by the FDA or is subject to any similar sanction of other Regulatory Authorities. Neither Takeda nor any of its Affiliates has used, or will engage, in any capacity, in connection with this Agreement or any
ancillary agreements (if any), any Person who either has been debarred by such a Regulatory Authority, or is the subject of a conviction described in Section 306 of the FFDCA. Takeda shall inform Licensee in writing [***] if it or any Person
engaged by Takeda or any of its Affiliates who is performing any activities under or in connection with this Agreement or any ancillary agreements (if any) is debarred or is the subject of a conviction described in Section 306 of the FFDCA, or
if any action, suit, claim, investigation or legal or administrative proceeding is pending or, to Takeda’s Knowledge, is threatened, relating to the debarment or conviction of Takeda, any of its Affiliates or any such Person performing
activities. 
 (i)    As of the Effective Date, to Takeda’s Knowledge, there are no material
claims, judgments, or settlements against, or amounts with respect thereto, owed by Takeda or any of its Affiliates to any Third Parties relating to the Regulatory Materials licensed by Takeda to Licensee or the Takeda
Know-How. As of the date Takeda includes any Takeda Compound Patents on Exhibit D to Takeda’s Knowledge, there are no material claims, judgments, or settlements against, or amounts with respect thereto,
owed by Takeda or any of its Affiliates to any Third Parties relating to such Takeda Compound Patents in the Territory except in each case to the extent otherwise expressly stated on Exhibit D as of the date on which any such Takeda Compound Patent
is first set forth on Exhibit D. 
 (j)    No claim or litigation has been brought or, to Takeda’s
Knowledge, threatened by any Person alleging, and Takeda has no Knowledge of any claim, whether or not asserted: (i) that any of the Takeda Compound Patents is invalid or unenforceable; except in each case to the extent otherwise expressly
stated on Exhibit D as of the date on which any such Takeda Compound Patent is first set forth on Exhibit D, (ii) that the Regulatory Materials licensed by Takeda to Licensee, the Takeda Compound Patents, the Takeda Know-How, or the disclosing, copying, making, assigning, or licensing of the Regulatory Materials by Takeda to Licensee, the Takeda 

  
 - 46 - 

 
Compound Patents or the Takeda Know-How, violates, infringes, or otherwise conflicts or interferes with, or would violate, infringe, or otherwise conflict
or interfere with, any intellectual property or proprietary right of any Person; or (iii) related to the Development of the Product except in each case to the extent otherwise expressly stated on Exhibit D. Takeda shall notify Licensee [***]
after becoming aware of any claim or litigation that has been brought or threatened by any Person alleging any of the foregoing. [***]. 

(k)    To Takeda’s Knowledge, Takeda and its Affiliates have provided or made available to Licensee
prior to the Effective Date, true, complete, and correct copies (as of the Effective Date) of all material adverse information known to Takeda with respect to the safety and efficacy of any Compound or Product, and all of the foregoing information
and documents provided are true, correct, and complete in all material respects. 
 (l)    Takeda owns
or otherwise controls all right, title and interest in and to the Regulatory Materials that Takeda licenses to Licensee hereunder, and to Takeda’s Knowledge, Takeda and its Affiliates have generated, prepared, maintained, and retained all
material Regulatory Materials in the Field that are required to be maintained or retained pursuant to and in accordance with GCP, GLP and other Applicable Law, and all such information is true, complete and correct in all material respects and what
it purports to be. 
 10.3    Additional Representations, Warranties and Covenants of Licensee. Licensee
represents and warrants as of the Effective Date and covenants to Takeda that: 
 (a)    As of the
Effective Date, Licensee has not been debarred by the FDA (and is not subject to any similar sanction of other Regulatory Authorities), and is not subject to any such debarment or similar sanction by any such Regulatory Authority. Licensee has not
used, and will not engage, in any capacity, in connection with this Agreement, any Person who either has been debarred by such a Regulatory Authority, or is the subject of a conviction described in Section 306 of the FFDCA. Licensee shall
inform Takeda in writing [***] if it or any Person engaged by Licensee who is performing services under this Agreement is debarred or is the subject of a conviction described in Section 306 of the FFDCA, or if any action, suit, claim,
investigation or legal or administrative proceeding is pending or, to Licensee’s Knowledge, is threatened, relating to the debarment or conviction of Licensee or any such Person performing services hereunder. 

(b)    To the extent permissible under Applicable Law, all employees of Licensee or its Affiliates
performing activities under this Agreement shall be under an obligation to assign all right, title and interest in and to their inventions and other know-how, whether or not patentable, and intellectual
property rights therein, to Licensee or its Affiliate(s) as the sole owner thereof. Takeda shall have no obligation to contribute to any remuneration of any inventor employed or previously employed by Licensee or any of its Affiliates in respect of
any such inventions, Information and discoveries and intellectual property rights therein that are so assigned to Licensee or its Affiliate(s). Licensee will pay all such remuneration, if any, due to such inventors with respect to such inventions
and other know-how and intellectual property rights therein. 

(c)    In performing its obligations under this Agreement, or any ancillary agreements (if any),
Licensee shall, and shall cause its Affiliates and (Sub)licensees to, comply with (i) all Applicable Law, including any applicable anti-corruption or anti-bribery laws or regulation, of any

  
 - 47 - 

 
Governmental Authority with jurisdiction over the activities performed by Licensee or its Affiliates or (Sub)licensees in furtherance of such obligations, and (ii) standard pharmaceutical
industry accepted guidelines regarding promotional materials, including Pharmaceutical Research and Manufacturers of America (PhRMA) guidelines. 

(d)    During the period commencing upon the Effective Date and until the first to occur of [***],
Licensee and its Affiliates, without the prior written consent of Takeda, during the Term, shall not solicit, induce, encourage, or participate in soliciting, inducing, or encouraging any employee of Takeda, or any of its Affiliates who has
been as of, or becomes after the Effective Date, involved in the discussion leading to this Agreement, or the Development, Manufacture or Commercialization of any Compound or Product (each, an “Involved Employee”) to terminate his
or her relationship with Takeda or Takeda’s Affiliate. An offer of employment to any such Involved Employee of Takeda by Licensee or its Affiliates which results directly from unsolicited responses to general advertisements for employment will
not be deemed to be in violation of this provision. 
 (e)    The Stock Issuance Agreement attached as
Exhibit F is substantially the same as the Common Stock purchase agreements entered into by Licensee and other founders on or prior to the Effective Date. 

(f)    The Up-Front Shares issued pursuant to Section 2.1
represent [***] of Fully-Diluted Capitalization of Licensee as of the Effective Date, excluding the securities issued in the Qualified Financing (and, for the avoidance of doubt, excluding any Series A preferred stock and any convertible
promissory notes that are converted into the securities issued in the Qualified Financing). 

(g)    The capitalization table provided to Takeda (i) reflects the information upon which the
calculation of the number of shares of Common Stock issued to Takeda pursuant to this Agreement has been made and (ii) is true, complete and correct as of the Effective Date. 

(h)    As of the date Licensee includes any Licensee Patents on Exhibit B Licensee shall have all rights
necessary to grant the license under such Licensee Patents that it grants to Takeda in this Agreement. During the Term, Licensee shall have all rights necessary to grant the rights of cross-reference under Regulatory Materials that it grants to
Takeda in this Agreement. 
 (i)    There are no Licensee Patents as of the Effective Date and
accordingly there are no Licensee Patents listed in Exhibit B as of the Effective Date. As of the date Licensee provides Takeda any update of Exhibit B, the Licensee Patents set forth in Exhibit B represent all Licensee Patents that Licensee or any
of its Affiliates (if any Affiliates) Controls that claim the Compound or Product in the Field. As of the date on which any Licensee Patent is first set forth on Exhibit B, Licensee is the sole and exclusive owner of the entire right, title and
interest in such Licensee Patent free of any encumbrance, lien, or claim of ownership by any Third Party, except to the extent otherwise expressly stated on Exhibit B. 

(j)    Licensee shall notify Takeda [***] after becoming aware of any actual or threatened infringement or
misappropriation of the Licensee Know-How or Licensee Patents by any Person. 

  
 - 48 - 

 (k)    As of the date on which any Licensee Patent is
first set forth on Exhibit B, such Licensee Patent is being diligently prosecuted in accordance with Applicable Law, and, to Licensee’s Knowledge, such Licensee Patent has been filed and maintained properly and correctly and all applicable fees
have been paid on or before the due date for payment. 
 (l)    As of the date on which any Licensee
Patent is first set forth on Exhibit B, such Licensee Patent does not fail to properly identify each and every inventor of the claims thereof as determined in accordance with Applicable Law of the jurisdiction in which such Licensee Patent is issued
or such application is pending. 
 (m)    As of the Effective Date, to Licensee’s Knowledge, the
Licensee Know-How has been kept confidential or has been disclosed to Third Parties only under terms of confidentiality. To the Knowledge of Licensee, no breach of such confidentiality has been committed by
any Third Party. 
 (n)    The inventions claimed or disclosed by any Licensee Patent (i) were not
conceived, discovered, developed, or otherwise made in connection with any research activities funded, in whole or in part, by the federal government of the U.S. or any agency thereof, (ii) are not a “subject invention” as that term
is described in 35 U.S.C. Section 201(f), and (iii) are not otherwise subject to the provisions of the Bayh-Dole Act; except in each case to the extent otherwise expressly stated on Exhibit B as of the date on which any such Licensee
Patent is first set forth on Exhibit B. 
 (o)    As of the Effective Date, to Licensee’s
Knowledge, there are no material claims, judgments, or settlements against, or amounts with respect thereto, owed by Licensee or any of its Affiliates to any Third Parties relating to the Regulatory Materials licensed by Licensee to Takeda or the
Licensee Know-How. As of the date Licensee includes any Licensee Patents on Exhibit B to Licensee’s Knowledge, there are no material claims, judgments, or settlements against, or amounts with respect
thereto, owed by Licensee or any of its Affiliates to any Third Parties relating to such Licensee Patents except in each case to the extent otherwise expressly stated on Exhibit B as of the date on which any such Licensee Patent is first set forth
on Exhibit B. 
 (p)    Licensee shall notify Takeda [***] after becoming aware of any claim or
litigation that has been brought or threatened by any Person alleging: (i) that any of the Licensee Patents is invalid or unenforceable, (ii) that the Regulatory Materials licensed by Licensee to Takeda, the Licensee Patents, the
Licensee Know-How, or the disclosing, copying, making, assigning, or licensing of the Regulatory Materials by Licensee to Takeda, the Licensee Patents or the Licensee
Know-How, violates, infringes, or otherwise conflicts or interferes with, or would violate, infringe, or otherwise conflict or interfere with, any intellectual property or proprietary right of any Person; or
(iii) related to the Development of the Product. 
 (q)    Licensee owns or otherwise controls all
right, title and interest in and to the Regulatory Materials that Licensee licenses to Takeda hereunder, and to Licensee’s Knowledge, Licensee and its Affiliates have generated, prepared, maintained, and retained all material Regulatory
Materials in the Field that are required to be maintained or retained pursuant to and in accordance with GCP, GLP and other Applicable Law, and all such information is true, complete and correct in all material respects and what it purports to be.

  
 - 49 - 

 10.4    No Other Representations or Warranties. EXCEPT AS
EXPRESSLY SET FORTH IN THIS ARTICLE 10, THE PARTIES MAKE NO REPRESENTATIONS OR WARRANTIES OF ANY KIND WHATSOEVER, EITHER EXPRESS OR IMPLIED, WRITTEN OR ORAL, EITHER IN FACT OR BY OPERATION OF LAW, BY STATUTE OR OTHERWISE, AND EACH PARTY
SPECIFICALLY DISCLAIMS ANY OTHER WARRANTIES, INCLUDING ANY EXPRESS OR IMPLIED WARRANTY OF QUALITY, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR WARRANTY OF NON-INFRINGEMENT OR AS TO THE VALIDITY OF
ANY PATENTS. 
 ARTICLE 11 – CONFIDENTIALITY 

11.1    Nondisclosure. Each Party agrees that, during the Term and for a period of [***] thereafter, a Party
(the “Receiving Party”) receiving Confidential Information of the other Party (the “Disclosing Party”) shall (a) maintain in confidence such Confidential Information using not less than the efforts such
Receiving Party uses to maintain in confidence its own confidential or proprietary information of similar kind and value, (b) not disclose such Confidential Information to any Third Party without the prior written consent of the Disclosing
Party, except for disclosures expressly permitted below, and (c) not use such Confidential Information for any purpose except those permitted by this Agreement (it being understood that this Section 11.1 shall not create or imply any
rights or licenses not expressly granted under this Agreement). Notwithstanding anything to the contrary in the foregoing, the obligations of confidentiality and non-use with respect to any trade secret (to
the extent understood by a Party to be a trade secret) within such Confidential Information shall survive such [***] period for so long as such Confidential Information remains protected as a trade secret under Applicable Law. 

11.2    Exceptions. The obligations in Section 11.1 shall not apply with respect to any portion of the
Confidential Information that the Receiving Party can show by competent evidence: 
 (a)    is publicly
disclosed by the Disclosing Party, either before or after it is disclosed to the Receiving Party hereunder; 

(b)    is known to the Receiving Party or any of its Affiliates, without any obligation to keep it
confidential or any restriction on its use, prior to disclosure by the Disclosing Party; 
 (c)    is
subsequently disclosed to the Receiving Party or any of its Affiliates on a non-confidential basis by a Third Party that, to the Receiving Party’s knowledge, is not bound by a similar duty of
confidentiality or restriction on its use; 
 (d)    is now, or hereafter becomes, through no act or
failure to act on the part of the Receiving Party or any of its Affiliates, generally known or available, either before or after it is disclosed to the Receiving Party; 

(e)    is independently discovered or developed by or on behalf of the Receiving Party or any of its
Affiliates without the use of or access to Confidential Information belonging to the Disclosing Party; or 

(f)    is the subject of written permission to disclose provided by the Disclosing Party. 

  
 - 50 - 

 11.3    Authorized Disclosure. The Receiving Party may
disclose Confidential Information belonging to the Disclosing Party only to the extent such disclosure is reasonably necessary in the following instances: 

(a)    filing or prosecuting Patents as permitted by this Agreement; 

(b)    filing Regulatory Materials in order to obtain or maintain Regulatory Approvals; 

(c)    prosecuting or defending litigation, including responding to a subpoena in a Third Party
litigation; 
 (d)    complying with Applicable Law or regulations or court or administrative orders; or

 (e)    to its Affiliates, (Sub)licensees or prospective (Sub)licensees, subcontractors or prospective
subcontractors, payors, consultants, agents and advisors on a “need-to-know” basis in order for the Receiving Party to exercise its rights or fulfill its
obligations under this Agreement, each of whom prior to disclosure must be bound by obligations of confidentiality and restrictions on use of such Confidential Information that are no less restrictive (except for the duration of such restrictions,
which shall be no less than [***] than those set forth in this Article 11; provided, however, that, in each of the above situations, the Receiving Party shall remain responsible for any failure by any Person who receives Confidential Information
pursuant to this Section 11.3(e) to treat such Confidential Information as required under this Article 11. 

(f)    to its actual or prospective investors, acquirers, merger-partners, and to any investment advisors,
each of whom prior to disclosure must be bound by obligations of confidentiality and restrictions on use of such Confidential Information that are no less restrictive than those set forth in this Article 11 (except for the duration of such
restrictions, which shall be [***] or, [***]); provided, however, that, in each of the above situations, the Receiving Party shall remain responsible for any failure by any Person who receives Confidential Information pursuant to this
Section 11.3(f) to treat such Confidential Information as required under this Article 11. 

(g)    If and whenever any Confidential Information is disclosed in accordance with this
Section 11.3, such disclosure shall not cause any such information to cease to be Confidential Information except to the extent that such disclosure results in a public disclosure of such information (other than by breach of this Agreement).
Notwithstanding the foregoing, in the event a Party is required to make a disclosure of the other Party’s Confidential Information pursuant to clauses (a) through (d) of this Section 11.3, it shall, except where impracticable, give
reasonable advance notice to the other Party of such disclosure and use not less than the same efforts to secure confidential treatment of such information as it would to protect its own confidential information from disclosure and shall be jointly
and severally liable for any breach of this Article 11 by such Person. 
 11.4    Terms of this Agreement.
The Parties acknowledge that this Agreement and all of the respective terms of this Agreement shall be treated as Confidential Information of both Parties. 

11.5    Publicity. After consummation of the Qualified Financing, the Parties shall make a joint public
announcement of the execution of this Agreement which shall be issued at a time to be mutually agreed by the Parties. The Parties intend that the content of the joint public 

  
 - 51 - 

 
announcement will be substantially similar to the form of press release attached hereto as Exhibit J, however the final content must be mutually agreed upon by both Parties prior to being issued
by either party.    Each Party agrees not to issue any other press release or other public statement disclosing other information relating to this Agreement or the transactions contemplated hereby that contains information
not previously publicly disclosed in accordance with this Section 11.5 without the prior written consent of the other Party, not to be unreasonably withheld, conditioned or delayed. 

11.6    Securities Filings. Notwithstanding anything to the contrary in this Article 11, in the event either Party
proposes to file with the Securities and Exchange Commission or the securities regulators of any state or other jurisdiction a registration statement or any other disclosure document that describes or refers to the terms and conditions of this
Agreement or any related agreements between the Parties, such Party shall notify the other Party of such intention and shall provide the other Party with a copy of relevant portions of the proposed filing at least [***] prior to such filing (and any
revisions to such portions of the proposed filing a reasonable time prior to the filing thereof), including any exhibits thereto that refer to the other Party or the terms and conditions of this Agreement or any related agreements between the
Parties. The Party making such filing shall cooperate in good faith with the other Party to obtain confidential treatment of the terms and conditions of this Agreement or any related agreements between the Parties that the other Party requests to be
kept confidential or otherwise afforded confidential treatment, and shall only disclose Confidential Information that it is reasonably advised by legal counsel is legally required to be disclosed. No such notice shall be required if the description
of or reference to this Agreement or a related agreement between the Parties contained in the proposed filing has been included in any previous filing made by the either Party in accordance with this Section 11.6 or otherwise approved by the
other Party or disclosed in a prior press release by the Parties or other prior public disclosure made by a Party in accordance with the terms of this Article 11. 

11.7    Publications and Promotional Materials.  

(a)    As between the Parties, (i) Licensee, its Affiliates and its or their (Sub)licensees will have
the sole right to publish academic, scientific or medical peer reviewed publications that relate to the Compound or a Product, other than any publication of data resulting from Clinical Trials conducted by Takeda, its Affiliates and its or their
(Sub)licensees with respect to Development of Product for Regulatory Approval in Japan, and (ii) Takeda, its Affiliates and its or their (Sub)licensees will have the sole right to publish data resulting from Clinical Trials conducted by Takeda,
its Affiliates and its or their (Sub)licensees with respect to Development of Product for Regulatory Approval in Japan. 

(b)    Each Party shall submit to the other Party for such other Party’s review any proposed
academic, scientific or medical peer reviewed publication by such Party, its Affiliates and its or their (Sub)licensees that relates to the Compound or a Product. Licensee shall also submit to Takeda for its review any proposed academic, scientific
or medical publication or public presentation that contains Takeda Know-How or Joint Know-How that has not been previously publicly disclosed or otherwise approved by
Takeda to be publicly disclosed, for the purposes of determining whether any portion of the proposed publication or presentation should be modified or deleted so as to preserve the value of such Takeda
Know-How and Joint Know-How. Takeda shall also submit to Licensee for its review any proposed academic, scientific or medical

  
 - 52 - 

 
publication or public presentation that contains Licensee Know-How or Joint Know-How that has not been previously
publicly disclosed or otherwise approved by Licensee to be publicly disclosed, for the purposes of determining whether any portion of the proposed publication or presentation should be modified or deleted so as to preserve the value of such Licensee
Know-How or Joint Know-How. Each Party shall consider all comments provided by the other Party in good faith, including comments regarding the potential adverse impact
on Exploitation of Compound and/or Product. 
 (c)    Written copies of any proposed publication or
presentation required to be submitted hereunder shall be submitted to the applicable Party no later than [***] before submission for publication or presentation (the “Review Period”). The Party receiving such submission shall
provide its comments with respect to such publications and presentations within [***] of its receipt of such written copy. The Review Period may be extended for an additional [***] in the event such receiving Party can, within [***] of receipt of
the written copy, demonstrate reasonable need for such extension including for the preparation and filing of patent applications. 

(d)    Each Party shall comply, and shall cause its Affiliates and (Sub)licensees to comply, with
(i) standard academic practice regarding authorship of scientific publications and recognition of contribution of the other Party in any publication governed by this Section 11.7, including International Committee of Medical Journal
Editors standards regarding authorship and contributions, and (ii) standard pharmaceutical industry accepted guidelines regarding promotional materials, including Pharmaceutical Research and Manufacturers of America (PhRMA) guidelines. 

11.8    Equitable Relief. Given the nature of the Confidential and the competitive damage that could result
to a Party upon unauthorized disclosure, use or transfer of its Confidential Information to any Third Party, the Parties agree that monetary damages may not be a sufficient remedy for any breach of this Article 11. In addition to all other
remedies, a Party shall be entitled to seek specific performance and injunctive and other equitable relief as a remedy for any breach or threatened breach of this Article 11. 

ARTICLE 12 – COMMITTEE 

12.1    Information Sharing Committee. Within [***] after the Effective Date, the Parties will establish an
information sharing committee (the “Information Sharing Committee”). The Information Sharing Committee will be comprised of two (2) representatives from each Party, or such other number of equal representatives as the Parties
may mutually agree upon. From time to time each Party may replace its Information Sharing Committee representatives by written notice to the other Party specifying the prior representative(s) and their replacement(s). The Information Sharing
Committee will meet at least [***], or as frequently as agreed to by the members of the Information Sharing Committee, on such dates and at such times and places as agreed to by the members of the Information Sharing Committee, provided that at
least [***] will be held in person unless otherwise mutually agreed. Each Party will be responsible for its own expenses relating to attendance at or participation in Information Sharing Committee meetings. The purpose of the Information Committee
will be for (i) Party to provide the other Party with updates regarding progress of such Party’s and its Affiliates’ and (Sub)licensees’ Development, Manufacturing, and 

  
 - 53 - 

 
Commercialization activities with respect to the Compound and Product, and (ii) the Parties, in accordance with Section 12.2, to exchange Licensee
Know-How and Takeda Know-How. 

12.2    Sharing of Know-How. 

(a)    At [***] Information Sharing Committee meeting each Calendar Year, the Information Sharing Committee
shall discuss, and in good faith attempt to agree upon, whether any Takeda Know-How first obtained or generated by Takeda after the Effective Date or any Licensee
Know-How is reasonably necessary or useful to enable Licensee or Takeda, respectively: (i) to perform its obligations under this Agreement; (ii) Develop or Manufacture the Product; and
(iii) Commercialize the Product in its respective territory. Takeda shall disclose to Licensee all Takeda Know-How first obtained or generated by Takeda after the Effective Date, and Licensee shall
disclose to Takeda all Licensee Know-How first obtained or generated by Licensee after the Effective Date, in each case that the Information Sharing Committee determines is reasonably necessary or useful to
enable Licensee and Takeda, respectively: (A) to perform its obligations under this Agreement; (B) Develop or Manufacture the Product; and (C) Commercialize the Product in its respective territory. All decisions by the Information
Sharing Committee as to any Information to be shared pursuant to this Section 12.2(a) shall be taken only following unanimous vote, with each Party having one (1) vote. 

(b)    In addition to the foregoing, during the Term, at either Party’s reasonable request, the other
Party will cooperate with the requesting party to transfer Information created after the Effective Date to the extent relating to CMC data and Clinical Trial data. 

12.3    Non-Member Participation. Additional
non-members of the Information Sharing Committee having relevant experience may from time to time be invited to participate in an Information Sharing Committee meeting, provided that such participants shall
have no voting rights or powers. Non-member participants who are not employees of a Party or its Affiliates shall only be allowed to attend if: (1) the other Party’s representatives have consented to
the attendance (such consent not to be unreasonably withheld, conditioned or delayed); and (2) such non-member participant is subject to confidentiality and non-use
obligations at least as restrictive as those set forth in this Agreement. 
 12.4    Alliance Managers. Promptly
following the Effective Date, each Party shall designate in writing an Alliance Manager to serve as the primary point of contact for the Parties regarding this Agreement. Each Alliance Manager shall facilitate communication and coordination of the
Parties’ activities under this Agreement. The Alliance Managers shall not be a member of the Information Sharing Committee but shall be allowed to attend any Information Sharing Committee meeting as a
non-voting observer. 
 12.5    English Language. With respect to the
following material communications with any Regulatory Authority which are required to be provided by one Party to the other under this Agreement, the providing Party shall provide such communication in the English language: communications or filings
with the PMDA prior to the Effective Date. Notwithstanding the above, Takeda shall not be required to translate the CMC section of any Regulatory Authority communication or filing. 

  
 - 54 - 

 ARTICLE 13 – TERM AND TERMINATION 

13.1    Term. This Agreement shall become effective as of the Effective Date and shall continue in full force and
effect until the expiration of this Agreement as described in this Section 13.1, unless earlier terminated pursuant to this Article 13 (the “Term”). This Agreement shall expire as follows: 

(a)    on a
country-by-country and Product-by-Product basis, upon the expiration of the Royalty Term
with respect to each Product in each country, as applicable; or 
 (b)    in its entirety, upon the
expiration of the Royalty Term with respect to the last Product Commercialized in the last country. 

13.2    Termination for Material Breach.  

(a)    Either Party (the “Non-breaching Party”) may
terminate this Agreement in its entirety in the event the other Party (the “Breaching Party”) has materially breached this Agreement, and such material breach has not been cured within [***] (other than any breach for failure to
pay, which shall be [***] or other than as provided in Section 13.2(b)) after receipt of written notice of such breach by the Breaching Party from the Non-Breaching Party (the “Cure
Period”); provided, however, that, to the extent termination is for uncured breach by Licensee, such termination shall apply only to those countries in the Territory to which such breach relates except for an uncured breach affecting the United
States, in which case this Agreement will terminate in its entirety. A material breach by Licensee of the Warrant, which is not cured by Licensee within [***] after written notice of such material breach to Licensee from Takeda, shall be
deemed a material breach of this Agreement which relates to the entire Territory. The written notice describing the alleged material breach shall provide sufficient detail to put the Breaching Party on notice of such material breach. Any
termination of this Agreement pursuant to this Section 13.2(a) shall become effective at the end of the Cure Period, unless the Breaching Party has cured any such material breach prior to the expiration of such Cure Period, or unless such
allegedly breaching Party disputes such breach. The right of either Party to terminate this Agreement as provided in this Section 13.2(a) shall not be affected in any way by such Party’s waiver of or failure to take action with respect to
any previous breach under this Agreement. 
 (b)    If the Parties reasonably and in good faith disagree
as to whether there has been a material breach, including whether such breach was material, the Party that disputes whether there has been a material breach may contest the allegation in accordance with Article 14. Notwithstanding anything to the
contrary contained in Section 13.2(a), the Cure Period for any Dispute shall run from the date that written notice was first provided to the Breaching Party by the Non-Breaching Party through the
resolution of such Dispute pursuant to Article 14, and it is understood and acknowledged that, during the pendency of a Dispute pursuant this Section 13.2(b), all of the terms and conditions of this Agreement shall remain in effect, and the
Parties shall continue to perform all of their respective obligations under this Agreement. 
 13.3    Termination by
Licensee. 
 (a)    Licensee shall have the unilateral right to terminate this entire Agreement upon
six (6) months prior written notice to Takeda. 

  
 - 55 - 

 (b)    Licensee shall have the right to terminate this
entire Agreement at any time upon providing [***] prior written notice to Takeda if Licensee determines that the Compound or the Product caused or is likely to cause a fatal, life-threatening or other serious adverse event that is reasonably
expected, based upon then available data, to preclude continued Development and/or Commercialization of the Product in the Field in the Territory. 

(c)    The Parties may agree to terminate this Agreement prior to expiration of the [***] notice
period provided in Section 13.3(b) above, where the Parties: (i) have reached consensus regarding the inability to continue Commercializing the Products in the Field in the Territory for the reasons set forth in Section 13.3(b); and
(ii) have completed all wind-down and other transition activities, including those set forth in Section 13.6. 

13.4    Termination for Patent Challenge. Takeda may terminate this entire Agreement at any time upon written
notice to Licensee, if Licensee, or any of Licensee’s Affiliates, or its or their (Sub)licensees, directly, or indirectly through assistance granted to a Third Party, commences any interference or opposition proceeding, challenges the validity
or enforceability of, or opposes any extension of or the grant of a supplementary protection certificate with respect to (a “Patent Proceeding”) any Takeda Patent anywhere in the Territory except for a country in the Territory in
which this Agreement has been terminated prior to the commencement of any such Patent Proceeding. However, Takeda’s right to terminate this Agreement under this Section 13.4 shall not apply to any Affiliate of Licensee that first becomes
an Affiliate of Licensee after the Effective Date in connection with a merger or acquisition event, or any (Sub)licensee, where such Affiliate or (Sub)licensee was undertaking activities in connection with a Patent Proceeding prior to such merger or
acquisition event or the grant of such sublicense, provided such Affiliate or (Sub)licensee promptly ceases all activities in the furtherance of such Patent Proceeding and withdraws or terminates with prejudice any such Patent Proceeding within
[***] of such merger or acquisition event or grant of sublicense. 
 13.5    Automatic Termination for Failure to
Consummate a Qualified Financing. This Agreement shall automatically terminate if Licensee has not consummated a Qualified Financing within [***] of the Effective Date. 

13.6    Termination for Insolvency. 

(a)    Either Party may terminate this Agreement in its entirety upon providing written notice to the other
Party on or after the time that such other Party makes a general assignment for the benefit of creditors, files an insolvency petition in bankruptcy, petitions for or acquiesces in the appointment of any receiver, trustee or similar officer to
liquidate or conserve its business or any substantial part of its assets, commences under the laws of any jurisdiction any proceeding involving its insolvency, bankruptcy, reorganization, adjustment of debt, dissolution, liquidation or any other
similar proceeding for the release of financially distressed debtors, or becomes a party to any proceeding or action of the type described above, and such proceeding or action remains un-dismissed or un-stayed for a period of more than [***]. 
 (b)    All rights and
licenses granted under or pursuant to this Agreement are, and shall otherwise be deemed to be, for purposes of Section 365(n) of Title 11 of the United States Code and other similar laws in any other jurisdiction (collectively, the
“Bankruptcy Laws”), licenses of 

  
 - 56 - 

 
rights to “intellectual property” as defined under the Bankruptcy Laws. If a case is commenced during the Term by or against a Party under Bankruptcy Laws then, unless and until this
Agreement is rejected as provided pursuant to such Bankruptcy Laws, such Party (in any capacity, including debtor-in-possession) and its successors and assigns
(including a Title 11 trustee) shall perform all of the obligations in this Agreement intended to be performed by such Party. If a case is commenced during the Term by or against a Party under the Bankruptcy Laws, this Agreement is rejected as
provided for under the Bankruptcy Laws, and the non-bankrupt Party elects to retain its rights hereunder as provided for under the Bankruptcy Laws, then the Party subject to such case under the Bankruptcy Laws
(in any capacity, including debtor-in-possession) and its successors and assigns (including a Title 11 trustee), shall provide to the
non-bankrupt Party copies of all Patents and Information necessary for the non-bankrupt Party to prosecute, maintain and enjoy its rights under the terms of this
Agreement. All rights, powers and remedies of the non-bankrupt Party as provided herein are in addition to and not in substitution for any and all other rights, powers and remedies now or hereafter existing at
law or in equity (including the Bankruptcy Laws) in the event of the commencement of a case by or against a Party under the Bankruptcy Laws. In particular, it is the intention and understanding of the Parties to this Agreement that the rights
granted to the Parties under this Section 13.5 are essential to the Parties’ respective businesses and the Parties acknowledge that damages are not an adequate remedy. 

13.7    Effects of Termination. All of the following effects of termination are in addition to the other rights and
remedies that may be available to either of the Parties under this Agreement and shall not be construed to limit any such rights or remedies. Upon the termination of this Agreement: 

(a)    Notwithstanding anything contained in this Agreement to the contrary, all rights and licenses
granted herein to Licensee shall terminate in the terminated countries and Licensee shall cease any and all Development, Manufacture, and Commercialization activities with respect to the Compound and the Product in such terminated countries except
for Licensee’s rights under Section 13.6(f) below; 
 (b)    All payment obligations to Takeda
under Article 8 (excluding Section 8.12) with respect to Licensee’s Net Sales of Product in the terminated countries shall terminate, other than those that are accrued and unpaid as of the effective date of such termination or that are
required to be paid pursuant to Section 8.12 or Section 13.6(f); 
 (c)    [***]. 

(d)    [***]; 

(e)    [***]; 

(f)    Subject to the payment of all amounts required under Sections 13.6(b) above and Article 8 with
respect to Licensee’s Net Sales of Product, for a period of up to [***] after termination of this Agreement, Licensee shall have the right to sell or otherwise dispose of any inventory of the Product on hand at the time of such termination or
in the process of Manufacturing; 
 (g)    [***]; and 

  
 - 57 - 

 (h)    [***]. 

13.8    Effect of Addition of Japan to Territory. Upon the addition of Japan to the Territory in accordance with
Section 7.1(b): 
 (a)    Notwithstanding anything contained in this Agreement to the contrary, all
rights and licenses granted herein to Takeda to Develop (for Commercialization in Japan), Manufacture (for Commercialization in Japan) and Commercialize in Japan shall terminate, Takeda shall cease any and all such Development, Manufacture, and
Commercialization activities with respect to the Compound and the Product for Japan, and the Territory shall be deemed to include the world, and accordingly all rights of Takeda to Exploit Compounds or Products with respect to Japan will terminate
except for Takeda’s rights under Section 13.7(d) below; 
 (b)    All Takeda payment
obligations to Licensee under Article 8 (excluding Section 8.12) with respect to Takeda’s Net Sales of the Product in Japan shall terminate, other than those that are accrued and unpaid as of the effective date of such termination or that
are required to be paid pursuant to Section 8.12 or Section 13.7(d); 
 (c)    [***]; 

(d)    Subject to the payment of all amounts required under Sections 13.7(b) above and Article 8 with
respect to Takeda’s Net Sales of Product, for a period of up to [***] after termination of this Agreement, Takeda shall have the right to sell or otherwise dispose of any inventory of the Product on hand at the time of such termination or in
the process of Manufacturing; 
 (e)    [***]; and 

(f)    [***]. 

13.9    Remedies. Notwithstanding anything to the contrary in this Agreement, except as otherwise set forth in this
Agreement, termination or expiration of this Agreement shall not relieve the Parties of any liability or obligation which accrued hereunder prior to the effective date of such termination or expiration, nor prejudice either Party’s right to
obtain performance of any obligation. Each Party shall be free, pursuant to Article 14, to seek, without restriction as to the number of times it may seek, damages, expenses and remedies that may be available to it under Applicable Law or in equity
and shall be entitled to offset the amount of any damages and expenses obtained against the other Party in a final determination under Section 14.3, against any amounts otherwise due to such other Party under this Agreement. 

13.10    Survival. The following provisions shall survive any expiration or termination of this Agreement for the
period of time specified therein (or, if no such period is specified, indefinitely): Articles 1, 8 (but only to the extent relating to milestone events occurring on or prior to the date of expiration or termination, and only with respect to
royalties owed, if any, on Products sold prior to the date of expiration or termination, or sold by Licensee, its Affiliates or (Sub)licensees after such termination to the extent expressly permitted under this Agreement), 11 (for the period set
forth in Section 11.1), 14, 15, and 16 and Sections 2.1 (b), (c), (d), (e) and (f), 3.1, 4.3(d), 4.4, 4.6, 4.7, 5.8 (first sentence only), 5.9 (last sentence only), 6.6 (solely following expiration if both Parties (or any of their
(Sub)licensees) are Commercializing Product), 9.1, 9.2 (with respect to any 

  
 - 58 - 

 
disclosure obligations that arise on or prior to expiration or termination), 9.3(b) (with respect to Licensee’s obligation to notify Takeda of Licensee’s decision to abandon or not
maintain Licensee Patents), 9.3(c) (solely with respect to any Joint Patents not assigned to Takeda), 9.3(d)(ii)-(iii), 9.5(d) (to the extent any suit or action under that section is still pending upon expiration or termination), 10.4, 13.7, 13.9,
and 13.10. Following the expiration of this Agreement pursuant to Section 13.1 with respect to a Product in a country of the Territory, Licensee will have a perpetual, irrevocable, non-exclusive,
fully-paid and royalty-free right and license, with the right, subject to Takeda’s prior written consent, which shall not be unreasonably withheld, conditioned or delayed, to grant sublicenses, under the Takeda Intellectual Property to Exploit
such Product in the Field in such country of the Territory. Following the expiration of this Agreement pursuant to Section 13.1 with respect to a Product in a country outside of the Territory, Takeda will have a perpetual, irrevocable, non-exclusive, fully-paid and royalty-free right and license, with the right, subject to Licensee’s prior written consent, which shall not be unreasonably withheld, conditioned or delayed, to grant sublicenses,
under the Licensee Intellectual Property to Exploit such Product in the Field in such country. 
 ARTICLE 14– DISPUTE
RESOLUTION 
 14.1    Exclusive Dispute Resolution Mechanism. The Parties agree that the procedures
set forth in this Article 14 shall be the exclusive mechanism for resolving any dispute, controversy, or claim between the Parties that may arise from time to time pursuant to this Agreement relating to either Party’s rights or obligations
hereunder (each, a “Dispute”, and collectively, the “Disputes”) that is not resolved through good faith negotiation between the Parties. 

14.2    Resolution by Executive Officers. Except as otherwise provided in this Section 14.2, in the
event of any Dispute, the Parties shall first attempt in good faith to resolve such Dispute by negotiation and consultation between themselves. In the event that such Dispute is not resolved on an informal basis within [***] after receipt of written
notice of such Dispute by a Party, either Party may, by written notice to the other Party, refer the Dispute to the senior executive officer (or his/her delegate) of the other Party for attempted resolution by good faith negotiation within [***]
after such notice is received. Each Party may, in its sole discretion, seek resolution of any and all Disputes that are not resolved under this Section 14.2 in accordance with Section 14.3. 

14.3    Litigation. Any unresolved Dispute which was subject to Section 14.2, shall be brought exclusively in
a court of competent jurisdiction, federal or state, located in New York, New York, and in no other jurisdiction. Each Party to this Agreement, by its execution hereof, (a) hereby irrevocably submits to the exclusive jurisdiction of the United
States District Court and state courts located in New York, New York for the purpose of any and all unresolved Disputes which were subject to Section 14.2; (b) hereby waives to the extent not prohibited by Applicable Law, and agrees not to
assert, by way of motion, as a defense or otherwise, in any such action, any claim that it is not subject personally to the jurisdiction of the above-named courts, that its property is exempt or immune from attachment or execution, that any such
action brought in one of the above-named courts in such jurisdiction should be dismissed on grounds of forum non-conveniens, should be transferred to any court other than one of the above-named courts, or should be stayed by reason of the pendency
of some other proceeding in any other court other than one of the above-named courts, or that this Agreement or the subject matter hereof may not be enforced in or by such court, and (c) hereby agrees not to commence any such action other than
before one of the 

  
 - 59 - 

 
above-named courts nor to make any motion or take any other action seeking or intending to cause the transfer or removal of any such action to any court other than one of the above-named courts
whether on the grounds of inconvenient forum or otherwise. Notwithstanding the foregoing, application may be made to any court of competent jurisdiction with respect to the enforcement of any judgment or award. 

14.4    Preliminary Injunctions. Notwithstanding anything in this Agreement to the contrary, a Party may seek a
temporary restraining order or a preliminary injunction from any court of competent jurisdiction in order to prevent immediate and irreparable injury, loss, or damage on a provisional basis, pending the decision of the arbitrator(s) on the ultimate
merits of any Dispute. 
 14.5    Payment Tolling. During the pendency of any dispute resolution proceeding
between the Parties under this Article 14, the obligation to make any payment, or portion thereof, under this Agreement from one Party to the other Party, which payment, or portion thereof, is the subject, in whole or in part, of a proceeding under
this Article 14, shall be tolled until the final outcome of such Dispute has been established. Any portion of a payment which is not in dispute shall be paid in accordance with the terms of this Agreement. 

14.6    Confidentiality. Any and all activities conducted under Article 14, including any and all proceedings and
decisions under Section 14.3, shall be deemed Confidential Information of each of the Parties, and shall be subject to Article 11. 

14.7    WAIVER OF RIGHT TO JURY TRIAL. In connection with the Parties’ rights under Section 14.3, EACH
PARTY, TO THE EXTENT PERMITTED BY APPLICABLE LAWS, KNOWINGLY, VOLUNTARILY, AND INTENTIONALLY WAIVES ITS RIGHT TO A TRIAL BY JURY IN ANY ACTION OR OTHER LEGAL PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT AND THE TRANSACTIONS IT
CONTEMPLATES. THIS WAIVER APPLIES TO ANY ACTION OR LEGAL PROCEEDING, WHETHER SOUNDING IN CONTRACT, TORT, OR OTHERWISE. 
 ARTICLE 15
– INDEMNIFICATION AND LIMITATION OF LIABILITY 
 15.1    Indemnification by Licensee. Licensee
hereby agrees to defend, indemnify and hold harmless Takeda and its Affiliates, and each of their respective directors, officers, employees, agents and representatives (each, a “Takeda Indemnitee”) from and against any and
all claims, suits, actions, demands, liabilities, expenses and/or loss, including reasonable legal expense and attorneys’ fees (collectively, the “Losses”), to which any Takeda Indemnitee may become subject as a result
of any claim, demand, action or other proceeding by any Third Party (each, a “Claim”) to the extent such Losses arise directly or indirectly out of: (i) the practice by Licensee or its Affiliate of any license granted to
it under Article 4; (ii) the use, handling, storage, sale or other disposition of the Compound or the Product by Licensee or its Affiliate or (Sub)licensee, including any use of the Compound or the Product for Development and Commercialization;
(iii) the breach by Licensee of any warranty, representation, covenant or agreement made by Licensee in this Agreement; or (iv) the negligence, gross negligence or willful misconduct of Licensee, its Affiliate or its (Sub)licensee, or any
officer, director, employee, agent or representative thereof; except, with respect to each of subsections (i) through (iv) above, to the extent such Losses arise directly or indirectly from the negligence, gross negligence or willful misconduct
of any Takeda 

  
 - 60 - 

 
Indemnitee or the breach by Takeda of any warranty, representation, covenant or agreement made by Takeda in this Agreement, or are subject to Takeda’s indemnification obligations pursuant to
Section 15.2. 
 15.2     Indemnification by Takeda. Takeda hereby agrees to defend, indemnify and
hold harmless Licensee and its Affiliates and each of their respective directors, officers, employees, agents and representatives (each, an “Licensee Indemnitee”) from and against any and all Losses to which any Licensee
Indemnitee may become subject as a result of any Claim to the extent such Losses arise directly or indirectly out of: (i) the practice by Takeda or its Affiliate of any license granted to it under Article 4; (ii) the manufacture, use, handling,
storage, sale or other disposition of the Compound or the Product (other than the manufacture, use, handling, storage, by Takeda or any of its Affiliates or licensees for any of the Licensee Indemnitees or the sale or other disposition of Compound
or Product by Takeda or its Affiliate or its licensee to any of the Licensee Indemnitees) by Takeda or its Affiliate or its licensee (other than Licensee or its Affiliate or (Sub)licensee); (iii) the breach by Takeda of any warranty,
representation, covenant or agreement made by Takeda in this Agreement; or (iv) the negligence, gross negligence or willful misconduct of Takeda or its Affiliate or its licensee (other than Licensee or its Affiliate), or any officer, director,
employee, agent or representative thereof; except, with respect to each of subsections (i) through (iv) above, to the extent such Losses arise directly or indirectly from the negligence, gross negligence or willful misconduct of any Licensee
Indemnitee or the breach by Licensee of any warranty, representation, covenant or agreement made by Licensee in this Agreement, or are subject to Licensee’s indemnification obligations pursuant to Section 15.1. 

15.3    Indemnification Procedures. 

(a)    Notice. Promptly after a Takeda Indemnitee or a Licensee Indemnitee (each, an
“Indemnitee”) receives notice of a pending or threatened Claim, such Indemnitee shall give written notice of the Claim to the Party from whom the Indemnitee is entitled to receive indemnification pursuant to
Sections 15.1 or 15.2, as applicable (the “Indemnifying Party”). However, an Indemnitee’s delay in providing or failure to provide such notice shall not relieve the Indemnifying Party of its indemnification obligations,
except to the extent it can demonstrate prejudice due to the delay or lack of notice. 

(b)    Defense. Upon receipt of notice under Section 15.3(a) from the Indemnitee, the
Indemnifying Party shall have the duty to either compromise or defend, at its own expense and by legal counsel (reasonably satisfactory to Indemnitee), such Claim. The Indemnifying Party shall promptly (and in any event not more than [***] after
receipt of the Indemnitee’s original notice) notify the Indemnitee in writing that it acknowledges its obligation to indemnify the Indemnitee with respect to the Claim pursuant to this Article 15 and of its intention either to compromise
or defend such Claim. Once the Indemnifying Party gives such notice to the Indemnitee, the Indemnifying Party is not liable to the Indemnitee for the fees of other legal counsel or any other expenses subsequently incurred by the Indemnitee in
connection with such defense, other than the Indemnitee’s reasonable expenses of investigation and cooperation. However, the Indemnitee shall have the right to employ separate legal counsel and to control the defense of a Claim at its own
expense. 

  
 - 61 - 

 (c)    Cooperation. The Indemnitee shall
cooperate fully with the Indemnifying Party and its legal representatives in the investigation and defense of any Claim. The Indemnifying Party shall keep the Indemnitee informed on a reasonable and timely basis as to the status of such Claim (to
the extent the Indemnitee is not participating in the defense of such Claim) and conduct the defense of such Claim in a prudent manner. 

(d)    Settlement. If an Indemnifying Party assumes the defense of a Claim, no compromise or
settlement of such Claim may be effected by the Indemnifying Party without the Indemnitee’s written consent (which consent shall not be unreasonably withheld, conditioned or delayed), unless: (i) there is no finding or admission of any
violation of law or any violation of the rights of any person and no effect on any other claims that may be made against the Indemnitee; (ii) the sole relief provided is monetary damages that are paid in full by the Indemnifying Party; and
(iii) the Indemnitee’s rights under this Agreement are not adversely affected. If the Indemnifying Party fails to assume defense of a Claim within a reasonable time, the Indemnitee may settle such Claim on such terms as it deems
appropriate with the consent of the Indemnifying Party (which consent shall not be unreasonably withheld, conditioned or delayed), and the Indemnifying Party shall be obligated to indemnify the Indemnitee for such settlement as provided in this
Article 15. 
 15.4    Limitation of Liability. EXCEPT FOR A PARTY’S OBLIGATIONS SET FORTH IN
THIS ARTICLE 15, AND ANY BREACH OF ARTICLE 11 (CONFIDENTIALITY), IN NO EVENT WILL EITHER PARTY BE LIABLE TO THE OTHER PARTY (OR THE OTHER PARTY’S AFFILIATES OR (SUB)LICENSEES) IN CONNECTION WITH THIS AGREEMENT FOR LOST REVENUE, LOST PROFITS,
LOST SAVINGS, LOSS OF USE, DAMAGE TO GOODWILL, OR ANY CONSEQUENTIAL, INCIDENTAL, SPECIAL, EXEMPLARY, PUNITIVE OR INDIRECT DAMAGES UNDER ANY THEORY, INCLUDING CONTRACT, NEGLIGENCE, OR STRICT LIABILITY, EVEN IF THAT PARTY HAS BEEN PLACED ON NOTICE OF
THE POSSIBILITY OF SUCH DAMAGES. 
 ARTICLE 16 – MISCELLANEOUS 

16.1    Notice. Any notice, request, or other communication permitted or required under this Agreement shall be in
writing, shall refer specifically to this Agreement and shall be hand delivered or sent by a recognized overnight delivery service, expenses prepaid, or by facsimile (with transmission confirmed), to the following addresses or to such other
addresses as a Party may designate by written notice in accordance with this Section 16.1: 
 If to Takeda: 

Takeda Vaccines, Inc. 

40 Landsdowne Street 

Cambridge, Massachusetts Attention: President of the Global Vaccine Business Unit 

  
 - 62 - 

 Copy to (which alone shall not constitute sufficient notice): 

Takeda Vaccines, Inc. 

75 Sidney Street 

Cambridge, Massachusetts Attention: Chief Counsel Specialty BUs R&D 

If to Licensee: 

HilleVax, Inc. 

601 Union Street, Suite 3200 

Seattle, WA, 98101, U.S.A. 

Attention: Chief Executive Officer 

Copy to (which alone shall not constitute sufficient notice): 

Latham & Watkins LLP 

12670 High Bluff Drive 

San Diego, CA 92103, U.S.A. 

Attention: Cheston J. Larson 

Email: cheston.larson@lw.com 

Facsimile No.: (858) 523-5450 

16.2    Designation of Affiliates. Each Party may discharge any obligations and exercise any rights
hereunder through delegation of its obligations or rights to any of its Affiliates. Each Party hereby guarantees the performance by its Affiliates of such Party’s obligations under this Agreement, and shall cause its Affiliates to comply with
the provisions of this Agreement in connection with such performance. Any breach by a Party’s Affiliate of any of such Party’s obligations under this Agreement shall be deemed a breach by such Party, and the other Party may proceed
directly against such Party without any obligation to first proceed against such Party’s Affiliate. 

16.3    Force Majeure. Both Parties shall be excused from the performance of their obligations under this
Agreement to the extent that such performance is prevented by Force Majeure and the nonperforming Party promptly provides notice of the prevention to the other Party. Such excuse shall be continued so long as the condition constituting Force Majeure
continues and the nonperforming Party takes reasonable efforts to remove the condition. The Parties agree the effects of the COVID-19 pandemic that is ongoing as of the Effective Date (including related
government orders) may be invoked as a Force Majeure for the purposes of this Agreement even though the pandemic is ongoing and those effects may be reasonably foreseeable (but are not known for certain) as of the Effective Date. Notwithstanding the
foregoing, a Party shall not be excused from making payments owed hereunder because of a Force Majeure affecting such Party. If a Force Majeure persists for more than [***], then the Parties shall discuss in good faith the modification of the
Parties’ obligations under this Agreement in order to mitigate the delays caused by such Force Majeure. 

16.4    Assignment. Neither Party may assign or transfer this Agreement or any rights or obligations
hereunder without the prior written consent of the other (which consent shall not be 

  
 - 63 - 

 
unreasonably withheld, conditioned or delayed), except that a Party may assign this Agreement (together with the other agreements between the Parties referenced in this Agreement, including the
Clinical Supply Agreement) without the other Party’s consent to any Affiliate or to a successor to all or substantially all of the business of such Party to which this Agreement relates, whether in a merger, sale of stock or units, sale of
assets or other transaction. Any other assignment or transfer shall require the prior written consent of the other Party (which consent shall not be unreasonably withheld, conditioned or delayed). Any successor or assignee of rights and/or
obligations permitted hereunder shall, in writing to the other Party, expressly assume performance of such rights and/or obligations. Any permitted assignment shall be binding on the successors of the assigning Party. [***]. 

16.5    Severability. If any one or more of the provisions of this Agreement is held to be invalid or
unenforceable by any court of competent jurisdiction from which no appeal can be or is taken, the provision shall be considered severed from this Agreement and shall not serve to invalidate any remaining provisions hereof. The Parties shall make a
good faith effort to replace any invalid or unenforceable provision with a valid and enforceable one such that the objectives contemplated by the Parties when entering this Agreement may be realized. 

16.6    Waiver and Non-Exclusion of Remedies. Any term or condition
of this Agreement may be waived at any time by the Party that is entitled to the benefit thereof, but no such waiver shall be effective unless set forth in a written instrument duly executed by or on behalf of the Party waiving such term or
condition. The waiver by either Party hereto of any right hereunder or of the failure to perform or of a breach by the other Party shall not be deemed a waiver of any other right hereunder or of any other breach or failure by such other Party
whether of a similar nature or otherwise. The rights and remedies provided herein are cumulative and do not exclude any other right or remedy provided by Applicable Law or otherwise available except as expressly set forth herein. 

16.7    Further Assurance. Each Party shall duly execute and deliver, or cause to be duly executed and
delivered, such further instruments and do and cause to be done such further acts and things, including the filing of such assignments, agreements, documents, and instruments, as may be necessary or as the other Party may reasonably request in
connection with this Agreement or to carry out more effectively the provisions and purposes hereof. 

16.8    Relationship of the Parties. It is expressly agreed that Takeda, on the one hand, and Licensee, on
the other hand, shall be independent contractors and that the relationship between the two Parties shall not constitute a partnership, joint venture or agency, including for Tax purposes. Neither Takeda nor Licensee shall have the authority to make
any statements, representations or commitments of any kind, or to take any action which shall be binding on the other, without the prior written consent of the other Party to do so. All persons employed by a Party shall be employees of that Party
and not of the other Party and all expenses and obligations incurred by reason of such employment shall be for the account and expense of such Party. 

16.9    Counterparts. This Agreement may be executed in two (2) or more counterparts, each of which shall be
deemed an original, but all of which together shall constitute one and the same instrument. This Agreement may be executed by facsimile, .pdf or other electronically transmitted 

  
 - 64 - 

 
signatures and such signatures shall be deemed to bind each Party hereto as if they were the original signatures. 

16.10    Construction. Except where the context otherwise requires, wherever used, the singular shall
include the plural, the plural the singular, and the use of any gender shall be applicable to all genders. Whenever this Agreement refers to a number of days, such number refers to calendar days. The captions of this Agreement are for the
convenience of reference only and in no way define, describe, extend, or limit the scope or intent of this Agreement or the intent of any provision contained in this Agreement. The terms “including,” “include,” or
“includes” as used herein shall mean “including, but not limited to,” and shall not limit the generality of any description preceding such term. The language of this Agreement shall be deemed to be the language mutually chosen by
the Parties and no rule of strict construction shall be applied against either Party hereto. Each Party represents that it has been represented by legal counsel in connection with this Agreement and acknowledges that it has participated in the
drafting hereof. In interpreting and applying the terms and provisions of this Agreement, the Parties agree that no presumption will apply against the Party which drafted such terms and provision. 

16.11    Governing Laws. This Agreement was prepared in the English language, which language shall govern
the interpretation of, and any dispute regarding, the terms of this Agreement. This Agreement and all disputes arising out of or related to this Agreement or any breach hereof shall be governed by and construed under the laws of the State of New
York, without giving effect to any choice of law principles that would require the application of the laws of a different state. 

16.12    Entire Agreement. This Agreement, including the Exhibits hereto, sets forth the complete, final and
exclusive agreement and all the covenants, promises, agreements, warranties, representations, conditions and understandings between the Parties with respect to the subject matter hereof and supersedes, as of the Effective Date, all prior agreements
and understandings between the Parties with respect to the subject matter hereof. There are no covenants, promises, agreements, warranties, representations, conditions or understandings, either oral or written, between the Parties other than as are
set forth herein and therein. No subsequent alteration, amendment, change or addition to this Agreement shall be binding upon the Parties unless reduced to writing and signed by an authorized officer of each Party. In the event of any inconsistency
between the body of this Agreement and the Exhibits to this Agreement or any subsequent agreements ancillary to this Agreement, unless otherwise expressly stated to the contrary in such Exhibit or subsequent ancillary agreement, the terms contained
in this Agreement shall control. 
 16.13    Headings. The headings of each Article and Section in this
Agreement have been inserted for convenience of reference only and are not intended to limit or expand on the meaning of the language contained in the particular Article or Section. 

SIGNATURE PAGE FOLLOWS 

  
 - 65 - 

 IN WITNESS WHEREOF, the Parties have signed this Agreement as of the Effective Date.

  

			
	 TAKEDA VACCINES, INC.

		
	 By:
	 	 /s/ Rajeev Venkayya, MD

		
	 Name:
	 	 Rajeev Venkayya

		
	 Title:
	 	 President, Global Vaccine Business

		 	 Unit Takeda Pharmaceuticals

		
	 Date:
	 	 July 2, 2021

	
	 HILLEVAX, INC.

		
	 By:
	 	 /s/ Rob Hershberg

		
	 Name:
	 	 Rob Hershberg

		
	 Title:
	 	 Chief Executive Officer

		
	 Date:
	 	 July 2, 2021

  
 [Signature page to
License Agreement]Exhibit
4.8

 

 

CuriosityStream
Inc.

 

INDENTURE

 

Dated as of                   ,
20  

 

[____]

 

Trustee

 

     

     

    

 

TABLE
OF CONTENTS

 

	 	Page
	ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE	1
	 	Section 1.1. 	Definitions	1
	 	Section 1.2. 	Other Definitions	3
	 	Section 1.3. 	Incorporation by Reference of Trust Indenture Act	3
	 	Section 1.4. 	Rules of Construction	4
	 	 	 	 
	ARTICLE II. THE SECURITIES	4
	 	Section 2.1. 	Issuable in Series	4
	 	Section 2.2. 	Establishment of Terms of Series of Securities	4
	 	Section 2.3. 	Execution and Authentication	6
	 	Section 2.4. 	Registrar and Paying Agent	6
	 	Section 2.5. 	Paying Agent to Hold Money in Trust	7
	 	Section 2.6. 	Securityholder Lists	7
	 	Section 2.7. 	Transfer and Exchange	7
	 	Section 2.8. 	Mutilated, Destroyed, Lost and Stolen Securities	7
	 	Section 2.9. 	Outstanding Securities	8
	 	Section 2.10. 	Treasury Securities	8
	 	Section 2.11. 	Temporary Securities	8
	 	Section 2.12. 	Cancellation	8
	 	Section 2.13. 	Defaulted Interest	9
	 	Section 2.14. 	Global Securities	9
	 	Section 2.15. 	CUSIP Numbers	10
	 	 	 	 
	ARTICLE III. REDEMPTION	10
	 	Section 3.1. 	Notice to Trustee	10
	 	Section 3.2. 	Selection of Securities to be Redeemed	10
	 	Section 3.3. 	Notice of Redemption	10
	 	Section 3.4. 	Effect of Notice of Redemption	11
	 	Section 3.5. 	Deposit of Redemption Price	11
	 	Section 3.6. 	Securities Redeemed in Part	11

 

    i

     

    

 

	ARTICLE IV. COVENANTS	11
	 	Section 4.1. 	Payment of Principal and Interest	11
	 	Section 4.2. 	SEC Reports	11
	 	Section 4.3. 	Compliance Certificate	12
	 	Section 4.4. 	Stay, Extension and Usury Laws	12
	 	 	 	 
	ARTICLE V. SUCCESSORS	12
	 	Section 5.1. 	When Company May Merge, Etc.	12
	 	Section 5.2. 	Successor Corporation Substituted	12
	 	 	 	 
	ARTICLE VI. DEFAULTS AND REMEDIES	13
	 	Section 6.1. 	Events of Default	13
	 	Section 6.2. 	Acceleration of Maturity; Rescission and Annulment	13
	 	Section 6.3. 	Collection of Indebtedness and Suits for Enforcement by Trustee	14
	 	Section 6.4. 	Trustee May File Proofs of Claim	14
	 	Section 6.5. 	Trustee May Enforce Claims Without Possession of Securities	15
	 	Section 6.6. 	Application of Money Collected	15
	 	Section 6.7. 	Limitation on Suits	15
	 	Section 6.8. 	Unconditional Right of Holders to Receive Principal and Interest	16
	 	Section 6.9. 	Restoration of Rights and Remedies	16
	 	Section 6.10. 	Rights and Remedies Cumulative	16
	 	Section 6.11. 	Delay or Omission Not Waiver	16
	 	Section 6.12. 	Control by Holders	16
	 	Section 6.13. 	Waiver of Past Defaults	17
	 	Section 6.14. 	Undertaking for Costs	17
	 	 	 	 
	ARTICLE VII. TRUSTEE	17
	 	Section 7.1. 	Duties of Trustee	17
	 	Section 7.2. 	Rights of Trustee	18
	 	Section 7.3. 	Individual Rights of Trustee	19
	 	Section 7.4. 	Trustee’s Disclaimer	19
	 	Section 7.5. 	Notice of Defaults	19
	 	Section 7.6. 	Reports by Trustee to Holders	19
	 	Section 7.7. 	Compensation and Indemnity	19
	 	Section 7.8. 	Replacement of Trustee	20
	 	Section 7.9. 	Successor Trustee by Merger, Etc.	20
	 	Section 7.10. 	Eligibility; Disqualification	20
	 	Section 7.11. 	Preferential Collection of Claims Against Company	20

 

    ii

     

    

 

	ARTICLE VIII. SATISFACTION AND DISCHARGE; DEFEASANCE	21
	 	Section 8.1. 	Satisfaction and Discharge of Indenture	21
	 	Section 8.2. 	Application of Trust Funds; Indemnification	21
	 	Section 8.3. 	Legal Defeasance of Securities of any Series	22
	 	Section 8.4. 	Covenant Defeasance	23
	 	Section 8.5. 	Repayment to Company	23
	 	Section 8.6. 	Reinstatement	24
	 	 	 	 
	ARTICLE IX. AMENDMENTS AND WAIVERS	24
	 	Section 9.1. 	Without Consent of Holders	24
	 	Section 9.2. 	With Consent of Holders	24
	 	Section 9.3. 	Limitations	25
	 	Section 9.4. 	Compliance with Trust Indenture Act	25
	 	Section 9.5. 	Revocation and Effect of Consents	25
	 	Section 9.6. 	Notation on or Exchange of Securities	25
	 	Section 9.7. 	Trustee Protected	26
	 	 	 	 
	ARTICLE X. MISCELLANEOUS	26
	 	Section 10.1. 	Trust Indenture Act Controls	26
	 	Section 10.2. 	Notices	26
	 	Section 10.3. 	Communication by Holders with Other Holders	27
	 	Section 10.4. 	Certificate and Opinion as to Conditions Precedent	27
	 	Section 10.5. 	Statements Required in Certificate or Opinion	27
	 	Section 10.6. 	Rules by Trustee and Agents	27
	 	Section 10.7. 	Legal Holidays	27
	 	Section 10.8. 	No Recourse Against Others	27
	 	Section 10.9. 	Counterparts	28
	 	Section 10.10. 	Governing Law; Waiver of Jury Trial; Consent to Jurisdiction	28
	 	Section 10.11. 	No Adverse Interpretation of Other Agreements	28
	 	Section 10.12. 	Successors	28
	 	Section 10.13. 	Severability	28
	 	Section 10.14. 	Table of Contents, Headings, Etc.	28
	 	Section 10.15. 	Securities in a Foreign Currency	28
	 	Section 10.16. 	Judgment Currency	29
	 	Section 10.17. 	Force Majeure	29
	 	Section 10.18. 	U.S.A. Patriot Act	29
	 	 	 	 
	ARTICLE XI. SINKING FUNDS	29
	 	Section 11.1. 	Applicability of Article	29
	 	Section 11.2. 	Satisfaction of Sinking Fund Payments with Securities	30
	 	Section 11.3. 	Redemption of Securities for Sinking Fund	30

 

    iii

     

    

 

CuriosityStream
Inc.

 

Reconciliation and tie between Trust Indenture
Act of 1939 and

Indenture, dated as of , 20

 

	§310(a)(1)	 	7.10
	(a)(2)	 	7.10
	(a)(3)	 	Not Applicable
	(a)(4)	 	Not Applicable
	(a)(5)	 	7.10
	(b)	 	7.10
	§311(a)	 	7.11
	(b)	 	7.11
	(c)	 	Not Applicable
	§312(a)	 	2.6
	(b)	 	10.3
	(c)	 	10.3
	§313(a)	 	7.6
	(b)(1)	 	7.6
	(b)(2)	 	7.6
	(c)(1)	 	7.6
	(d)	 	7.6
	§314(a)	 	4.2, 10.5
	(b)	 	Not Applicable
	(c)(1)	 	10.4
	(c)(2)	 	10.4
	(c)(3)	 	Not Applicable
	(d)	 	Not Applicable
	(e)	 	10.5
	(f)	 	Not Applicable
	§315(a)	 	7.1
	(b)	 	7.5
	(c)	 	7.1
	(d)	 	7.1
	(e)	 	6.14
	§316(a)	 	2.10
	(a)(1)(A)	 	6.12
	(a)(1)(B)	 	6.13
	(b)	 	6.8
	§317(a)(1)	 	6.3
	(a)(2)	 	6.4
	(b)	 	2.5
	§318(a)	 	10.1

 

Note: This reconciliation and tie shall not, for
any purpose, be deemed to be part of the Indenture.

 

    iv

     

    

 

Indenture dated as of             ,
20    between CuriosityStream Inc., a Delaware corporation (“Company”), and [ ] (“Trustee”).

 

Each party agrees as follows
for the benefit of the other party and for the equal and ratable benefit of the Holders of the Securities issued under this Indenture.

 

ARTICLE I.

DEFINITIONS AND INCORPORATION BY REFERENCE

 

Section 1.1. Definitions.

 

“Affiliate”
of any specified person means any other person directly or indirectly controlling or controlled by or under common control with such specified
person. For the purposes of this definition, “control” (including, with correlative meanings, the terms “controlled
by” and “under common control with”), as used with respect to any person, shall mean the possession, directly or indirectly,
of the power to direct or cause the direction of the management or policies of such person, whether through the ownership of voting securities
or by agreement or otherwise.

 

“Agent” means
any Registrar, Paying Agent or Notice Agent.

 

“Board of Directors”
means the board of directors of the Company or any duly authorized committee thereof.

 

“Board Resolution”
means a copy of a resolution certified by the Secretary or an Assistant Secretary of the Company to have been adopted by the Board of
Directors or pursuant to authorization by the Board of Directors and to be in full force and effect on the date of the certificate and
delivered to the Trustee.

 

“Business Day”
means any day except a Saturday, Sunday or a legal holiday in The City of New York, New York (or in connection with any payment, the place
of payment) on which banking institutions are authorized or required by law, regulation or executive order to close.

 

“Capital Stock”
means any and all shares, interests, participations, rights or other equivalents (however designated) of corporate stock.

 

“Company”
means the party named as such above until a successor replaces it and thereafter means the successor.

 

“Company Order”
means a written order signed in the name of the Company by an Officer.

 

“Corporate Trust Office”
means the office of the Trustee at which at any particular time its corporate trust business related to this Indenture shall be principally
administered.

 

“Default”
means any event which is, or after notice or passage of time or both would be, an Event of Default.

 

“Depositary”
means, with respect to the Securities of any Series issuable or issued in whole or in part in the form of one or more Global Securities,
the person designated as Depositary for such Series by the Company, which Depositary shall be a clearing agency registered under the Exchange
Act; and if at any time there is more than one such person, “Depositary” as used with respect to the Securities of any Series
shall mean the Depositary with respect to the Securities of such Series.

 

“Discount Security”
means any Security that provides for an amount less than the stated principal amount thereof to be due and payable upon declaration of
acceleration of the maturity thereof pursuant to Section 6.2.

 

“Dollars”
and “$” means the currency of The United States of America.

 

“Exchange Act”
means the Securities Exchange Act of 1934, as amended.

 

“Foreign Currency”
means any currency or currency unit issued by a government other than the government of The United States of America.

 

“Foreign Government
Obligations” means, with respect to Securities of any Series that are denominated in a Foreign Currency, direct obligations
of, or obligations guaranteed by, the government that issued or caused to be issued such currency for the payment of which obligations
its full faith and credit is pledged and which are not callable or redeemable at the option of the issuer thereof.

 

    1

     

    

 

“GAAP” means
accounting principles generally accepted in the United States of America set forth in the opinions and pronouncements of the Accounting
Principles Board of the American Institute of Certified Public Accountants and statements and pronouncements of the Financial Accounting
Standards Board or in such other statements by such other entity as have been approved by a significant segment of the accounting profession,
which are in effect as of the date of determination.

 

“Global Security”
or “Global Securities” means a Security or Securities, as the case may be, in the form established pursuant to Section
2.2 evidencing all or part of a Series of Securities, issued to the Depositary for such Series or its nominee, and registered in the name
of such Depositary or nominee.

 

“Holder”
or “Securityholder” means a person in whose name a Security is registered.

 

“Indenture”
means this Indenture as amended or supplemented from time to time and shall include the form and terms of particular Series of Securities
established as contemplated hereunder.

 

“interest”
with respect to any Discount Security which by its terms bears interest only after Maturity, means interest payable after Maturity.

 

“Maturity,”
when used with respect to any Security, means the date on which the principal of such Security becomes due and payable as therein or herein
provided, whether at the Stated Maturity or by declaration of acceleration, call for redemption or otherwise.

 

“Officer”
means the Chief Executive Officer, President, the Chief Financial Officer, the Treasurer or any Assistant Treasurer, the Secretary or
any Assistant Secretary, and any Vice President of the Company.

 

“Officer’s Certificate”
means a certificate signed by any Officer.

 

“Opinion of Counsel”
means a written opinion of legal counsel who is acceptable to the Trustee. The counsel may be an employee of or counsel to the Company.
The opinion may contain customary limitations, conditions and exceptions.

 

“person”
means any individual, corporation, partnership, joint venture, association, limited liability company, joint-stock company, trust, unincorporated
organization or government or any agency or political subdivision thereof.

 

“principal”
of a Security means the principal of the Security plus, when appropriate, the premium, if any, on the Security.

 

“Responsible Officer”
means any officer of the Trustee in its Corporate Trust Office having responsibility for administration of this Indenture and also means,
with respect to a particular corporate trust matter, any other officer to whom any corporate trust matter is referred because of his or
her knowledge of and familiarity with a particular subject.

 

“SEC” means
the Securities and Exchange Commission.

 

“Securities”
means the debentures, notes or other debt instruments of the Company of any Series authenticated and delivered under this Indenture.

 

“Series”
or “Series of Securities” means each series of debentures, notes or other debt instruments of the Company created pursuant
to Sections 2.1 and 2.2 hereof.

 

“Stated Maturity”
when used with respect to any Security, means the date specified in such Security as the fixed date on which the principal of such Security
or interest is due and payable.

 

“Subsidiary”
of any specified person means any corporation, association or other business entity of which more than 50% of the total voting power of
shares of Capital Stock entitled (without regard to the occurrence of any contingency) to vote in the election of directors, managers
or trustees thereof is at the time owned or controlled, directly or indirectly, by such person or one or more of the other Subsidiaries
of that person or a combination thereof.

 

    2

     

    

 

“TIA” means
the Trust Indenture Act of 1939 (15 U.S. Code §§ 77aaa-77bbbb) as in effect on the date of this Indenture; provided,
however, that in the event the Trust Indenture Act of 1939 is amended after such date, “TIA” means, to the extent required
by any such amendment, the Trust Indenture Act as so amended.

 

“Trustee”
means the person named as the “Trustee” in the first paragraph of this instrument until a successor Trustee shall have become
such pursuant to the applicable provisions of this Indenture, and thereafter “Trustee” shall mean or include each person who
is then a Trustee hereunder, and if at any time there is more than one such person, “Trustee” as used with respect to the
Securities of any Series shall mean the Trustee with respect to Securities of that Series.

 

“U.S. Government Obligations”
means securities which are direct obligations of, or guaranteed by, The United States of America for the payment of which its full faith
and credit is pledged and which are not callable or redeemable at the option of the issuer thereof, and shall also include a depositary
receipt issued by a bank or trust company as custodian with respect to any such U.S. Government Obligation or a specific payment of interest
on or principal of any such U.S. Government Obligation held by such custodian for the account of the holder of a depository receipt, provided
that (except as required by law) such custodian is not authorized to make any deduction from the amount payable to the holder of such
depositary receipt from any amount received by the custodian in respect of the U.S. Government Obligation evidenced by such depositary
receipt.

 

Other
Definitions.

 

	TERM	 	DEFINED IN

    SECTION
	“Bankruptcy Law”	 	6.1
	“Custodian”	 	6.1
	“Event of Default”	 	6.1
	“Judgment Currency”	 	10.16
	“Legal Holiday”	 	10.7
	“mandatory sinking fund payment”	 	11.1
	“New York Banking Day”	 	10.16
	“Notice Agent”	 	2.4
	“optional sinking fund payment”	 	11.1
	“Paying Agent”	 	2.4
	“Registrar”	 	2.4
	“Required Currency”	 	10.16
	“Specified Courts”	 	10.10
	“successor person”	 	5.1

 

Section 1.2. Incorporation by Reference of Trust Indenture
Act.

 

Whenever this Indenture refers
to a provision of the TIA, the provision is incorporated by reference in and made a part of this Indenture. The following TIA terms used
in this Indenture have the following meanings:

 

“Commission”
means the SEC.

 

“indenture securities”
means the Securities.

 

“indenture security
holder” means a Securityholder.

 

“indenture to be qualified”
means this Indenture.

 

“indenture trustee”
or “institutional trustee” means the Trustee.

 

“obligor” on the indenture
securities means the Company and any successor obligor upon the Securities.

 

All other terms used in this
Indenture that are defined by the TIA, defined by TIA reference to another statute or defined by SEC rule under the TIA and not otherwise
defined herein are used herein as so defined.

 

    3

     

    

 

Section 1.3. Rules of Construction.

 

Unless the context otherwise
requires:

 

(a) a term has the
meaning assigned to it;

 

(b) an accounting
term not otherwise defined has the meaning assigned to it in accordance with GAAP;

 

(c) “or”
is not exclusive;

 

(d) words in the
singular include the plural, and in the plural include the singular; and

 

(e) provisions apply
to successive events and transactions.

 

ARTICLE II.

THE SECURITIES

 

Section 2.1. Issuable in Series.

 

The aggregate principal amount
of Securities that may be authenticated and delivered under this Indenture is unlimited. The Securities may be issued in one or more Series.
All Securities of a Series shall be identical except as may be set forth or determined in the manner provided in a Board Resolution, a
supplemental indenture or an Officer’s Certificate detailing the adoption of the terms thereof pursuant to authority granted under
a Board Resolution. In the case of Securities of a Series to be issued from time to time, the Board Resolution, Officer’s Certificate
or supplemental indenture detailing the adoption of the terms thereof pursuant to authority granted under a Board Resolution may provide
for the method by which specified terms (such as interest rate, maturity date, record date or date from which interest shall accrue) are
to be determined. Securities may differ between Series in respect of any matters, provided that all Series of Securities shall be equally
and ratably entitled to the benefits of the Indenture.

 

Section 2.2. Establishment of Terms of Series of Securities.

 

At or prior to the issuance
of any Securities within a Series, the following shall be established (as to the Series generally, in the case of Subsection 2.2.1 and
either as to such Securities within the Series or as to the Series generally in the case of Subsections 2.2.2 through 2.2.23) by or pursuant
to a Board Resolution, and set forth or determined in the manner provided in a Board Resolution, supplemental indenture hereto or Officer’s
Certificate:

 

2.2.1. the title (which shall
distinguish the Securities of that particular Series from the Securities of any other Series) and ranking (including the terms of any
subordination provisions) of the Series;

 

2.2.2. the price or prices (expressed
as a percentage of the principal amount thereof) at which the Securities of the Series will be issued;

 

2.2.3. any limit upon the aggregate
principal amount of the Securities of the Series which may be authenticated and delivered under this Indenture (except for Securities
authenticated and delivered upon registration of transfer of, or in exchange for, or in lieu of, other Securities of the Series pursuant
to Section 2.7, 2.8, 2.11, 3.6 or 9.6);

 

2.2.4. the date or dates on
which the principal of the Securities of the Series is payable;

 

2.2.5. the rate or rates (which
may be fixed or variable) per annum or, if applicable, the method used to determine such rate or rates (including, but not limited to,
any commodity, commodity index, stock exchange index or financial index) at which the Securities of the Series shall bear interest, if
any, the date or dates from which such interest, if any, shall accrue, the date or dates on which such interest, if any, shall commence
and be payable and any regular record date for the interest payable on any interest payment date;

 

2.2.6. the place or places where
the principal of and interest, if any, on the Securities of the Series shall be payable, where the Securities of such Series may be surrendered
for registration of transfer or exchange and where notices and demands to or upon the Company in respect of the Securities of such Series
and this Indenture may be delivered, and the method of such payment, if by wire transfer, mail or other means;

 

2.2.7. if applicable, the period
or periods within which, the price or prices at which and the terms and conditions upon which the Securities of the Series may be redeemed,
in whole or in part, at the option of the Company;

 

    4

     

    

 

2.2.8. the obligation, if any,
of the Company to redeem or purchase the Securities of the Series pursuant to any sinking fund or analogous provisions or at the option
of a Holder thereof and the period or periods within which, the price or prices at which and the terms and conditions upon which Securities
of the Series shall be redeemed or purchased, in whole or in part, pursuant to such obligation;

 

2.2.9. the dates, if any, on
which and the price or prices at which the Securities of the Series will be repurchased by the Company at the option of the Holders thereof
and other detailed terms and provisions of such repurchase obligations;

 

2.2.10. if other than denominations
of $1,000 and any integral multiple thereof, the denominations in which the Securities of the Series shall be issuable;

 

2.2.11. the forms of the Securities
of the Series and whether the Securities will be issuable as Global Securities;

 

2.2.12. if other than the principal
amount thereof, the portion of the principal amount of the Securities of the Series that shall be payable upon declaration of acceleration
of the maturity thereof pursuant to Section 6.2;

 

2.2.13. the currency of denomination
of the Securities of the Series, which may be Dollars or any Foreign Currency, and if such currency of denomination is a composite currency,
the agency or organization, if any, responsible for overseeing such composite currency;

 

2.2.14. the designation of the
currency, currencies or currency units in which payment of the principal of and interest, if any, on the Securities of the Series will
be made;

 

2.2.15. if payments of principal
of or interest, if any, on the Securities of the Series are to be made in one or more currencies or currency units other than that or
those in which such Securities are denominated, the manner in which the exchange rate with respect to such payments will be determined;

 

2.2.16. the manner in which
the amounts of payment of principal of or interest, if any, on the Securities of the Series will be determined, if such amounts may be
determined by reference to an index based on a currency or currencies or by reference to a commodity, commodity index, stock exchange
index or financial index;

 

2.2.17. the provisions, if any,
relating to any security provided for the Securities of the Series;

 

2.2.18. any addition to, deletion
of or change in the Events of Default which applies to any Securities of the Series and any change in the right of the Trustee or the
requisite Holders of such Securities to declare the principal amount thereof due and payable pursuant to Section 6.2;

 

2.2.19. any addition to, deletion
of or change in the covenants set forth in Articles IV or V which applies to Securities of the Series;

 

2.2.20. any Depositaries, interest
rate calculation agents, exchange rate calculation agents or other agents with respect to Securities of such Series if other than those
appointed herein;

 

2.2.21. the provisions, if any,
relating to conversion or exchange of any Securities of such Series, including if applicable, the conversion or exchange price, the conversion
or exchange period, provisions as to whether conversion or exchange will be mandatory, at the option of the Holders thereof or at the
option of the Company, the events requiring an adjustment of the conversion price or exchange price and provisions affecting conversion
or exchange if such Series of Securities are redeemed;

 

2.2.22. any other terms of the
Series (which may supplement, modify or delete any provision of this Indenture insofar as it applies to such Series), including any terms
that may be required under applicable law or regulations or advisable in connection with the marketing of Securities of that Series; and

 

2.2.23. whether any of the Company’s
direct or indirect Subsidiaries will guarantee the Securities of that Series, including the terms of subordination, if any, of such guarantees.

 

All Securities of any one Series
need not be issued at the same time and may be issued from time to time, consistent with the terms of this Indenture, if so provided by
or pursuant to the Board Resolution, supplemental indenture hereto or Officer’s Certificate referred to above.

 

    5

     

    

 

Section 2.3. Execution and Authentication.

 

An Officer shall sign the Securities
for the Company by manual or facsimile signature.

 

If an Officer whose signature
is on a Security no longer holds that office at the time the Security is authenticated, the Security shall nevertheless be valid.

 

A Security shall not be valid
until authenticated by the manual signature of the Trustee or an authenticating agent. The signature shall be conclusive evidence that
the Security has been authenticated under this Indenture.

 

The Trustee shall at any time,
and from time to time, authenticate Securities for original issue in the principal amount provided in the Board Resolution, supplemental
indenture hereto or Officer’s Certificate, upon receipt by the Trustee of a Company Order. Each Security shall be dated the date
of its authentication.

 

The aggregate principal amount
of Securities of any Series outstanding at any time may not exceed any limit upon the maximum principal amount for such Series set forth
in the Board Resolution, supplemental indenture hereto or Officer’s Certificate delivered pursuant to Section 2.2, except as provided
in Section 2.8.

 

Prior to the issuance of Securities
of any Series, the Trustee shall have received and (subject to Section 7.2) shall be fully protected in relying on: (a) the Board Resolution,
supplemental indenture hereto or Officer’s Certificate establishing the form of the Securities of that Series or of Securities within
that Series and the terms of the Securities of that Series or of Securities within that Series, (b) an Officer’s Certificate complying
with Section 10.4, and (c) an Opinion of Counsel complying with Section 10.4.

 

The Trustee shall have the right
to decline to authenticate and deliver any Securities of such Series: (a) if the Trustee, being advised by counsel, determines that such
action may not be taken lawfully; or (b) if the Trustee in good faith by its board of directors or trustees, executive committee or a
trust committee of directors and/or vice-presidents or a committee of Responsible Officers shall determine that such action would expose
the Trustee to personal liability to Holders of any then outstanding Series of Securities.

 

The Trustee may appoint an authenticating
agent acceptable to the Company to authenticate Securities. An authenticating agent may authenticate Securities whenever the Trustee may
do so. Each reference in this Indenture to authentication by the Trustee includes authentication by such agent. An authenticating agent
has the same rights as an Agent to deal with the Company or an Affiliate of the Company.

 

Section 2.4. Registrar and Paying Agent.

 

The Company shall maintain,
with respect to each Series of Securities, at the place or places specified with respect to such Series pursuant to Section 2.2, an office
or agency where Securities of such Series may be presented or surrendered for payment (“Paying Agent”), where Securities
of such Series may be surrendered for registration of transfer or exchange (“Registrar”) and where notices and demands
to or upon the Company in respect of the Securities of such Series and this Indenture may be delivered (“Notice Agent”).
The Registrar shall keep a register with respect to each Series of Securities and to their transfer and exchange. The Company will give
prompt written notice to the Trustee of the name and address, and any change in the name or address, of each Registrar, Paying Agent or
Notice Agent. If at any time the Company shall fail to maintain any such required Registrar, Paying Agent or Notice Agent or shall fail
to furnish the Trustee with the name and address thereof, such presentations, surrenders, notices and demands may be made or served at
the Corporate Trust Office of the Trustee, and the Company hereby appoints the Trustee as its agent to receive all such presentations,
surrenders, notices and demands; provided, however, that any appointment of the Trustee as the Notice Agent shall exclude
the appointment of the Trustee or any office of the Trustee as an agent to receive the service of legal process on the Company.

 

The Company may also from time
to time designate one or more co-registrars, additional paying agents or additional notice agents and may from time to time rescind such
designations; provided, however, that no such designation or rescission shall in any manner relieve the Company of its obligations
to maintain a Registrar, Paying Agent and Notice Agent in each place so specified pursuant to Section 2.2 for Securities of any Series
for such purposes. The Company will give prompt written notice to the Trustee of any such designation or rescission and of any change
in the name or address of any such co-registrar, additional paying agent or additional notice agent. The term “Registrar”
includes any co-registrar; the term “Paying Agent” includes any additional paying agent; and the term “Notice
Agent” includes any additional notice agent. The Company or any of its Affiliates may serve as Registrar or Paying Agent.

 

    6

     

    

 

The Company hereby appoints
the Trustee the initial Registrar, Paying Agent and Notice Agent for each Series unless another Registrar, Paying Agent or Notice Agent,
as the case may be, is appointed prior to the time Securities of that Series are first issued.

 

Section 2.5. Paying Agent to Hold Money in Trust.

 

The Company shall require each
Paying Agent other than the Trustee to agree in writing that the Paying Agent will hold in trust, for the benefit of Securityholders of
any Series of Securities, or the Trustee, all money held by the Paying Agent for the payment of principal of or interest on the Series
of Securities, and will notify the Trustee in writing of any default by the Company in making any such payment. While any such default
continues, the Trustee may require a Paying Agent to pay all money held by it to the Trustee. The Company at any time may require a Paying
Agent to pay all money held by it to the Trustee. Upon payment over to the Trustee, the Paying Agent (if other than the Company or a Subsidiary
of the Company) shall have no further liability for the money. If the Company or a Subsidiary of the Company acts as Paying Agent, it
shall segregate and hold in a separate trust fund for the benefit of Securityholders of any Series of Securities all money held by it
as Paying Agent. Upon any bankruptcy, reorganization or similar proceeding with respect to the Company, the Trustee shall serve as Paying
Agent for the Securities.

 

Section 2.6. Securityholder Lists.

 

The Trustee shall preserve in
as current a form as is reasonably practicable the most recent list available to it of the names and addresses of Securityholders of each
Series of Securities and shall otherwise comply with TIA § 312(a). If the Trustee is not the Registrar, the Company shall furnish
to the Trustee at least ten days before each interest payment date and at such other times as the Trustee may request in writing a list,
in such form and as of such date as the Trustee may reasonably require, of the names and addresses of Securityholders of each Series of
Securities.

 

Section 2.7. Transfer and Exchange.

 

Where Securities of a Series
are presented to the Registrar or a co-registrar with a request to register a transfer or to exchange them for an equal principal amount
of Securities of the same Series, the Registrar shall register the transfer or make the exchange if its requirements for such transactions
are met. To permit registrations of transfers and exchanges, the Trustee shall authenticate Securities at the Registrar’s request.
No service charge shall be made for any registration of transfer or exchange (except as otherwise expressly permitted herein), but the
Company may require payment of a sum sufficient to cover any transfer tax or similar governmental charge payable in connection therewith
(other than any such transfer tax or similar governmental charge payable upon exchanges pursuant to Sections 2.11, 3.6 or 9.6).

 

Neither the Company nor the
Registrar shall be required (a) to issue, register the transfer of, or exchange Securities of any Series for the period beginning at the
opening of business fifteen days immediately preceding the sending of a notice of redemption of Securities of that Series selected for
redemption and ending at the close of business on the day such notice is sent, or (b) to register the transfer of or exchange Securities
of any Series selected, called or being called for redemption as a whole or the portion being redeemed of any such Securities selected,
called or being called for redemption in part.

 

Section 2.8. Mutilated, Destroyed, Lost and Stolen Securities.

 

If any mutilated Security is
surrendered to the Trustee, the Company shall execute and the Trustee shall authenticate and deliver in exchange therefor a new Security
of the same Series and of like tenor and principal amount and bearing a number not contemporaneously outstanding.

 

If there shall be delivered
to the Company and the Trustee (i) evidence to their satisfaction of the destruction, loss or theft of any Security and (ii) such security
or indemnity bond as may be required by each of them to hold itself and any of its agents harmless, then, in the absence of notice to
the Company or the Trustee that such Security has been acquired by a bona fide purchaser, the Company shall execute and upon receipt of
a Company Order the Trustee shall authenticate and make available for delivery, in lieu of any such destroyed, lost or stolen Security,
a new Security of the same Series and of like tenor and principal amount and bearing a number not contemporaneously outstanding.

 

In case any such mutilated,
destroyed, lost or stolen Security has become or is about to become due and payable, the Company in its discretion may, instead of issuing
a new Security, pay such Security.

 

    7

     

    

 

Upon the issuance of any new
Security under this Section, the Company may require the payment of a sum sufficient to cover any tax or other governmental charge that
may be imposed in relation thereto and any other expenses (including the fees and expenses of the Trustee) connected therewith.

 

Every new Security of any Series
issued pursuant to this Section in lieu of any destroyed, lost or stolen Security shall constitute an original additional contractual
obligation of the Company, whether or not the destroyed, lost or stolen Security shall be at any time enforceable by anyone, and shall
be entitled to all the benefits of this Indenture equally and proportionately with any and all other Securities of that Series duly issued
hereunder.

 

The provisions of this Section
are exclusive and shall preclude (to the extent lawful) all other rights and remedies with respect to the replacement or payment of mutilated,
destroyed, lost or stolen Securities.

 

Section 2.9. Outstanding Securities.

 

The Securities outstanding at
any time are all the Securities authenticated by the Trustee except for those canceled by it, those delivered to it for cancellation,
those reductions in the interest on a Global Security effected by the Trustee in accordance with the provisions hereof and those described
in this Section as not outstanding.

 

If a Security is replaced pursuant
to Section 2.8, it ceases to be outstanding until the Trustee receives proof satisfactory to it that the replaced Security is held by
a bona fide purchaser.

 

If the Paying Agent (other than
the Company, a Subsidiary of the Company or an Affiliate of the Company) holds on the Maturity of Securities of a Series money sufficient
to pay such Securities payable on that date, then on and after that date such Securities of the Series cease to be outstanding and interest
on them ceases to accrue.

 

The Company may purchase or
otherwise acquire the Securities, whether by open market purchases, negotiated transactions or otherwise. A Security does not cease to
be outstanding because the Company or an Affiliate of the Company holds the Security (but see Section 2.10 below).

 

In determining whether the Holders
of the requisite principal amount of outstanding Securities have given any request, demand, authorization, direction, notice, consent
or waiver hereunder, the principal amount of a Discount Security that shall be deemed to be outstanding for such purposes shall be the
amount of the principal thereof that would be due and payable as of the date of such determination upon a declaration of acceleration
of the Maturity thereof pursuant to Section 6.2.

 

Section 2.10. Treasury Securities.

 

In determining whether the Holders
of the required principal amount of Securities of a Series have concurred in any request, demand, authorization, direction, notice, consent
or waiver, Securities of a Series owned by the Company or any Affiliate of the Company shall be disregarded, except that for the purposes
of determining whether the Trustee shall be protected in relying on any such request, demand, authorization, direction, notice, consent
or waiver only Securities of a Series that a Responsible Officer of the Trustee knows are so owned shall be so disregarded.

 

Section 2.11. Temporary Securities.

 

Until definitive Securities
are ready for delivery, the Company may prepare and the Trustee shall authenticate temporary Securities upon a Company Order. Temporary
Securities shall be substantially in the form of definitive Securities but may have variations that the Company considers appropriate
for temporary Securities. Without unreasonable delay, the Company shall prepare and the Trustee upon receipt of a Company Order shall
authenticate definitive Securities of the same Series and date of maturity in exchange for temporary Securities. Until so exchanged, temporary
securities shall have the same rights under this Indenture as the definitive Securities.

 

Section 2.12. Cancellation.

 

The Company at any time may
deliver Securities to the Trustee for cancellation. The Registrar and the Paying Agent shall forward to the Trustee any Securities surrendered
to them for registration of transfer, exchange or payment. The Trustee shall cancel all Securities surrendered for transfer, exchange,
payment, replacement or cancellation and shall destroy such canceled Securities (subject to the record retention requirement of the Exchange
Act and the Trustee) and deliver a certificate of such cancellation to the Company upon written request of the Company. The Company may
not issue new Securities to replace Securities that it has paid or delivered to the Trustee for cancellation.

 

    8

     

    

 

Section 2.13. Defaulted Interest.

 

If the Company defaults in a
payment of interest on a Series of Securities, it shall pay the defaulted interest, plus, to the extent permitted by law, any interest
payable on the defaulted interest, to the persons who are Securityholders of the Series on a subsequent special record date. The Company
shall fix the record date and payment date. At least 10 days before the special record date, the Company shall send to the Trustee and
to each Securityholder of the Series a notice that states the special record date, the payment date and the amount of interest to be paid.
The Company may pay defaulted interest in any other lawful manner.

 

Section 2.14. Global Securities.

 

2.14.1. Terms of Securities.
A Board Resolution, a supplemental indenture hereto or an Officer’s Certificate shall establish whether the Securities of a Series
shall be issued in whole or in part in the form of one or more Global Securities and the Depositary for such Global Security or Securities.

 

2.14.2. Transfer and Exchange.
Notwithstanding any provisions to the contrary contained in Section 2.7 of the Indenture and in addition thereto, any Global Security
shall be exchangeable pursuant to Section 2.7 of the Indenture for Securities registered in the names of Holders other than the Depositary
for such Security or its nominee only if (i) such Depositary notifies the Company that it is unwilling or unable to continue as Depositary
for such Global Security or if at any time such Depositary ceases to be a clearing agency registered under the Exchange Act, and, in either
case, the Company fails to appoint a successor Depositary registered as a clearing agency under the Exchange Act within 90 days of such
event or (ii) the Company executes and delivers to the Trustee an Officer’s Certificate to the effect that such Global Security
shall be so exchangeable. Any Global Security that is exchangeable pursuant to the preceding sentence shall be exchangeable for Securities
registered in such names as the Depositary shall direct in writing in an aggregate principal amount equal to the principal amount of the
Global Security with like tenor and terms.

 

Except as provided in this Section
2.14.2, a Global Security may not be transferred except as a whole by the Depositary with respect to such Global Security to a nominee
of such Depositary, by a nominee of such Depositary to such Depositary or another nominee of such Depositary or by the Depositary or any
such nominee to a successor Depositary or a nominee of such a successor Depositary.

 

2.14.3. Legends. Any
Global Security issued hereunder shall bear a legend in substantially the following form:

 

“THIS SECURITY IS A GLOBAL
SECURITY WITHIN THE MEANING OF THE INDENTURE HEREINAFTER REFERRED TO AND IS REGISTERED IN THE NAME OF THE DEPOSITARY OR A NOMINEE OF THE
DEPOSITARY. THIS SECURITY IS EXCHANGEABLE FOR SECURITIES REGISTERED IN THE NAME OF A PERSON OTHER THAN THE DEPOSITARY OR ITS NOMINEE ONLY
IN THE LIMITED CIRCUMSTANCES DESCRIBED IN THE INDENTURE, AND MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF
THE DEPOSITARY, BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE OF THE DEPOSITARY OR BY THE DEPOSITARY OR ANY SUCH
NOMINEE TO A SUCCESSOR DEPOSITARY OR A NOMINEE OF SUCH A SUCCESSOR DEPOSITARY.”

 

In addition, so long as the
Depository Trust Company (“DTC”) is the Depositary, each Global Note registered in the name of DTC or its nominee shall bear
a legend in substantially the following form:

 

“UNLESS THIS GLOBAL NOTE
IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY, A NEW YORK CORPORATION (“DTC”), TO THE COMPANY
OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE OR PAYMENT, AND ANY GLOBAL NOTE ISSUED IS REGISTERED IN THE NAME OF CEDE & CO.
OR IN SUCH OTHER NAME AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC (AND ANY PAYMENT IS MADE TO CEDE & CO. OR TO SUCH OTHER
ENTITY AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC), ANY TRANSFER, PLEDGE OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR
TO ANY PERSON IS WRONGFUL INASMUCH AS THE REGISTERED OWNER HEREOF, CEDE & CO., HAS AN INTEREST HEREIN.”

 

2.14.4. Acts of Holders.
The Depositary, as a Holder, may appoint agents and otherwise authorize participants to give or take any request, demand, authorization,
direction, notice, consent, waiver or other action which a Holder is entitled to give or take under the Indenture.

 

    9

     

    

 

2.14.5. Payments. Notwithstanding
the other provisions of this Indenture, unless otherwise specified as contemplated by Section 2.2, payment of the principal of and interest,
if any, on any Global Security shall be made to the Holder thereof.

 

2.14.6. Consents, Declaration
and Directions. The Company, the Trustee and any Agent shall treat a person as the Holder of such principal amount of outstanding
Securities of such Series represented by a Global Security as shall be specified in a written statement of the Depositary or by the applicable
procedures of such Depositary with respect to such Global Security, for purposes of obtaining any consents, declarations, waivers or directions
required to be given by the Holders pursuant to this Indenture.

 

Section 2.15. CUSIP Numbers.

 

The Company in issuing the Securities
may use “CUSIP” numbers (if then generally in use), and, if so, the Trustee shall use “CUSIP” numbers in notices
of redemption as a convenience to Holders; provided that any such notice may state that no representation is made as to the correctness
of such numbers either as printed on the Securities or as contained in any notice of a redemption and that reliance may be placed only
on the other elements of identification printed on the Securities, and any such redemption shall not be affected by any defect in or omission
of such numbers.

 

ARTICLE III.

REDEMPTION

 

Section 3.1. Notice to Trustee.

 

The Company may, with respect
to any Series of Securities, reserve the right to redeem and pay the Series of Securities or may covenant to redeem and pay the Series
of Securities or any part thereof prior to the Stated Maturity thereof at such time and on such terms as provided for in such Securities.
If a Series of Securities is redeemable and the Company wants or is obligated to redeem prior to the Stated Maturity thereof all or part
of the Series of Securities pursuant to the terms of such Securities, it shall notify the Trustee in writing of the redemption date and
the principal amount of Series of Securities to be redeemed. The Company shall give the notice at least 15 days before the redemption
date, unless a shorter period is satisfactory to the Trustee.

 

Section 3.2. Selection of Securities to be Redeemed.

 

Unless otherwise indicated for
a particular Series by a Board Resolution, a supplemental indenture hereto or an Officer’s Certificate, if less than all the Securities
of a Series are to be redeemed, the Securities of the Series to be redeemed will be selected as follows: (a) if the Securities are in
the form of Global Securities, in accordance with the procedures of the Depositary, (b) if the Securities are listed on any national securities
exchange, in compliance with the requirements of the principal national securities exchange, if any, on which the Securities are listed,
or (c) if not otherwise provided for under clause (a) or (b) in the manner that the Trustee deems fair and appropriate, including by lot
or other method, unless otherwise required by law or applicable stock exchange requirements, subject, in the case of Global Securities,
to the applicable rules and procedures of the Depositary. The Securities to be redeemed shall be selected from Securities of the Series
outstanding not previously called for redemption. Portions of the principal of Securities of the Series that have denominations larger
than $1,000 may be selected for redemption. Securities of the Series and portions of them it selected for redemption shall be in amounts
of $1,000 or whole multiples of $1,000 or, with respect to Securities of any Series issuable in other denominations pursuant to Section
2.2.10, the minimum principal denomination for each Series and the authorized integral multiples thereof. Provisions of this Indenture
that apply to Securities of a Series called for redemption also apply to portions of Securities of that Series called for redemption.

 

Section 3.3. Notice of Redemption.

 

Unless otherwise indicated for
a particular Series by Board Resolution, a supplemental indenture hereto or an Officer’s Certificate, at least 15 days but not more
than 60 days before a redemption date, the Company shall send or cause to be sent by first-class mail or electronically, in accordance
with the procedures of the Depositary, a notice of redemption to each Holder whose Securities are to be redeemed.

 

The notice shall identify the
Securities of the Series to be redeemed and shall state:

 

(a) the redemption
date;

 

(b) the redemption
price;

 

    10

     

    

 

(c) the name and
address of the Paying Agent;

 

(d) if any Securities
are being redeemed in part, the portion of the principal amount of such Securities to be redeemed and that, after the redemption date
and upon surrender of such Security, a new Security or Securities in principal amount equal to the unredeemed portion of the original
Security shall be issued in the name of the Holder thereof upon cancellation of the original Security;

 

(e) that Securities
of the Series called for redemption must be surrendered to the Paying Agent to collect the redemption price;

 

(f) that interest
on Securities of the Series called for redemption ceases to accrue on and after the redemption date unless the Company defaults in the
deposit of the redemption price;

 

(g) the CUSIP number,
if any; and

 

(h) any other information
as may be required by the terms of the particular Series or the Securities of a Series being redeemed.

 

At the Company’s request,
the Trustee shall give the notice of redemption in the Company’s name and at its expense, provided, however, that the Company has
delivered to the Trustee, at least 10 days (unless a shorter time shall be acceptable to the Trustee) prior to the notice date, an Officer’s
Certificate requesting that the Trustee give such notice and setting forth the information to be stated in such notice.

 

Section 3.4. Effect of Notice of Redemption.

 

Once notice of redemption is
sent as provided in Section 3.3, Securities of a Series called for redemption become due and payable on the redemption date and at the
redemption price. Except as otherwise provided in the supplemental indenture, Board Resolution or Officer’s Certificate for a Series,
a notice of redemption may not be conditional. Upon surrender to the Paying Agent, such Securities shall be paid at the redemption price
plus accrued interest to the redemption date.

 

Section 3.5. Deposit of Redemption Price.

 

On or before 11:00 a.m., New
York City time, on the redemption date, the Company shall deposit with the Paying Agent money sufficient to pay the redemption price of
and accrued interest, if any, on all Securities to be redeemed on that date.

 

Section 3.6. Securities Redeemed in Part.

 

Upon surrender of a Security
that is redeemed in part, the Trustee shall authenticate for the Holder a new Security of the same Series and the same maturity equal
in principal amount to the unredeemed portion of the Security surrendered.

 

ARTICLE IV.

COVENANTS

 

Section 4.1. Payment of Principal and Interest.

 

The Company covenants and agrees
for the benefit of the Holders of each Series of Securities that it will duly and punctually pay the principal of and interest, if any,
on the Securities of that Series in accordance with the terms of such Securities and this Indenture. On or before 11:00 a.m., New York
City time, on the applicable payment date, the Company shall deposit with the Paying Agent money sufficient to pay the principal of and
interest, if any, on the Securities of each Series in accordance with the terms of such Securities and this Indenture.

 

Section 4.2. SEC Reports.

 

To the extent any Securities
of a Series are outstanding, the Company shall deliver to the Trustee within 15 days after it files them with the SEC copies of the annual
reports and of the information, documents, and other reports (or copies of such portions of any of the foregoing as the SEC may by rules
and regulations prescribe) which the Company is required to file with the SEC pursuant to Section 13 or 15(d) of the Exchange Act. The
Company also shall comply with the other provisions of TIA § 314(a). Reports, information and documents filed with the SEC via the
EDGAR system will be deemed to be delivered to the Trustee as of the time of such filing via EDGAR for purposes of this Section 4.2.

 

    11

     

    

 

Delivery of reports, information
and documents to the Trustee under this Section 4.2 are for informational purposes only and the Trustee’s receipt of the foregoing
shall not constitute constructive or actual notice of any information contained therein or determinable from information contained therein,
including the Company’s compliance with any of their covenants hereunder (as to which the Trustee is entitled to rely exclusively
on Officer’s Certificates).

 

Section 4.3. Compliance Certificate.

 

To the extent any Securities
of a Series are outstanding, the Company shall deliver to the Trustee, within 120 days after the end of each fiscal year of the Company,
an Officer’s Certificate stating that a review of the activities of the Company and its Subsidiaries during the preceding fiscal
year has been made under the supervision of the signing Officers with a view to determining whether the Company has kept, observed, performed
and fulfilled its obligations under this Indenture, and further stating, as to each such Officer signing such certificate, that to the
best of his/her knowledge the Company has kept, observed, performed and fulfilled each and every covenant contained in this Indenture
and is not in default in the performance or observance of any of the terms, provisions and conditions hereof (or, if a Default or Event
of Default shall have occurred, describing all such Defaults or Events of Default of which the Officer may have knowledge).

 

Section 4.4. Stay, Extension and Usury Laws.

 

The Company covenants (to the
extent that it may lawfully do so) that it will not at any time insist upon, plead, or in any manner whatsoever claim or take the benefit
or advantage of, any stay, extension or usury law wherever enacted, now or at any time hereafter in force, which may affect the covenants
or the performance of this Indenture or the Securities; and the Company (to the extent it may lawfully do so) hereby expressly waives
all benefit or advantage of any such law and covenants that it will not, by resort to any such law, hinder, delay or impede the execution
of any power herein granted to the Trustee, but will suffer and permit the execution of every such power as though no such law has been
enacted.

 

ARTICLE
V.

SUCCESSORS

 

Section 5.1. When Company May Merge, Etc.

 

The Company shall not consolidate
with or merge with or into, or convey, transfer or lease all or substantially all of its properties and assets to, any person (a “successor
person”) unless:

 

(a) the Company
is the surviving corporation or the successor person (if other than the Company) is a corporation organized and validly existing under
the laws of any U.S. domestic jurisdiction and expressly assumes the Company’s obligations on the Securities and under this Indenture;
and

 

(b) immediately
after giving effect to the transaction, no Default or Event of Default, shall have occurred and be continuing.

 

The Company shall deliver to
the Trustee prior to the consummation of the proposed transaction an Officer’s Certificate to the foregoing effect and an Opinion
of Counsel stating that the proposed transaction and any supplemental indenture comply with this Indenture.

 

Notwithstanding the above, any
Subsidiary of the Company may consolidate with, merge into or transfer all or part of its properties to the Company. Neither an Officer’s
Certificate nor an Opinion of Counsel shall be required to be delivered in connection therewith.

 

Section 5.2. Successor Corporation Substituted.

 

Upon any consolidation or merger,
or any sale, lease, conveyance or other disposition of all or substantially all of the assets of the Company in accordance with Section
5.1, the successor corporation formed by such consolidation or into or with which the Company is merged or to which such sale, lease,
conveyance or other disposition is made shall succeed to, and be substituted for, and may exercise every right and power of, the Company
under this Indenture with the same effect as if such successor person has been named as the Company herein; provided, however,
that the predecessor Company in the case of a sale, conveyance or other disposition (other than a lease) shall be released from all obligations
and covenants under this Indenture and the Securities.

 

    12

     

    

 

ARTICLE VI.

DEFAULTS AND REMEDIES

 

Section 6.1. Events of Default.

 

“Event of Default,”
wherever used herein with respect to Securities of any Series, means any one of the following events, unless in the establishing Board
Resolution, supplemental indenture or Officer’s Certificate, it is provided that such Series shall not have the benefit of said
Event of Default:

 

(a) default in the
payment of any interest on any Security of that Series when it becomes due and payable, and continuance of such default for a period of
30 days (unless the entire amount of such payment is deposited by the Company with the Trustee or with a Paying Agent prior to 11:00 a.m.,
New York City time, on the 30th day of such period); or

 

(b) default in the
payment of principal of any Security of that Series at its Maturity; or

 

(c) default in the
performance or breach of any covenant or warranty of the Company in this Indenture (other than defaults pursuant to paragraphs (a) or
(b) above or pursuant to a covenant or warranty that has been included in this Indenture solely for the benefit of Series of Securities
other than that Series), which default continues uncured for a period of 60 days after there has been given, by registered or certified
mail, to the Company by the Trustee or to the Company and the Trustee by the Holders of at least 25% in principal amount of the outstanding
Securities of that Series a written notice specifying such default or breach and requiring it to be remedied and stating that such notice
is a “Notice of Default” hereunder; or

 

(d) the Company
pursuant to or within the meaning of any Bankruptcy Law:

 

(i) commences a voluntary
case,

 

(ii) consents to the
entry of an order for relief against it in an involuntary case,

 

(iii) consents to
the appointment of a Custodian of it or for all or substantially all of its property,

 

(iv) makes a general
assignment for the benefit of its creditors, or

 

(v) generally is unable
to pay its debts as the same become due; or

 

(e) a court of competent
jurisdiction enters an order or decree under any Bankruptcy Law that:

 

(i) is for relief
against the Company in an involuntary case,

 

(ii) appoints a Custodian
of the Company or for all or substantially all of its property, or

 

(iii) orders the liquidation
of the Company,

 

and the order or decree remains unstayed
and in effect for 60 days; or

 

(f) any other Event
of Default provided with respect to Securities of that Series, which is specified in a Board Resolution, a supplemental indenture hereto
or an Officer’s Certificate, in accordance with Section 2.2.18.

 

The term “Bankruptcy
Law” means title 11, U.S. Code or any similar Federal or State law for the relief of debtors. The term “Custodian”
means any receiver, trustee, assignee, liquidator or similar official under any Bankruptcy Law.

 

The Company will provide the
Trustee written notice of any Default or Event of Default within 30 days of becoming aware of the occurrence of such Default or Event
of Default, which notice will describe in reasonable detail the status of such Default or Event of Default and what action the Company
is taking or proposes to take in respect thereof.

 

Section 6.2. Acceleration of Maturity; Rescission and Annulment.

 

If an Event of Default with
respect to Securities of any Series at the time outstanding occurs and is continuing (other than an Event of Default referred to in Section
6.1(d) or (e)) then in every such case the Trustee or the Holders of not less than 25% in principal amount of the outstanding Securities
of that Series may declare the principal amount (or, if any Securities of that Series are Discount Securities, such portion of the principal
amount as may be specified in the terms of such Securities) of and accrued and unpaid interest, if any, on all of the Securities of that
Series to be due and payable immediately, by a notice in writing to the Company (and to the Trustee if given by Holders), and upon any
such declaration such principal amount (or specified amount) and accrued and unpaid interest, if any, shall become immediately due and
payable. If an Event of Default specified in Section 6.1(d) or (e) shall occur, the principal amount (or specified amount) of and accrued
and unpaid interest, if any, on all outstanding Securities shall ipso facto become and be immediately due and payable without any
declaration or other act on the part of the Trustee or any Holder.

 

    13

     

    

 

At any time after such a declaration
of acceleration with respect to any Series has been made and before a judgment or decree for payment of the money due has been obtained
by the Trustee as hereinafter in this Article provided, the Holders of a majority in principal amount of the outstanding Securities of
that Series, by written notice to the Company and the Trustee, may rescind and annul such declaration and its consequences if all Events
of Default with respect to Securities of that Series, other than the non-payment of the principal and interest, if any, of Securities
of that Series which have become due solely by such declaration of acceleration, have been cured or waived as provided in Section 6.13.

 

No such rescission shall affect
any subsequent Default or impair any right consequent thereon.

 

Section 6.3. Collection of Indebtedness and Suits for Enforcement
by Trustee.

 

The Company covenants that if

 

(a) default is made
in the payment of any interest on any Security when such interest becomes due and payable and such default continues for a period of 30
days, or

 

(b) default is made
in the payment of principal of any Security at the Maturity thereof, or

 

(c) default is made
in the deposit of any sinking fund payment, if any, when and as due by the terms of a Security,

 

then, the Company will, upon demand of
the Trustee, pay to it, for the benefit of the Holders of such Securities, the whole amount then due and payable on such Securities for
principal and interest and, to the extent that payment of such interest shall be legally enforceable, interest on any overdue principal
and any overdue interest at the rate or rates prescribed therefor in such Securities, and, in addition thereto, such further amount as
shall be sufficient to cover the costs and expenses of collection, including the compensation, reasonable expenses, disbursements and
advances of the Trustee, its agents and counsel.

 

If the Company fails to pay
such amounts forthwith upon such demand, the Trustee, in its own name and as trustee of an express trust, may institute a judicial proceeding
for the collection of the sums so due and unpaid, may prosecute such proceeding to judgment or final decree and may enforce the same against
the Company or any other obligor upon such Securities and collect the moneys adjudged or deemed to be payable in the manner provided by
law out of the property of the Company or any other obligor upon such Securities, wherever situated.

 

If an Event of Default with
respect to any Securities of any Series occurs and is continuing, the Trustee may in its discretion proceed to protect and enforce its
rights and the rights of the Holders of Securities of such Series by such appropriate judicial proceedings as the Trustee shall deem most
effectual to protect and enforce any such rights, whether for the specific enforcement of any covenant or agreement in this Indenture
or in aid of the exercise of any power granted herein, or to enforce any other proper remedy.

 

Section 6.4. Trustee May File Proofs of Claim.

 

In case of the pendency of any
receivership, insolvency, liquidation, bankruptcy, reorganization, arrangement, adjustment, composition or other judicial proceeding relative
to the Company or any other obligor upon the Securities or the property of the Company or of such other obligor or their creditors, the
Trustee (irrespective of whether the principal of the Securities shall then be due and payable as therein expressed or by declaration
or otherwise and irrespective of whether the Trustee shall have made any demand on the Company for the payment of overdue principal or
interest) shall be entitled and empowered, by intervention in such proceeding or otherwise,

 

(a) to file and
prove a claim for the whole amount of principal and interest owing and unpaid in respect of the Securities and to file such other papers
or documents as may be necessary or advisable in order to have the claims of the Trustee (including any claim for the compensation, reasonable
expenses, disbursements and advances of the Trustee, its agents and counsel) and of the Holders allowed in such judicial proceeding, and

 

    14

     

    

 

(b) to collect and
receive any moneys or other property payable or deliverable on any such claims and to distribute the same,

 

and any custodian, receiver, assignee, trustee,
liquidator, sequestrator or other similar official in any such judicial proceeding is hereby authorized by each Holder to make such payments
to the Trustee and, in the event that the Trustee shall consent to the making of such payments directly to the Holders, to pay to the
Trustee any amount due it for the compensation, reasonable expenses, disbursements and advances of the Trustee, its agents and counsel,
and any other amounts due the Trustee under Section 7.7.

 

Nothing herein contained shall
be deemed to authorize the Trustee to authorize or consent to or accept or adopt on behalf of any Holder any plan of reorganization, arrangement,
adjustment or composition affecting the Securities or the rights of any Holder thereof or to authorize the Trustee to vote in respect
of the claim of any Holder in any such proceeding.

 

Section 6.5. Trustee May Enforce Claims Without Possession
of Securities.

 

All rights of action and claims
under this Indenture or the Securities may be prosecuted and enforced by the Trustee without the possession of any of the Securities or
the production thereof in any proceeding relating thereto, and any such proceeding instituted by the Trustee shall be brought in its own
name as trustee of an express trust, and any recovery of judgment shall, after provision for the payment of the compensation, reasonable
expenses, disbursements and advances of the Trustee, its agents and counsel, be for the ratable benefit of the Holders of the Securities
in respect of which such judgment has been recovered.

 

Section 6.6. Application of Money Collected.

 

Any money or property collected
by the Trustee pursuant to this Article shall be applied in the following order, at the date or dates fixed by the Trustee and, in case
of the distribution of such money or property on account of principal or interest, upon presentation of the Securities and the notation
thereon of the payment if only partially paid and upon surrender thereof if fully paid:

 

First: To the payment of all
amounts due the Trustee under Section 7.7; and

 

Second: To the payment of the
amounts then due and unpaid for principal of and interest on the Securities in respect of which or for the benefit of which such money
has been collected, ratably, without preference or priority of any kind, according to the amounts due and payable on such Securities for
principal and interest, respectively; and

 

Third: To the Company.

 

Section 6.7. Limitation on Suits.

 

No Holder of any Security of
any Series shall have any right to institute any proceeding, judicial or otherwise, with respect to this Indenture, or for the appointment
of a receiver or trustee, or for any other remedy hereunder, unless

 

(a) such Holder
has previously given written notice to the Trustee of a continuing Event of Default with respect to the Securities of that Series;

 

(b) the Holders
of not less than 25% in principal amount of the outstanding Securities of that Series shall have made written request to the Trustee to
institute proceedings in respect of such Event of Default in its own name as Trustee hereunder;

 

(c) such Holder
or Holders have offered to the Trustee indemnity or security satisfactory to the Trustee against the costs, expenses and liabilities which
might be incurred by the Trustee in compliance with such request;

 

(d) the Trustee
for 60 days after its receipt of such notice, request and offer of indemnity has failed to institute any such proceeding; and

 

(e) no direction
inconsistent with such written request has been given to the Trustee during such 60-day period by the Holders of a majority in principal
amount of the outstanding Securities of that Series;

 

    15

     

    

 

it being understood, intended and expressly covenanted
by the Holder of every Security with every other Holder and the Trustee that no one or more of such Holders shall have any right in any
manner whatever by virtue of, or by availing of, any provision of this Indenture to affect, disturb or prejudice the rights of any other
of such Holders, or to obtain or to seek to obtain priority or preference over any other of such Holders or to enforce any right under
this Indenture, except in the manner herein provided and for the equal and ratable benefit of all such Holders of the applicable Series.

 

Section 6.8. Unconditional Right of Holders to Receive Principal
and Interest.

 

Notwithstanding any other provision
in this Indenture, the Holder of any Security shall have the right, which is absolute and unconditional, to receive payment of the principal
of and interest, if any, on such Security on the Maturity of such Security, including the Stated Maturity expressed in such Security (or,
in the case of redemption, on the redemption date) and to institute suit for the enforcement of any such payment, and such rights shall
not be impaired without the consent of such Holder.

 

Section 6.9. Restoration of Rights and Remedies.

 

If the Trustee or any Holder
has instituted any proceeding to enforce any right or remedy under this Indenture and such proceeding has been discontinued or abandoned
for any reason, or has been determined adversely to the Trustee or to such Holder, then and in every such case, subject to any determination
in such proceeding, the Company, the Trustee and the Holders shall be restored severally and respectively to their former positions hereunder
and thereafter all rights and remedies of the Trustee and the Holders shall continue as though no such proceeding had been instituted.

 

Section 6.10. Rights and Remedies Cumulative.

 

Except as otherwise provided
with respect to the replacement or payment of mutilated, destroyed, lost or stolen Securities in Section 2.8, no right or remedy herein
conferred upon or reserved to the Trustee or to the Holders is intended to be exclusive of any other right or remedy, and every right
and remedy shall, to the extent permitted by law, be cumulative and in addition to every other right and remedy given hereunder or now
or hereafter existing at law or in equity or otherwise. The assertion or employment of any right or remedy hereunder, or otherwise, shall
not, to the extent permitted by law, prevent the concurrent assertion or employment of any other appropriate right or remedy.

 

Section 6.11. Delay or Omission Not Waiver.

 

No delay or omission of the
Trustee or of any Holder of any Securities to exercise any right or remedy accruing upon any Event of Default shall impair any such right
or remedy or constitute a waiver of any such Event of Default or an acquiescence therein. Every right and remedy given by this Article
or by law to the Trustee or to the Holders may be exercised from time to time, and as often as may be deemed expedient, by the Trustee
or by the Holders, as the case may be.

 

Section 6.12. Control by Holders.

 

The Holders of a majority in
principal amount of the outstanding Securities of any Series shall have the right to direct the time, method and place of conducting any
proceeding for any remedy available to the Trustee, or exercising any trust or power conferred on the Trustee, with respect to the Securities
of such Series, provided that

 

(a) such direction
shall not be in conflict with any rule of law or with this Indenture,

 

(b) the Trustee
may take any other action deemed proper by the Trustee which is not inconsistent with such direction,

 

(c) subject to the
provisions of Section 7.1, the Trustee shall have the right to decline to follow any such direction if the Trustee in good faith shall,
by a Responsible Officer of the Trustee, determine that the proceeding so directed would involve the Trustee in personal liability, and

 

(d) prior to taking
any action as directed under this Section 6.12, the Trustee shall be entitled to indemnity satisfactory to it against the costs, expenses
and liabilities which might be incurred by it in compliance with such request or direction.

 

    16

     

    

 

Section 6.13. Waiver of Past Defaults.

 

The Holders of not less than
a majority in principal amount of the outstanding Securities of any Series may on behalf of the Holders of all the Securities of such
Series, by written notice to the Trustee and the Company, waive any past Default hereunder with respect to such Series and its consequences,
except a Default in the payment of the principal of or interest on any Security of such Series (provided, however, that the Holders of
a majority in principal amount of the outstanding Securities of any Series may rescind an acceleration and its consequences, including
any related payment default that resulted from such acceleration). Upon any such waiver, such Default shall cease to exist, and any Event
of Default arising therefrom shall be deemed to have been cured, for every purpose of this Indenture; but no such waiver shall extend
to any subsequent or other Default or impair any right consequent thereon.

 

Section 6.14. Undertaking for Costs.

 

All parties to this Indenture
agree, and each Holder of any Security by his acceptance thereof shall be deemed to have agreed, that any court may in its discretion
require, in any suit for the enforcement of any right or remedy under this Indenture, or in any suit against the Trustee for any action
taken, suffered or omitted by it as Trustee, the filing by any party litigant in such suit of an undertaking to pay the costs of such
suit, and that such court may in its discretion assess reasonable costs, including reasonable attorneys’ fees, against any party
litigant in such suit, having due regard to the merits and good faith of the claims or defenses made by such party litigant; but the provisions
of this Section shall not apply to any suit instituted by the Company, to any suit instituted by the Trustee, to any suit instituted by
any Holder, or group of Holders, holding in the aggregate more than 10% in principal amount of the outstanding Securities of any Series,
or to any suit instituted by any Holder for the enforcement of the payment of the principal of or interest on any Security on or after
the Maturity of such Security, including the Stated Maturity expressed in such Security (or, in the case of redemption, on the redemption
date).

 

ARTICLE VII.

TRUSTEE

 

Section 7.1. Duties of Trustee.

 

(a) If an Event
of Default has occurred and is continuing, the Trustee shall exercise the rights and powers vested in it by this Indenture and use the
same degree of care and skill in their exercise as a prudent person would exercise or use under the circumstances in the conduct of such
person’s own affairs.

 

(b) Except during
the continuance of an Event of Default:

 

(i) The Trustee need
perform only those duties that are specifically set forth in this Indenture and no others.

 

(ii) In the absence
of bad faith on its part, the Trustee may conclusively rely, as to the truth of the statements and the correctness of the opinions expressed
therein, upon Officer’s Certificates or Opinions of Counsel furnished to the Trustee and conforming to the requirements of this
Indenture; however, in the case of any such Officer’s Certificates or Opinions of Counsel which by any provisions hereof
are specifically required to be furnished to the Trustee, the Trustee shall examine such Officer’s Certificates and Opinions of
Counsel to determine whether or not they conform to the form requirements of this Indenture.

 

(c) The Trustee
may not be relieved from liability for its own negligent action, its own negligent failure to act or its own willful misconduct, except
that:

 

(i) This paragraph
does not limit the effect of paragraph (b) of this Section.

 

(ii) The Trustee shall
not be liable for any error of judgment made in good faith by a Responsible Officer, unless it is proved that the Trustee was negligent
in ascertaining the pertinent facts.

 

(iii) The Trustee
shall not be liable with respect to any action taken, suffered or omitted to be taken by it with respect to Securities of any Series in
good faith in accordance with the direction of the Holders of a majority in principal amount of the outstanding Securities of such Series
relating to the time, method and place of conducting any proceeding for any remedy available to the Trustee, or exercising any trust or
power conferred upon the Trustee, under this Indenture with respect to the Securities of such Series in accordance with Section 6.12.

 

    17

     

    

 

(d) Every provision
of this Indenture that in any way relates to the Trustee is subject to paragraph (a), (b) and (c) of this Section.

 

(e) The Trustee
may refuse to perform any duty or exercise any right or power unless it receives indemnity satisfactory to it against the costs, expenses
and liabilities which might be incurred by it in performing such duty or exercising such right or power.

 

(f) The Trustee
shall not be liable for interest on any money received by it except as the Trustee may agree in writing with the Company. Money held in
trust by the Trustee need not be segregated from other funds except to the extent required by law.

 

(g) No provision
of this Indenture shall require the Trustee to risk its own funds or otherwise incur any financial liability in the performance of any
of its duties, or in the exercise of any of its rights or powers, if adequate indemnity against such risk is not assured to the Trustee
in its satisfaction.

 

(h) The Paying Agent,
the Registrar and any authenticating agent shall be entitled to the protections and immunities as are set forth in paragraphs (e), (f)
and (g) of this Section and in Section 7.2, each with respect to the Trustee.

 

Section 7.2. Rights of Trustee.

 

(a) The Trustee
may rely on and shall be protected in acting or refraining from acting upon any document (whether in its original or facsimile form) believed
by it to be genuine and to have been signed or presented by the proper person. The Trustee need not investigate any fact or matter stated
in the document.

 

(b) Before the Trustee
acts or refrains from acting, it may require an Officer’s Certificate or an Opinion of Counsel or both. The Trustee shall not be
liable for any action it takes or omits to take in good faith in reliance on such Officer’s Certificate or Opinion of Counsel.

 

(c) The Trustee
may act through agents and shall not be responsible for the misconduct or negligence of any agent appointed with due care. No Depositary
shall be deemed an agent of the Trustee and the Trustee shall not be responsible for any act or omission by any Depositary.

 

(d) The Trustee
shall not be liable for any action it takes or omits to take in good faith which it believes to be authorized or within its rights or
powers, provided that the Trustee’s conduct does not constitute willful misconduct or negligence.

 

(e) The Trustee
may consult with counsel and the advice of such counsel or any Opinion of Counsel shall be full and complete authorization and protection
in respect of any action taken, suffered or omitted by it hereunder without willful misconduct or negligence, and in reliance thereon.

 

(f) The Trustee
shall be under no obligation to exercise any of the rights or powers vested in it by this Indenture at the request or direction of any
of the Holders of Securities unless such Holders shall have offered to the Trustee security or indemnity satisfactory to it against the
costs, expenses and liabilities which might be incurred by it in compliance with such request or direction.

 

(g) The Trustee
shall not be bound to make any investigation into the facts or matters stated in any resolution, certificate, statement, instrument, opinion,
report, notice, request, direction, consent, order, bond, debenture, note, other evidence of indebtedness or other paper or document,
but the Trustee, in its discretion, may make such further inquiry or investigation into such facts or matters as it may see fit.

 

(h) The Trustee
shall not be deemed to have notice of any Default or Event of Default unless a Responsible Officer of the Trustee has actual knowledge
thereof or unless written notice of any event which is in fact such a default is received by the Trustee at the Corporate Trust Office
of the Trustee, and such notice references the Securities generally or the Securities of a particular Series and this Indenture.

 

(i) In no event
shall the Trustee be liable to any person for special, punitive, indirect, consequential or incidental loss or damage of any kind whatsoever
(including but not limited to lost profits), even if the Trustee has been advised of the likelihood of such loss or damage.

 

(j) The permissive
right of the Trustee to take the actions permitted by this Indenture shall not be construed as an obligation or duty to do so.

 

    18

     

    

 

Section 7.3. Individual Rights of Trustee.

 

The Trustee in its individual
or any other capacity may become the owner or pledgee of Securities and may otherwise deal with the Company or an Affiliate of the Company
with the same rights it would have if it were not Trustee. Any Agent may do the same with like rights. The Trustee is also subject to
Sections 7.10 and 7.11.

 

Section 7.4. Trustee’s Disclaimer.

 

The Trustee makes no representation
as to the validity or adequacy of this Indenture or the Securities, it shall not be accountable for the Company’s use of the proceeds
from the Securities, and it shall not be responsible for any statement in the Securities other than its authentication.

 

Section 7.5. Notice of Defaults.

 

If a Default or Event of Default
occurs and is continuing with respect to the Securities of any Series and if it is known to a Responsible Officer of the Trustee, the
Trustee shall send to each Securityholder of the Securities of that Series notice of a Default or Event of Default within 90 days after
it occurs or, if later, after a Responsible Officer of the Trustee has knowledge of such Default or Event of Default. Except in the case
of a Default or Event of Default in payment of principal of or interest on any Security of any Series, the Trustee may withhold the notice
if and so long as its corporate trust committee or a committee of its Responsible Officers in good faith determines that withholding the
notice is in the interests of Securityholders of that Series.

 

Section 7.6. Reports by Trustee to Holders.

 

Within 60 days prior to each
anniversary of the date of this Indenture the Trustee shall transmit by mail to all Securityholders, as their names and addresses appear
on the register kept by the Registrar, a brief report dated as of such anniversary date, in accordance with, and to the extent required
under, TIA § 313.

 

A copy of each report at the
time of its mailing to Securityholders of any Series shall be filed with the SEC and each national securities exchange on which the Securities
of that Series are listed. The Company shall promptly notify the Trustee in writing when Securities of any Series are listed on any national
securities exchange.

 

Section 7.7. Compensation and Indemnity.

 

The Company shall pay to the
Trustee from time to time compensation for its services as the Company and the Trustee shall from time to time agree upon in writing.
The Trustee’s compensation shall not be limited by any law on compensation of a trustee of an express trust. The Company shall reimburse
the Trustee upon request for all reasonable out of pocket expenses incurred by it. Such expenses shall include the reasonable compensation
and expenses of the Trustee’s agents and counsel.

 

The Company shall indemnify
each of the Trustee and any predecessor Trustee (including for the cost of defending itself) against any cost, expense or liability, including
taxes (other than taxes based upon, measured by or determined by the income of the Trustee) incurred by it except as set forth in the
next paragraph in the performance of its duties under this Indenture as Trustee or Agent. The Trustee shall notify the Company promptly
of any claim for which it may seek indemnity. Failure by the Trustee to so notify the Company shall not relieve the Company of its obligations
hereunder, unless and to the extent that the Company is materially prejudiced thereby. The Company shall defend the claim and the Trustee
shall cooperate in the defense. The Trustee may have one separate counsel and the Company shall pay the reasonable fees and expenses of
such counsel. The Company need not pay for any settlement made without its consent, which consent will not be unreasonably withheld. This
indemnification shall apply to officers, directors, employees, shareholders and agents of the Trustee.

 

The Company need not reimburse
any expense or indemnify against any loss or liability incurred by the Trustee or by any officer, director, employee, shareholder or agent
of the Trustee through willful misconduct or negligence.

 

To secure the Company’s
payment obligations in this Section, the Trustee shall have a lien prior to the Securities of any Series on all money or property held
or collected by the Trustee, except that held in trust to pay principal of and interest on particular Securities of that Series.

 

    19

     

    

 

When the Trustee incurs expenses
or renders services after an Event of Default specified in Section 6.1(d) or (e) occurs, the expenses and the compensation for the services
are intended to constitute expenses of administration under any Bankruptcy Law.

 

The provisions of this Section
shall survive the termination of this Indenture.

 

Section 7.8. Replacement of Trustee.

 

A resignation or removal of
the Trustee and appointment of a successor Trustee shall become effective only upon the successor Trustee’s acceptance of appointment
as provided in this Section.

 

The Trustee may resign with
respect to the Securities of one or more Series by so notifying the Company at least 30 days prior to the date of the proposed resignation.
The Holders of a majority in principal amount of the Securities of any Series may remove the Trustee with respect to that Series by so
notifying the Trustee and the Company. The Company may remove the Trustee with respect to Securities of one or more Series if:

 

(a) the Trustee
fails to comply with Section 7.10;

 

(b) the Trustee
is adjudged a bankrupt or an insolvent or an order for relief is entered with respect to the Trustee under any Bankruptcy Law;

 

(c) a Custodian
or public officer takes charge of the Trustee or its property; or

 

(d) the Trustee
becomes incapable of acting.

 

If the Trustee resigns or is
removed or if a vacancy exists in the office of Trustee for any reason, the Company shall promptly appoint a successor Trustee. Within
one year after the successor Trustee takes office, the Holders of a majority in principal amount of the then outstanding Securities may
appoint a successor Trustee to replace the successor Trustee appointed by the Company.

 

If a successor Trustee with
respect to the Securities of any one or more Series does not take office within 60 days after the retiring Trustee resigns or is removed,
the retiring Trustee, the Company or the Holders of at least a majority in principal amount of the Securities of the applicable Series
may petition any court of competent jurisdiction for the appointment of a successor Trustee.

 

A successor Trustee shall deliver
a written acceptance of its appointment to the retiring Trustee and to the Company. Immediately after that, the retiring Trustee shall
transfer all property held by it as Trustee to the successor Trustee subject to the lien provided for in Section 7.7, the resignation
or removal of the retiring Trustee shall become effective, and the successor Trustee shall have all the rights, powers and duties of the
Trustee with respect to each Series of Securities for which it is acting as Trustee under this Indenture. A successor Trustee shall mail
a notice of its succession to each Securityholder of each such Series. Notwithstanding replacement of the Trustee pursuant to this Section
7.8, the Company’s obligations under Section 7.7 hereof shall continue for the benefit of the retiring Trustee with respect to expenses
and liabilities incurred by it for actions taken or omitted to be taken in accordance with its rights, powers and duties under this Indenture
prior to such replacement.

 

Section 7.9. Successor Trustee by Merger, Etc.

 

If the Trustee consolidates
with, merges or converts into, or transfers all or substantially all of its corporate trust business to, another corporation, the successor
corporation without any further act shall be the successor Trustee, subject to Section 7.10.

 

Section 7.10. Eligibility; Disqualification.

 

This Indenture shall always
have a Trustee who satisfies the requirements of TIA § 310(a)(1), (2) and (5). The Trustee shall always have a combined capital and
surplus of at least $25,000,000 as set forth in its most recent published annual report of condition. The Trustee shall comply with TIA
§ 310(b).

 

Section 7.11. Preferential Collection of Claims Against Company.

 

The Trustee is subject to TIA
§ 311(a), excluding any creditor relationship listed in TIA § 311(b). A Trustee who has resigned or been removed shall be subject
to TIA § 311(a) to the extent indicated.

 

    20

     

    

 

ARTICLE VIII.

SATISFACTION AND DISCHARGE; DEFEASANCE

 

Section 8.1. Satisfaction and Discharge of Indenture.

 

This Indenture shall upon Company
Order be discharged with respect to the Securities of any Series and cease to be of further effect as to all Securities of such Series
(except as hereinafter provided in this Section 8.1), and the Trustee, at the expense of the Company, shall execute instruments acknowledging
satisfaction and discharge of this Indenture, when

 

(a) either

 

(i) all Securities
of such Series theretofore authenticated and delivered (other than Securities that have been destroyed, lost or stolen and that have been
replaced or paid) have been delivered to the Trustee for cancellation; or

 

(ii) all such Securities
of such Series not theretofore delivered to the Trustee for cancellation

 

(1) have become
due and payable by reason of sending a notice of redemption or otherwise, or

 

(2) will become
due and payable at their Stated Maturity within one year, or

 

(3) have been called
for redemption or are to be called for redemption within one year under arrangements satisfactory to the Trustee for the giving of notice
of redemption by the Trustee in the name, and at the expense, of the Company, or

 

(4) are deemed paid
and discharged pursuant to Section 8.3, as applicable;

 

and the Company, in the case of (1), (2) or (3)
above, shall have irrevocably deposited or caused to be deposited with the Trustee as trust funds in trust an amount of money or U.S.
Government Obligations, which amount shall be sufficient for the purpose of paying and discharging each installment of principal (including
mandatory sinking fund or analogous payments) of and interest on all the Securities of such Series on the dates such installments of principal
or interest are due;

 

(b) the Company
has paid or caused to be paid all other sums payable hereunder by the Company; and

 

(c) the Company
shall have delivered to the Trustee an Officer’s Certificate and an Opinion of Counsel, each stating that all conditions precedent
provided for relating to the satisfaction and discharge contemplated by this Section have been complied with.

 

Notwithstanding the satisfaction
and discharge of this Indenture, the obligations of the Company to the Trustee under Section 7.7, and, if money shall have been deposited
with the Trustee pursuant to clause (a) of this Section, the provisions of Sections 2.4, 2.7, 2.8, 8.2 and 8.5 shall survive.

 

Section 8.2. Application of Trust Funds; Indemnification.

 

(a) Subject to the
provisions of Section 8.5, all money and U.S. Government Obligations or Foreign Government Obligations deposited with the Trustee pursuant
to Section 8.1, 8.3 or 8.4 and all money received by the Trustee in respect of U.S. Government Obligations or Foreign Government Obligations
deposited with the Trustee pursuant to Section 8.1, 8.3 or 8.4, shall be held in trust and applied by it, in accordance with the provisions
of the Securities and this Indenture, to the payment, either directly or through any Paying Agent (including the Company acting as its
own Paying Agent) as the Trustee may determine, to the persons entitled thereto, of the principal and interest for whose payment such
money has been deposited with or received by the Trustee or to make mandatory sinking fund payments or analogous payments as contemplated
by Sections 8.1, 8.3 or 8.4.

 

(b) The Company
shall pay and shall indemnify the Trustee against any tax, fee or other charge imposed on or assessed against U.S. Government Obligations
or Foreign Government Obligations deposited pursuant to Sections 8.1, 8.3 or 8.4 or the interest and principal received in respect of
such obligations other than any payable by or on behalf of Holders.

 

    21

     

    

 

(c) The Trustee
shall deliver or pay to the Company from time to time upon Company Order any U.S. Government Obligations or Foreign Government Obligations
or money held by it as provided in Sections 8.3 or 8.4 which, in the opinion of a nationally recognized firm of independent certified
public accountants or investment bank expressed in a written certification thereof delivered to the Trustee, are then in excess of the
amount thereof which then would have been required to be deposited for the purpose for which such U.S. Government Obligations or Foreign
Government Obligations or money were deposited or received. This provision shall not authorize the sale by the Trustee of any U.S. Government
Obligations or Foreign Government Obligations held under this Indenture.

 

Section 8.3. Legal Defeasance of Securities of any Series.

 

Unless this Section 8.3 is otherwise
specified, pursuant to Section 2.2, to be inapplicable to Securities of any Series, the Company shall be deemed to have paid and discharged
the entire indebtedness on all the outstanding Securities of any Series on the 91st day after the date of the deposit referred to in subparagraph
(d) hereof, and the provisions of this Indenture, as it relates to such outstanding Securities of such Series, shall no longer be in effect
(and the Trustee, at the expense of the Company, shall, upon receipt of a Company Order, execute instruments acknowledging the same),
except as to:

 

(a) the rights of
Holders of Securities of such Series to receive, from the trust funds described in subparagraph (d) hereof, (i) payment of the principal
of and each installment of principal of and interest on the outstanding Securities of such Series on the Maturity of such principal or
installment of principal or interest and (ii) the benefit of any mandatory sinking fund payments applicable to the Securities of such
Series on the day on which such payments are due and payable in accordance with the terms of this Indenture and the Securities of such
Series;

 

(b) the provisions
of Sections 2.4, 2.5, 2.7, 2.8, 7.7, 8.2, 8.3, 8.5 and 8.6; and

 

(c) the rights,
powers, trusts and immunities of the Trustee hereunder and the Company’s obligations in connection therewith;

 

provided that, the following conditions shall
have been satisfied:

 

(d) the Company
shall have irrevocably deposited or caused to be deposited (except as provided in Section 8.2(c)) with the Trustee as trust funds specifically
pledged as security for and dedicated solely to the benefit of the Holders of such Securities (i) in the case of Securities of such Series
denominated in Dollars, cash in Dollars and/or U.S. Government Obligations, or (ii) in the case of Securities of such Series denominated
in a Foreign Currency (other than a composite currency), money and/or Foreign Government Obligations, which through the payment of interest
and principal in respect thereof in accordance with their terms, will provide (and without reinvestment and assuming no tax liability
will be imposed on such Trustee), not later than one day before the due date of any payment of money, an amount in cash, sufficient, in
the opinion of a nationally recognized firm of independent public accountants or investment bank expressed in a written certification
thereof delivered to the Trustee, to pay and discharge each installment of principal of and interest, on and any mandatory sinking fund
payments in respect of all the Securities of such Series on the dates such installments of principal or interest and such sinking fund
payments are due;

 

(e) such deposit
will not result in a breach or violation of, or constitute a default under, this Indenture or any other agreement or instrument to which
the Company is a party or by which it is bound;

 

(f) no Default or
Event of Default with respect to the Securities of such Series shall have occurred and be continuing on the date of such deposit or during
the period ending on the 91st day after such date;

 

(g) the Company
shall have delivered to the Trustee an Officer’s Certificate and an Opinion of Counsel to the effect that (i) the Company has received
from, or there has been published by, the Internal Revenue Service a ruling, or (ii) since the date of execution of this Indenture, there
has been a change in the applicable Federal income tax law, in either case to the effect that, and based thereon such Opinion of Counsel
shall confirm that, the Holders of the Securities of such Series will not recognize income, gain or loss for Federal income tax purposes
as a result of such deposit, defeasance and discharge and will be subject to Federal income tax on the same amount and in the same manner
and at the same times as would have been the case if such deposit, defeasance and discharge had not occurred;

 

    22

     

    

 

(h) the Company
shall have delivered to the Trustee an Officer’s Certificate stating that the deposit was not made by the Company with the intent
of defeating, hindering, delaying or defrauding any other creditors of the Company; and

 

(i) the Company
shall have delivered to the Trustee an Officer’s Certificate and an Opinion of Counsel, each stating that all conditions precedent
provided for relating to the defeasance contemplated by this Section have been complied with.

 

Section 8.4. Covenant Defeasance.

 

Unless this Section 8.4 is otherwise
specified pursuant to Section 2.2 to be inapplicable to Securities of any Series, the Company may omit to comply with respect to the Securities
of any Series with any term, provision or condition set forth under Sections 4.2, 4.3, 4.4 and 5.1 and, unless otherwise specified therein,
any additional covenants specified in a supplemental indenture for such Series of Securities or a Board Resolution or an Officer’s
Certificate delivered pursuant to Section 2.2 (and the failure to comply with any such covenants shall not constitute a Default or Event
of Default with respect to such Series under Section 6.1) and the occurrence of any event specified in a supplemental indenture for such
Series of Securities or a Board Resolution or an Officer’s Certificate delivered pursuant to Section 2.2 and designated as an Event
of Default shall not constitute a Default or Event of Default hereunder, with respect to the Securities of such Series, but, except as
specified above, the remainder of this Indenture and such Securities will be unaffected thereby; provided that the following conditions
shall have been satisfied:

 

(a) with reference
to this Section 8.4, the Company has irrevocably deposited or caused to be irrevocably deposited (except as provided in Section 8.2(c))
with the Trustee as trust funds in trust for the purpose of making the following payments specifically pledged as security for, and dedicated
solely to, the benefit of the Holders of such Securities (i) in the case of Securities of such Series denominated in Dollars, cash in
Dollars and/or U.S. Government Obligations, or (ii) in the case of Securities of such Series denominated in a Foreign Currency (other
than a composite currency), money and/or Foreign Government Obligations, which through the payment of interest and principal in respect
thereof in accordance with their terms, will provide (and without reinvestment and assuming no tax liability will be imposed on such Trustee),
not later than one day before the due date of any payment of money, an amount in cash, sufficient, in the opinion of a nationally recognized
firm of independent certified public accountants or investment bank expressed in a written certification thereof delivered to the Trustee,
to pay and discharge each installment of principal (including mandatory sinking fund or analogous payments) of and interest on all the
Securities of such Series on the dates such installments of principal or interest are due;

 

(b) such deposit
will not result in a breach or violation of, or constitute a default under, this Indenture or any other agreement or instrument to which
the Company is a party or by which it is bound;

 

(c) no Default or
Event of Default with respect to the Securities of such Series shall have occurred and be continuing on the date of such deposit;

 

(d) the Company
shall have delivered to the Trustee an Officers’ Certificate and an Opinion of Counsel to the effect that the Holders of the Securities
of such Series will not recognize income, gain or loss for Federal income tax purposes as a result of such deposit and covenant defeasance
and will be subject to Federal income tax on the same amount and in the same manner and at the same times as would have been the case
if such deposit and covenant defeasance had not occurred;

 

(e) The Company
shall have delivered to the Trustee an Officer’s Certificate stating the deposit was not made by the Company with the intent of
defeating, hindering, delaying or defrauding any other creditors of the Company; and

 

(f) The Company
shall have delivered to the Trustee an Officer’s Certificate and an Opinion of Counsel, each stating that all conditions precedent
herein provided for relating to the covenant defeasance contemplated by this Section have been complied with.

 

Section 8.5. Repayment to Company.

 

Subject to applicable abandoned
property law, the Trustee and the Paying Agent shall pay to the Company upon request any money held by them for the payment of principal
and interest that remains unclaimed for two years. After that, Securityholders entitled to the money must look to the Company for payment
as general creditors unless an applicable abandoned property law designates another person.

 

    23

     

    

 

Section 8.6. Reinstatement.

 

If the Trustee or the Paying
Agent is unable to apply any money deposited with respect to Securities of any Series in accordance with Section 8.1 by reason of any
legal proceeding or by reason of any order or judgment of any court or governmental authority enjoining, restraining or otherwise prohibiting
such application, the obligations of the Company under this Indenture with respect to the Securities of such Series and under the Securities
of such Series shall be revived and reinstated as though no deposit had occurred pursuant to Section 8.1 until such time as the Trustee
or the Paying Agent is permitted to apply all such money in accordance with Section 8.1; provided, however, that if the
Company has made any payment of principal of or interest on any Securities because of the reinstatement of its obligations, the Company
shall be subrogated to the rights of the Holders of such Securities to receive such payment from the money or U.S. Government Obligations
held by the Trustee or Paying Agent after payment in full to the Holders.

 

ARTICLE IX.

AMENDMENTS AND WAIVERS

 

Section 9.1. Without Consent of Holders.

 

The Company and the Trustee
may amend or supplement this Indenture or the Securities of one or more Series without the consent of any Securityholder:

 

(a) to cure any
ambiguity, defect or inconsistency;

 

(b) to comply with
Article V;

 

(c) to provide for
uncertificated Securities in addition to or in place of certificated Securities;

 

(d) to add guarantees
with respect to Securities of any Series or secure Securities of any Series;

 

(e) to surrender
any of the Company’s rights or powers under this Indenture;

 

(f) to add covenants
or events of default for the benefit of the holders of Securities of any Series;

 

(g) to comply with
the applicable procedures of the applicable depositary;

 

(h) to make any
change that does not adversely affect the rights of any Securityholder;

 

(i) to provide for
the issuance of and establish the form and terms and conditions of Securities of any Series as permitted by this Indenture;

 

(j) to evidence
and provide for the acceptance of appointment hereunder by a successor Trustee with respect to the Securities of one or more Series and
to add to or change any of the provisions of this Indenture as shall be necessary to provide for or facilitate the administration of the
trusts hereunder by more than one Trustee; or

 

(k) to comply with
requirements of the SEC in order to effect or maintain the qualification of this Indenture under the TIA.

 

Section 9.2. With Consent of Holders.

 

The Company and the Trustee
may enter into a supplemental indenture with the written consent of the Holders of at least a majority in principal amount of the outstanding
Securities of each Series affected by such supplemental indenture (including consents obtained in connection with a tender offer or exchange
offer for the Securities of such Series), for the purpose of adding any provisions to or changing in any manner or eliminating any of
the provisions of this Indenture or of any supplemental indenture or of modifying in any manner the rights of the Securityholders of each
such Series. Except as provided in Section 6.13, the Holders of at least a majority in principal amount of the outstanding Securities
of any Series by notice to the Trustee (including consents obtained in connection with a tender offer or exchange offer for the Securities
of such Series) may waive compliance by the Company with any provision of this Indenture or the Securities with respect to such Series.

 

It shall not be necessary for
the consent of the Holders of Securities under this Section 9.2 to approve the particular form of any proposed supplemental indenture
or waiver, but it shall be sufficient if such consent approves the substance thereof. After a supplemental indenture or waiver under this
section becomes effective, the Company shall send to the Holders of Securities affected thereby, a notice briefly describing the supplemental
indenture or waiver. Any failure by the Company to send such notice, or any defect therein, shall not, however, in any way impair or affect
the validity of any such supplemental indenture or waiver.

 

    24

     

    

 

Section 9.3. Limitations.

 

Without the consent of each
Securityholder affected, an amendment or waiver may not:

 

(a) reduce the principal
amount of Securities whose Holders must consent to an amendment, supplement or waiver;

 

(b) reduce the rate
of or extend the time for payment of interest (including default interest) on any Security;

 

(c) reduce the principal
or change the Stated Maturity of any Security or reduce the amount of, or postpone the date fixed for, the payment of any sinking fund
or analogous obligation;

 

(d) reduce the principal
amount of Discount Securities payable upon acceleration of the maturity thereof;

 

(e) waive a Default
or Event of Default in the payment of the principal of or interest, if any, on any Security (except a rescission of acceleration of the
Securities of any Series by the Holders of at least a majority in principal amount of the outstanding Securities of such Series and a
waiver of the payment default that resulted from such acceleration);

 

(f) make the principal
of or interest, if any, on any Security payable in any currency other than that stated in the Security;

 

(g) make any change
in Sections 6.8, 6.13 or 9.3 (this sentence); or

 

(h) waive a redemption
payment with respect to any Security, provided that such redemption is made at the Company’s option.

 

Section 9.4. Compliance with Trust Indenture Act.

 

Every amendment to this Indenture
or the Securities of one or more Series shall be set forth in a supplemental indenture hereto that complies with the TIA as then in effect.

 

Section 9.5. Revocation and Effect of Consents.

 

Until an amendment is set forth
in a supplemental indenture or a waiver becomes effective, a consent to it by a Holder of a Security is a continuing consent by the Holder
and every subsequent Holder of a Security or portion of a Security that evidences the same debt as the consenting Holder’s Security,
even if notation of the consent is not made on any Security. However, any such Holder or subsequent Holder may revoke the consent as to
his Security or portion of a Security if the Trustee receives the notice of revocation before the date of the supplemental indenture or
the date the waiver becomes effective.

 

Any amendment or waiver once
effective shall bind every Securityholder of each Series affected by such amendment or waiver unless it is of the type described in any
of clauses (a) through (h) of Section 9.3. In that case, the amendment or waiver shall bind each Holder of a Security who has consented
to it and every subsequent Holder of a Security or portion of a Security that evidences the same debt as the consenting Holder’s
Security.

 

The Company may, but shall not
be obligated to, fix a record date for the purpose of determining the Holders entitled to give their consent or take any other action
described above or required or permitted to be taken pursuant to this Indenture. If a record date is fixed, then notwithstanding the second
immediately preceding paragraph, those Persons who were Holders at such record date (or their duly designated proxies), and only those
persons, shall be entitled to give such consent or to revoke any consent previously given or take any such action, whether or not such
Persons continue to be Holders after such record date. No such consent shall be valid or effective for more than 120 days after such record
date.

 

Section 9.6. Notation on or Exchange of Securities.

 

The Company or the Trustee may
place an appropriate notation about an amendment or waiver on any Security of any Series thereafter authenticated. The Company in exchange
for Securities of that Series may issue and the Trustee shall authenticate upon receipt of a Company Order in accordance with Section
2.3 new Securities of that Series that reflect the amendment or waiver.

 

    25

     

    

 

Section 9.7. Trustee Protected.

 

In executing, or accepting the
additional trusts created by, any supplemental indenture permitted by this Article or the modifications thereby of the trusts created
by this Indenture, the Trustee shall be entitled to receive, and (subject to Section 7.1) shall be fully protected in relying upon, an
Officer’s Certificate or an Opinion of Counsel or both complying with Section 10.4. The Trustee shall sign all supplemental indentures
upon delivery of such an Officer’s Certificate or Opinion of Counsel or both, except that the Trustee need not sign any supplemental
indenture that adversely affects its rights, duties, liabilities or immunities under this Indenture.

 

ARTICLE X.

MISCELLANEOUS

 

Section 10.1. Trust Indenture Act Controls.

 

If any provision of this Indenture
limits, qualifies, or conflicts with another provision which is required or deemed to be included in this Indenture by the TIA, such required
or deemed provision shall control.

 

Section 10.2. Notices.

 

Any notice or communication
by the Company or the Trustee to the other, or by a Holder to the Company or the Trustee, is duly given if in writing and delivered in
person or mailed by first-class mail (registered or certified, return receipt requested), facsimile transmission, email or overnight air
courier guaranteeing next day delivery, to the others’ address:

 

if to the Company:

CuriosityStream Inc.

8484 Georgia Ave., Suite 700

Silver Spring, Maryland, 20910

Attention: Clint Stinchcomb

Email: clint@curiositystream.com

 

with a copy to:

Arnold & Porter LLP

250 West 55th Street

New York, NY 10019

Attention: Christopher Peterson

Email: Christopher.peterson@arnoldporter.com

 

if to the Trustee:

[  ]

Attention: [  ]

Telephone: [  ]

with a copy to:

[  ]

Attention: [  ]

Telephone: [  ]

 

The Company or the Trustee by
notice to the other may designate additional or different addresses for subsequent notices or communications.

 

Any notice or communication
to a Securityholder shall be sent electronically or by first-class mail to his, her or its address shown on the register kept by the Registrar,
in accordance with the procedures of the Depositary. Failure to send a notice or communication to a Securityholder of any Series or any
defect in it shall not affect its sufficiency with respect to other Securityholders of that or any other Series.

 

If a notice or communication
is sent or published in the manner provided above, within the time prescribed, it is duly given, whether or not the Securityholder receives
it.

 

    26

     

    

 

If the Company sends a notice
or communication to Securityholders, it shall send a copy to the Trustee and each Agent at the same time.

 

Notwithstanding any other provision
of this Indenture or any Security, where this Indenture or any Security provides for notice of any event (including any notice of redemption)
to a Holder of a Global Security (whether by mail or otherwise), such notice shall be sufficiently given to the Depositary for such Security
(or its designee) pursuant to the customary procedures of such Depositary.

 

Section 10.3. Communication by Holders with Other Holders.

 

Securityholders of any Series
may communicate pursuant to TIA § 312(b) with other Securityholders of that Series or any other Series with respect to their rights
under this Indenture or the Securities of that Series or all Series. The Company, the Trustee, the Registrar and anyone else shall have
the protection of TIA § 312(c).

 

Section 10.4. Certificate and Opinion as to Conditions Precedent.

 

Upon any request or application
by the Company to the Trustee to take any action under this Indenture, the Company shall furnish to the Trustee:

 

(a) an Officer’s
Certificate stating that, in the opinion of the signers, all conditions precedent, if any, provided for in this Indenture relating to
the proposed action have been complied with; and

 

(b) an Opinion of
Counsel stating that, in the opinion of such counsel, all such conditions precedent have been complied with.

 

Section 10.5. Statements Required in Certificate or Opinion.

 

Each certificate or opinion
with respect to compliance with a condition or covenant provided for in this Indenture (other than a certificate provided pursuant to
TIA § 314(a)(4)) shall comply with the provisions of TIA § 314(e) and shall include:

 

(a) a statement
that the person making such certificate or opinion has read such covenant or condition;

 

(b) a brief statement
as to the nature and scope of the examination or investigation upon which the statements or opinions contained in such certificate or
opinion are based;

 

(c) a statement
that, in the opinion of such person, he has made such examination or investigation as is necessary to enable him to express an informed
opinion as to whether or not such covenant or condition has been complied with; and

 

(d) a statement
as to whether or not, in the opinion of such person, such condition or covenant has been complied with.

 

Section 10.6. Rules by Trustee and Agents.

 

The Trustee may make reasonable
rules for action by or a meeting of Securityholders of one or more Series. Any Agent may make reasonable rules and set reasonable requirements
for its functions.

 

Section 10.7. Legal Holidays.

 

A “Legal Holiday”
is any day that is not a Business Day. If a payment date is a Legal Holiday at a place of payment, payment may be made at that place on
the next succeeding day that is not a Legal Holiday, and no interest shall accrue for the intervening period.

 

Section 10.8. No Recourse Against Others.

 

A director, officer, employee
or stockholder (past or present), as such, of the Company shall not have any liability for any obligations of the Company under the Securities
or the Indenture or for any claim based on, in respect of or by reason of such obligations or their creation. Each Securityholder by accepting
a Security waives and releases all such liability. The waiver and release are part of the consideration for the issue of the Securities.

 

    27

     

    

 

Section 10.9. Counterparts.

 

This Indenture may be executed
in any number of counterparts and by the parties hereto in separate counterparts, each of which when so executed shall be deemed to be
an original and all of which taken together shall constitute one and the same agreement. The exchange of copies of this Indenture and
of signature pages by facsimile or PDF transmission shall constitute effective execution and delivery of this Indenture as to the parties
hereto and may be used in lieu of the original Indenture for all purposes. Signatures of the parties hereto transmitted by facsimile or
PDF shall be deemed to be their original signatures for all purposes.

 

Section 10.10. Governing Law; Waiver of Jury Trial; Consent
to Jurisdiction.

 

THIS INDENTURE AND THE SECURITIES,
INCLUDING ANY CLAIM OR CONTROVERSY ARISING OUT OF OR RELATING TO THE INDENTURE OR THE SECURITIES, SHALL BE GOVERNED BY THE LAWS OF THE
STATE OF NEW YORK.

 

THE
COMPANY, THE TRUSTEE AND THE HOLDERS (BY THEIR ACCEPTANCE OF THE SECURITIES) EACH HEREBY IRREVOCABLY WAIVE, TO THE FULLEST EXTENT PERMITTED
BY APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATING TO THIS INDENTURE, THE NOTES
OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY.

 

Any legal suit, action or proceeding
arising out of or based upon this Indenture or the transactions contemplated hereby may be instituted in the federal courts of the United
States of America located in the City of New York or the courts of the State of New York in each case located in the City of New York
(collectively, the “Specified Courts”), and each party irrevocably submits to the non exclusive jurisdiction of such
courts in any such suit, action or proceeding. Service of any process, summons, notice or document by mail (to the extent allowed under
any applicable statute or rule of court) to such party’s address set forth above shall be effective service of process for any suit,
action or other proceeding brought in any such court. The Company, the Trustee and the Holders (by their acceptance of the Securities)
each hereby irrevocably and unconditionally waive any objection to the laying of venue of any suit, action or other proceeding in the
Specified Courts and irrevocably and unconditionally waive and agree not to plead or claim any such suit, action or other proceeding has
been brought in an inconvenient forum.

 

Section 10.11. No Adverse Interpretation of Other Agreements.

 

This Indenture may not be used
to interpret another indenture, loan or debt agreement of the Company or a Subsidiary of the Company. Any such indenture, loan or debt
agreement may not be used to interpret this Indenture.

 

Section 10.12. Successors.

 

All agreements of the Company
in this Indenture and the Securities shall bind its successor. All agreements of the Trustee in this Indenture shall bind its successor.

 

Section 10.13. Severability.

 

In case any provision in this
Indenture or in the Securities shall be invalid, illegal or unenforceable, the validity, legality and enforceability of the remaining
provisions shall not in any way be affected or impaired thereby.

 

Section 10.14. Table of Contents, Headings, Etc.

 

The Table of Contents, Cross
Reference Table, and headings of the Articles and Sections of this Indenture have been inserted for convenience of reference only, are
not to be considered a part hereof, and shall in no way modify or restrict any of the terms or provisions hereof.

 

Section 10.15. Securities in a Foreign Currency.

 

Unless otherwise specified in
a Board Resolution, a supplemental indenture hereto or an Officer’s Certificate delivered pursuant to Section 2.2 of this Indenture
with respect to a particular Series of Securities, whenever for purposes of this Indenture any action may be taken by the Holders of a
specified percentage in aggregate principal amount of Securities of all Series or all Series affected by a particular action at the time
outstanding and, at such time, there are outstanding Securities of any Series which are denominated in more than one currency, then the
principal amount of Securities of such Series which shall be deemed to be outstanding for the purpose of taking such action shall be determined
by converting any such other currency into a currency that is designated upon issuance of any particular Series of Securities. Unless
otherwise specified in a Board Resolution, a supplemental indenture hereto or an Officer’s Certificate delivered pursuant to Section
2.2 of this Indenture with respect to a particular Series of Securities, such conversion shall be at the spot rate for the purchase of
the designated currency as published in The Financial Times in the “Currency Rates” section (or, if The Financial Times is
no longer published, or if such information is no longer available in The Financial Times, such source as may be selected in good faith
by the Company) on any date of determination. The provisions of this paragraph shall apply in determining the equivalent principal amount
in respect of Securities of a Series denominated in currency other than Dollars in connection with any action taken by Holders of Securities
pursuant to the terms of this Indenture.

 

    28

     

    

 

All decisions and determinations
provided for in the preceding paragraph shall, in the absence of manifest error, to the extent permitted by law, be conclusive for all
purposes and irrevocably binding upon the Trustee and all Holders.

 

Section 10.16. Judgment Currency.

 

The Company agrees, to the fullest
extent that it may effectively do so under applicable law, that (a) if for the purpose of obtaining judgment in any court it is necessary
to convert the sum due in respect of the principal of or interest or other amount on the Securities of any Series (the “Required
Currency”) into a currency in which a judgment will be rendered (the “Judgment Currency”), the rate of exchange
used shall be the rate at which in accordance with normal banking procedures the Trustee could purchase in The City of New York the Required
Currency with the Judgment Currency on the day on which final unappealable judgment is entered, unless such day is not a New York Banking
Day, then the rate of exchange used shall be the rate at which in accordance with normal banking procedures the Trustee could purchase
in The City of New York the Required Currency with the Judgment Currency on the New York Banking Day preceding the day on which final
unappealable judgment is entered and (b) its obligations under this Indenture to make payments in the Required Currency (i) shall not
be discharged or satisfied by any tender, any recovery pursuant to any judgment (whether or not entered in accordance with subsection
(a)), in any currency other than the Required Currency, except to the extent that such tender or recovery shall result in the actual receipt,
by the payee, of the full amount of the Required Currency expressed to be payable in respect of such payments, (ii) shall be enforceable
as an alternative or additional cause of action for the purpose of recovering in the Required Currency the amount, if any, by which such
actual receipt shall fall short of the full amount of the Required Currency so expressed to be payable, and (iii) shall not be affected
by judgment being obtained for any other sum due under this Indenture. For purposes of the foregoing, “New York Banking Day”
means any day except a Saturday, Sunday or a legal holiday in The City of New York on which banking institutions are authorized or required
by law, regulation or executive order to close.

 

Section 10.17. Force Majeure.

 

In no event shall the Trustee
be responsible or liable for any failure or delay in the performance of its obligations hereunder arising out of or caused by, directly
or indirectly, forces beyond its control, including, without limitation, strikes, work stoppages, accidents, acts of war or terrorism,
civil or military disturbances, nuclear or natural catastrophes or acts of God, and interruptions, loss or malfunctions of utilities,
communications or computer (software and hardware) services, it being understood that the Trustee shall use reasonable best efforts which
are consistent with accepted practices in the banking industry to resume performance as soon as practicable under the circumstances.

 

Section 10.18. U.S.A. Patriot Act.

 

The parties hereto acknowledge
that in accordance with Section 326 of the U.S.A. Patriot Act, the Trustee is required to obtain, verify, and record information that
identifies each person or legal entity that establishes a relationship or opens an account with the Trustee. The parties to this Indenture
agree that they will provide the Trustee with such information as it may request in order for the Trustee to satisfy the requirements
of the U.S.A. Patriot Act.

 

ARTICLE XI.

SINKING FUNDS

 

Section 11.1. Applicability of Article.

 

The provisions of this Article
shall be applicable to any sinking fund for the retirement of the Securities of a Series if so provided by the terms of such Securities
pursuant to Section 2.2 and except as otherwise permitted or required by any form of Security of such Series issued pursuant to this Indenture.

 

    29

     

    

 

The minimum amount of any sinking
fund payment provided for by the terms of the Securities of any Series is herein referred to as a “mandatory sinking fund payment”
and any other amount provided for by the terms of Securities of such Series is herein referred to as an “optional sinking fund
payment.” If provided for by the terms of Securities of any Series, the cash amount of any sinking fund payment may be subject
to reduction as provided in Section 11.2. Each sinking fund payment shall be applied to the redemption of Securities of any Series as
provided for by the terms of the Securities of such Series.

 

Section 11.2. Satisfaction of Sinking Fund Payments with Securities.

 

The Company may, in satisfaction
of all or any part of any sinking fund payment with respect to the Securities of any Series to be made pursuant to the terms of such Securities
(1) deliver outstanding Securities of such Series to which such sinking fund payment is applicable (other than any of such Securities
previously called for mandatory sinking fund redemption) and (2) apply as credit Securities of such Series to which such sinking fund
payment is applicable and which have been repurchased by the Company or redeemed either at the election of the Company pursuant to the
terms of such Series of Securities (except pursuant to any mandatory sinking fund) or through the application of permitted optional sinking
fund payments or other optional redemptions pursuant to the terms of such Securities, provided that such Securities have not been previously
so credited. Such Securities shall be received by the Trustee, together with an Officer’s Certificate with respect thereto, not
later than 15 days prior to the date on which the Trustee begins the process of selecting Securities for redemption, and shall be credited
for such purpose by the Trustee at the price specified in such Securities for redemption through operation of the sinking fund and the
amount of such sinking fund payment shall be reduced accordingly. If as a result of the delivery or credit of Securities in lieu of cash
payments pursuant to this Section 11.2, the principal amount of Securities of such Series to be redeemed in order to exhaust the aforesaid
cash payment shall be less than $100,000, the Trustee need not call Securities of such Series for redemption, except upon receipt of a
Company Order that such action be taken, and such cash payment shall be held by the Trustee or a Paying Agent and applied to the next
succeeding sinking fund payment, provided, however, that the Trustee or such Paying Agent shall from time to time upon receipt
of a Company Order pay over and deliver to the Company any cash payment so being held by the Trustee or such Paying Agent upon delivery
by the Company to the Trustee of Securities of that Series purchased by the Company having an unpaid principal amount equal to the cash
payment required to be released to the Company.

 

Section 11.3. Redemption of Securities for Sinking Fund.

 

Not less than 45 days (unless
otherwise indicated in the Board Resolution, supplemental indenture hereto or Officer’s Certificate in respect of a particular Series
of Securities) prior to each sinking fund payment date for any Series of Securities, the Company will deliver to the Trustee an Officer’s
Certificate specifying the amount of the next ensuing mandatory sinking fund payment for that Series pursuant to the terms of that Series,
the portion thereof, if any, which is to be satisfied by payment of cash and the portion thereof, if any, which is to be satisfied by
delivering and crediting of Securities of that Series pursuant to Section 11.2, and the optional amount, if any, to be added in cash to
the next ensuing mandatory sinking fund payment, and the Company shall thereupon be obligated to pay the amount therein specified. Not
less than 30 days (unless otherwise indicated in the Board Resolution, Officer’s Certificate or supplemental indenture in respect
of a particular Series of Securities) before each such sinking fund payment date the Securities to be redeemed upon such sinking fund
payment date will be selected in the manner specified in Section 3.2 and the Company shall send or cause to be sent a notice of the redemption
thereof to be given in the name of and at the expense of the Company in the manner provided in and in accordance with Section 3.3. Such
notice having been duly given, the redemption of such Securities shall be made upon the terms and in the manner stated in Sections 3.4,
3.5 and 3.6.

 

    30

     

    

 

IN WITNESS WHEREOF, the parties
hereto have caused this Indenture to be duly executed as of the day and year first above written.

 

	 	CuriosityStream Inc.
	 	 
	 	By:	 
	 	 	Name:
	 	 	Its:
	 	 
	 	[  ], as Trustee
	 	 
	 	By:	 
	 	 	Name:
	 	 	Its:

 

 

31

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00343-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00343-of-00352.parquet"}]]